AB 1906: Health care coverage: home test kits.
- Session Year: 2025-2026
- House: Assembly
- Latest Version Date: 2026-09-27
Current Status:
Passed
(2026-09-27: Chaptered by Secretary of State - Chapter 560, Statutes of 2026.)
Introduced
In Committee
Awaiting First Chamber Vote
Passed First Chamber
In Committee
Awaiting Second Chamber Vote
Passed Second Chamber
Enacted
(1)Existing law, the Knox-Keene Health Care Service Plan Act of 1975, provides for the licensure and regulation of health care service plans by the Department of Managed Health Care, and makes a willful violation of the act a crime. Existing law provides for the regulation of health insurers by the Department of Insurance. Existing law requires a health care service plan contract or health insurance policy issued, amended, or renewed on or after January 1, 2002, to provide coverage for an annual cervical cancer screening test upon the referral of the patients health care provider.
This bill would require a health care service plan contract or health insurance policy, except for a vision-only, dental-only, or Medicare supplement contract or policy, issued, amended, or renewed on or after January 1, 2027, to provide coverage without cost sharing for cervical cancer screening, including the United States Food and Drug Administration (FDA)-authorized or cleared self-collected cervical screening kits, when ordered or provided by an in-network provider and consistent with specified recommendations published by the State Department of Public Health. For health savings account-eligible plans or policies, the bill would require the above-described coverage only to the extent the plan is a high deductible health plan under specified federal law. Because a willful violation of the bills requirements relative to health care service plans would be a crime, the bill would impose a state-mandated local program.
(2)Existing law provides for the Medi-Cal program, administered by the State Department of Health Care Services and under which health care services are provided to low-income individuals pursuant to a schedule of benefits. The Medi-Cal program is, in part, governed and funded by federal Medicaid program provisions. An annual cervical cancer test for screening or diagnostic purposes, upon the referral of a patients physician, is a covered benefit under the Medi-Cal program to the extent required or permitted by federal law.
This bill would instead include cervical cancer tests for screening that are ordered by a patients health care provider and consistent with specified recommendations published by the State Department of Public Health as a covered benefit under the Medi-Cal program on or after January 1, 2027. The bill would additionally include FDA-authorized or cleared cervical cancer home test kits for screening that are ordered by a patients health care provider and consistent with specified recommendations published by the State Department of Public Health and Medi-Cal policies as a covered benefit under the Medi-Cal program on or after January 1, 2027, without cost sharing, to the extent that federal financial participation is available and not otherwise jeopardized and any necessary federal approvals have been obtained.
(3)The California Constitution requires the state to reimburse local agencies and school districts for certain costs mandated by the state. Statutory provisions establish procedures for making that reimbursement.
This bill would provide that no reimbursement is required by this act for a specified reason.
(1)Existing law, the Knox-Keene Health Care Service Plan Act of 1975, provides for the licensure and regulation of health care service plans by the Department of Managed Health Care, and makes a willful violation of the act a crime. Existing law provides for the regulation of health insurers by the Department of Insurance. Existing law requires a health care service plan contract or health insurance policy issued, amended, or renewed on or after January 1, 2002, to provide coverage for an annual cervical cancer screening test upon the referral of the patients health care provider.
This bill would require a health care service plan contract or health insurance policy, except for a vision-only, dental-only, or Medicare supplement contract or policy, issued, amended, or renewed on or after January 1, 2027, to provide coverage without cost sharing for cervical cancer screening, including the United States Food and Drug Administration (FDA)-authorized or cleared self-collected cervical screening kits, when ordered or provided by an in-network provider and consistent with specified recommendations published by the State Department of Public Health. For health savings account-eligible plans or policies, the bill would require the above-described coverage only to the extent the plan is a high deductible health plan under specified federal law. Because a willful violation of the bills requirements relative to health care service plans would be a crime, the bill would impose a state-mandated local program.
(2)Existing law provides for the Medi-Cal program, administered by the State Department of Health Care Services and under which health care services are provided to low-income individuals pursuant to a schedule of benefits. The Medi-Cal program is, in part, governed and funded by federal Medicaid program provisions. An annual cervical cancer test for screening or diagnostic purposes, upon the referral of a patients physician, is a covered benefit under the Medi-Cal program to the extent required or permitted by federal law.
This bill would instead include cervical cancer tests for screening that are ordered by a patients health care provider and consistent with specified recommendations published by the State Department of Public Health as a covered benefit under the Medi-Cal program on or after January 1, 2027. The bill would additionally include FDA-authorized or cleared cervical cancer home test kits for screening that are ordered by a patients health care provider and consistent with specified recommendations published by the State Department of Public Health and Medi-Cal policies as a covered benefit under the Medi-Cal program on or after January 1, 2027, without cost sharing, to the extent that federal financial participation is available and not otherwise jeopardized and any necessary federal approvals have been obtained.
(3)The California Constitution requires the state to reimburse local agencies and school districts for certain costs mandated by the state. Statutory provisions establish procedures for making that reimbursement.
This bill would provide that no reimbursement is required by this act for a specified reason.
(1)Existing law, the Knox-Keene Health Care Service Plan Act of 1975, provides for the licensure and regulation of health care service plans by the Department of Managed Health Care, and makes a willful violation of the act a crime. Existing law provides for the regulation of health insurers by the Department of Insurance. Existing law requires a health care service plan contract or health insurance policy issued, amended, or renewed on or after January 1, 2002, to provide coverage for an annual cervical cancer screening test upon the referral of the patients health care provider.
This bill would require a health care service plan contract or health insurance policy policy, except for a vision-only, dental-only, or Medicare supplement contract or policy, issued, amended, or renewed on or after January 1, 2027, to provide coverage without cost sharing for cervical cancer screening, including the United States Food and Drug Administration (FDA)-authorized or cleared self-collected cervical screening kits, when ordered or provided by an in-network provider and consistent with nationally recognized clinical guidelines. specified recommendations published by the State Department of Public Health. For health savings account-eligible plans or policies, the bill would require the above-described coverage only to the extent the plan is a high deductible health plan under specified federal law. Because a willful violation of the bills requirements relative to health care service plans would be a crime, the bill would impose a state-mandated local program.
(2)Existing law provides for the Medi-Cal program, administered by the State Department of Health Care Services and under which health care services are provided to low-income individuals pursuant to a schedule of benefits. The Medi-Cal program is, in part, governed and funded by federal Medicaid program provisions. An annual cervical cancer test for screening or diagnostic purposes, upon the referral of a patients physician, is a covered benefit under the Medi-Cal program to the extent required or permitted by federal law.
This bill would instead include cervical cancer tests for screening that are ordered by a patients health care provider and consistent with nationally recognized clinical guidelines specified recommendations published by the State Department of Public Health as a covered benefit under the Medi-Cal program on or after January 1, 2027. The bill would additionally include FDA-authorized or cleared cervical cancer home test kits for screening that are ordered by a patients health care provider and consistent with nationally recognized clinical guidelines specified recommendations published by the State Department of Public Health and Medi-Cal policies as a covered benefit under the Medi-Cal program on or after January 1, 2027, without cost sharing, to the extent required or permitted by federal law. that federal financial participation is available and not otherwise jeopardized and any necessary federal approvals have been obtained.
(3)Under existing law, the Medi-Cal program administers the Family Planning, Access, Care, and Treatment (Family PACT) Program within the State Department of Health Care Services to provide comprehensive clinical family planning services to a person with a family income at or below 200% of the federal poverty level. Existing law authorizes the department to provide reimbursement for sexually transmitted disease-related services as part of the Family PACT Program. Existing law establishes within the department the State-Only Family Planning Program to provide comprehensive clinical family planning services to any individual who is a resident of the state, has a family income at or below 200% of the federal poverty level, has no other health coverage, except as described, and is not otherwise eligible for Medi-Cal services without a share of cost. Existing law includes in the benefits for Medi-Cal, the Family PACT Program, and the State-Only Family Planning Program home test kits for sexually transmitted diseases and the laboratory testing required to process those kits that are deemed medically necessary or appropriate and are ordered directly by a health care provider or furnished through a standing order for patient use based on clinical guidelines and individual patient health needs, contingent upon the addition of billing codes specific to home test kits in the Current Procedural Terminology or Healthcare Common Procedure Coding System.This bill would remove the above-described requirements related to the addition of billing codes for the above-described programs. (4)(3)The California Constitution requires the state to reimburse local agencies and school districts for certain costs mandated by the state. Statutory provisions establish procedures for making that reimbursement.
This bill would provide that no reimbursement is required by this act for a specified reason.
(1)Existing law, the Knox-Keene Health Care Service Plan Act of 1975, provides for the licensure and regulation of health care service plans by the Department of Managed Health Care, and makes a willful violation of the act a crime. Existing law provides for the regulation of health insurers by the Department of Insurance. Existing law requires a health care service plan contract or health insurance policy issued, amended, or renewed on or after January 1, 2002, to provide coverage for an annual cervical cancer screening test upon the referral of the patients health care provider.
Existing law provides for the Medi-Cal program, administered by the State Department of Health Care Services and under which health care services are provided to low-income individuals pursuant to a schedule of benefits. The Medi-Cal program is, in part, governed and funded by federal Medicaid program provisions. An annual cervical cancer test for screening or diagnostic purposes, upon the referral of a patients physician, is a covered benefit under the Medi-Cal program to the extent required or permitted by federal law.This bill would require a health care service plan contract or health insurance policy issued, amended, or renewed on or after January 1, 2027, to provide coverage without cost sharing for an annual cervical cancer screening home test kit upon the referral of the patients health care provider. cervical cancer screening, including the United States Food and Drug Administration (FDA)-authorized or cleared self-collected cervical screening kits, when ordered or provided by an in-network provider and consistent with nationally recognized clinical guidelines. For health savings account-eligible plans or policies, the bill would require the above-described coverage only to the extent the plan is a high deductible health plan under specified federal law. Because a willful violation of the bills requirements relative to health care service plans would be a crime, the bill would impose a state-mandated local program. The bill would also include cervical cancer home test kits, upon the referral of a patients health care provider, as a covered benefit under the Medi-Cal program on or after January 1, 2027, without cost sharing, to the extent required or permitted by federal law.
(2)Existing law provides for the Medi-Cal program, administered by the State Department of Health Care Services and under which health care services are provided to low-income individuals pursuant to a schedule of benefits. The Medi-Cal program is, in part, governed and funded by federal Medicaid program provisions. An annual cervical cancer test for screening or diagnostic purposes, upon the referral of a patients physician, is a covered benefit under the Medi-Cal program to the extent required or permitted by federal law.
This bill would instead include cervical cancer tests for screening that are ordered by a patients health care provider and consistent with nationally recognized clinical guidelines as a covered benefit under the Medi-Cal program on or after January 1, 2027. The bill would additionally include FDA-authorized or cleared cervical cancer home test kits for screening that are ordered by a patients health care provider and consistent with nationally recognized clinical guidelines as a covered benefit under the Medi-Cal program on or after January 1, 2027, without cost sharing, to the extent required or permitted by federal law.
(2)(3)Under existing law, the Medi-Cal program administers the Family Planning, Access, Care, and Treatment (Family PACT) Program within the State Department of Health Care Services to provide comprehensive clinical family planning services to a person with a family income at or below 200% of the federal poverty level. Existing law authorizes the department to provide reimbursement for sexually transmitted disease-related services as part of the Family PACT Program. Existing law establishes within the department the State-Only Family Planning Program to provide comprehensive clinical family planning services to any individual who is a resident of the state, has a family income at or below 200% of the federal poverty level, has no other health coverage, except as described, and is not otherwise eligible for Medi-Cal services without a share of cost. Existing law includes in the benefits for Medi-Cal, the Family PACT Program, and the State-Only Family Planning Program home test kits for sexually transmitted diseases and the laboratory testing required to process those kits that are deemed medically necessary or appropriate and are ordered directly by a health care provider or furnished through a standing order for patient use based on clinical guidelines and individual patient health needs, contingent upon the addition of billing codes specific to home test kits in the Current Procedural Terminology or Healthcare Common Procedure Coding System.
This bill would remove the above-described requirements related to the addition of billing codes for the above-described programs.
The(4)The California Constitution requires the state to reimburse local agencies and school districts for certain costs mandated by the state. Statutory provisions establish procedures for making that reimbursement.
This bill would provide that no reimbursement is required by this act for a specified reason.
Existing
(1)Existing law, the Knox-Keene Health Care Service Plan Act of 1975, provides for the licensure and regulation of health care service plans by the Department of Managed Health Care, and makes a willful violation of the act a crime. Existing law provides for the regulation of health insurers by the Department of Insurance. Existing law requires a health care service plan contract or health insurance policy issued, amended, or renewed on or after January 1, 2002, to provide coverage for an annual cervical cancer screening test upon the referral of the patients health care provider.
Existing law provides for the Medi-Cal program, administered by the State Department of Health Care Services and under which health care services are provided to low-income individuals pursuant to a schedule of benefits. The Medi-Cal program is, in part, governed and funded by federal Medicaid program provisions. An annual cervical cancer test for screening or diagnostic purposes, upon the referral of a patients physician, is a covered benefit under the Medi-Cal program to the extent required or permitted by federal law.
This bill would require a health care service plan contract or health insurance policy issued, amended, or renewed on or after January 1, 2027, to provide coverage without cost sharing for an annual cervical cancer screening home test kit upon the referral of the patients health care provider. Because a willful violation of the bills requirements relative to health care service plans would be a crime, the bill would impose a state-mandated local program. The bill would also include cervical cancer home test kits, upon the referral of a patients health care provider, as a covered benefit under the Medi-Cal program on or after January 1, 2027, without cost sharing, to the extent required or permitted by federal law.
(2)Under existing law, the Medi-Cal program administers the Family Planning, Access, Care, and Treatment (Family PACT) Program within the State Department of Health Care Services to provide comprehensive clinical family planning services to a person with a family income at or below 200% of the federal poverty level. Existing law authorizes the department to provide reimbursement for sexually transmitted disease-related services as part of the Family PACT Program. Existing law establishes within the department the State-Only Family Planning Program to provide comprehensive clinical family planning services to any individual who is a resident of the state, has a family income at or below 200% of the federal poverty level, has no other health coverage, except as described, and is not otherwise eligible for Medi-Cal services without a share of cost. Existing law includes in the benefits for Medi-Cal, the Family PACT Program, and the State-Only Family Planning Program home test kits for sexually transmitted diseases and the laboratory testing required to process those kits that are deemed medically necessary or appropriate and are ordered directly by a health care provider or furnished through a standing order for patient use based on clinical guidelines and individual patient health needs, contingent upon the addition of billing codes specific to home test kits in the Current Procedural Terminology or Healthcare Common Procedure Coding System.
This bill would remove the above-described requirements related to the addition of billing codes for the above-described programs.
The California Constitution requires the state to reimburse local agencies and school districts for certain costs mandated by the state. Statutory provisions establish procedures for making that reimbursement.
This bill would provide that no reimbursement is required by this act for a specified reason.
Existing law, the Knox-Keene Health Care Service Plan Act of 1975, provides for the licensure and regulation of health care service plans by the Department of Managed Health Care, and makes a willful violation of the act a crime. Existing law provides for the regulation of health insurers by the Department of Insurance. Existing law requires a health care service plan contract or health insurance policy issued, amended, or renewed on or after January 1, 2002, to provide coverage for an annual cervical cancer screening test upon the referral of the patients health care provider.
Existing law provides for the Medi-Cal program, administered by the State Department of Health Care Services and under which health care services are provided to low-income individuals pursuant to a schedule of benefits. The Medi-Cal program is, in part, governed and funded by federal Medicaid program provisions. An annual cervical cancer test for screening or diagnostic purposes, upon the referral of a patients physician, is a covered benefit under the Medi-Cal program to the extent required or permitted by federal law.
This bill would require a health care service plan contract or health insurance policy issued, amended, or renewed on or after January 1, 2027, to provide coverage without cost sharing for an annual cervical cancer screening home test kit upon the referral of the patients health care provider. Because a willful violation of the bills requirements relative to health care service plans would be a crime, the bill would impose a state-mandated local program. The bill would also include cervical cancer home test kits, upon the referral of a patients health care provider, as a covered benefit under the Medi-Cal program on or after January 1, 2027, without cost sharing, to the extent required or permitted by federal law.
The California Constitution requires the state to reimburse local agencies and school districts for certain costs mandated by the state. Statutory provisions establish procedures for making that reimbursement.
This bill would provide that no reimbursement is required by this act for a specified reason.
(a)(1)A individual or group health care service plan contract, except for a specialized health care service plan, issued, amended, or renewed on or after January 1, 2027, shall provide coverage for cervical cancer screening when ordered or provided by an in-network provider operating within their permitted scope of practice and consistent with any relevant recommendations published pursuant to Section 120164.
(2)The coverage for a cervical cancer screening test provided pursuant to this subdivision shall include the conventional Pap test, a human papillomavirus screening test that is approved by the United States Food and Drug Administration (FDA), including FDA-authorized or cleared self-collected cervical screening kits that allow patients to self-collect samples at a location outside of a clinical setting, and the option of any cervical cancer screening test approved by the FDA that is ordered or provided by the patients health care provider.
(b)A health care service plan contract, except for a specialized health care service plan, issued, amended, or renewed on or after January 1, 2024, shall provide coverage for the human papillomavirus vaccine for enrollees for whom the vaccine is approved by the FDA.
(c)A health care service plan contract shall not impose a deductible, coinsurance, copayment, or any other cost-sharing requirement on the coverage provided pursuant to this section.
(d)The cost-sharing requirements described in subdivision (c) shall only apply to a health savings account-eligible health care service plan to the extent the plan does not fail to be treated as a high deductible health plan under Section 223 of Title 26 of the United States Code.
(e)This section does not apply to a vision-only, dental-only, or Medicare supplement health care service plan contract.
(f)This section does not limit the application of Section 1367.002.
(g)This section does not apply to Medi-Cal managed care plan contracts with the State Department of Health Care Services pursuant to Chapter 7 (commencing with Section 14000), Chapter 8 (commencing with Section 14200), or Chapter 8.75 (commencing with Section 14591) of Part 3 of Division 9 of the Welfare and Institutions Code.
SEC. 2.Section 10123.18 of the Insurance Code is amended to read:10123.18.(a)(1)A health insurance policy issued, amended, or renewed on or after January 1, 2027, shall provide coverage for cervical cancer screening when ordered or provided by an in-network provider operating within their permitted scope of practice and consistent with any relevant recommendations published pursuant to Section 120164 of the Health and Safety Code.
(2)The coverage for a cervical cancer screening test provided pursuant to this subdivision shall include the conventional Pap test, a human papillomavirus screening test that is approved by the United States Food and Drug Administration (FDA), including FDA-authorized or cleared self-collected cervical screening kits that allow patients to self-collect samples at a location outside of a clinical setting, and the option of any cervical cancer screening test approved by the FDA that is ordered or provided by the patients health care provider.
(3)This subdivision does not require an individual or group policy to cover treatment or surgery for cervical cancer or to prevent application of deductible or copayment provisions contained in the policy or certificate, and does not require that coverage under an individual or group policy be extended to any other procedures.
(b)A health insurance policy issued, amended, or renewed on or after January 1, 2024, that provides coverage for hospital, medical, or surgical benefits shall provide coverage for the human papillomavirus vaccine for insureds for whom the vaccine is approved by the FDA.
(c)A health insurance policy shall not impose a deductible, coinsurance, copayment, or any other cost-sharing requirement on the coverage provided pursuant to this section.
(d)The cost-sharing requirements described in subdivision (c) shall only apply to a health savings account-eligible health insurance policy to the extent it does not fail to be treated as a high deductible health plan under Section 223 of Title 26 of the United States Code.
(e)This section does not apply to a vision-only, dental-only, or Medicare supplement insurance policy.
(f)This section does not limit the application of Section 10112.2.
SEC. 3.Section 14132.17 of the Welfare and Institutions Code is amended to read:14132.17.(a)Cervical cancer tests for screening that are ordered by a patients health care provider and consistent with any relevant recommendations published pursuant to Section 120164 of the Health and Safety Code are a covered benefit under this chapter, on or after January 1, 2027, subject to medical necessity and utilization management controls, to the extent required or permitted by federal law.
(b)(1)Cervical cancer home test kits for screening that allow patients to self-collect samples and are United States Food and Drug Administration-authorized or cleared are a covered benefit under this chapter, on or after January 1, 2027, subject to medical necessity and utilization management controls, to the extent required or permitted by federal law.
(2)A test described in paragraph (1) shall be ordered or provided by a patients health care provider and shall be consistent with both of the following:
(A)Any relevant recommendations published pursuant to Section 120164 of the Health and Safety Code.
(B)Medi-Cal policies.
(3)Reimbursement for a test described in paragraph (1) shall use a clinically appropriate Current Procedural Terminology or Healthcare Common Procedure Coding System billing code in order to comply with Health Insurance Portability and Accountability Act requirements.
(4)A Medi-Cal beneficiary is not subject to any cost sharing, including, but not limited to, a share of cost or spend down of excess income as described in Section 14054 for the benefit described in this subdivision.
(5)This subdivision applies to both the fee-for-service delivery system and the managed care delivery system under the Medi-Cal program.
(6)The coverage described in this subdivision is a covered benefit only to the extent that federal financial participation is available and not otherwise jeopardized and any necessary federal approvals have been obtained.
(7)Notwithstanding any other law, the department, without taking any further regulatory action, may implement, interpret, or make specific this subdivision by means of all-county letters, plan letters, plan or provider bulletins, or similar instructions.
SEC. 4.No reimbursement is required by this act pursuant to Section 6 of Article XIIIB of the California Constitution because the only costs that may be incurred by a local agency or school district will be incurred because this act creates a new crime or infraction, eliminates a crime or infraction, or changes the penalty for a crime or infraction, within the meaning of Section 17556 of the Government Code, or changes the definition of a crime within the meaning of Section 6 of Article XIIIB of the California Constitution.
(a)(1)A individual or group health care service plan contract, except for a specialized health care service plan, issued, amended, or renewed on or after January 1, 2027, shall provide coverage for cervical cancer screening when ordered or provided by an in-network provider operating within their permitted scope of practice and consistent with any relevant recommendations published pursuant to Section 120164.
(2)The coverage for a cervical cancer screening test provided pursuant to this subdivision shall include the conventional Pap test, a human papillomavirus screening test that is approved by the United States Food and Drug Administration (FDA), including FDA-authorized or cleared self-collected cervical screening kits that allow patients to self-collect samples at a location outside of a clinical setting, and the option of any cervical cancer screening test approved by the FDA that is ordered or provided by the patients health care provider.
(b)A health care service plan contract, except for a specialized health care service plan, issued, amended, or renewed on or after January 1, 2024, shall provide coverage for the human papillomavirus vaccine for enrollees for whom the vaccine is approved by the FDA.
(c)A health care service plan contract shall not impose a deductible, coinsurance, copayment, or any other cost-sharing requirement on the coverage provided pursuant to this section.
(d)The cost-sharing requirements described in subdivision (c) shall only apply to a health savings account-eligible health care service plan to the extent the plan does not fail to be treated as a high deductible health plan under Section 223 of Title 26 of the United States Code.
(e)This section does not apply to a vision-only, dental-only, or Medicare supplement health care service plan contract.
(f)This section does not limit the application of Section 1367.002.
(g)This section does not apply to Medi-Cal managed care plan contracts with the State Department of Health Care Services pursuant to Chapter 7 (commencing with Section 14000), Chapter 8 (commencing with Section 14200), or Chapter 8.75 (commencing with Section 14591) of Part 3 of Division 9 of the Welfare and Institutions Code.
SEC. 2.Section 10123.18 of the Insurance Code is amended to read:10123.18.(a)(1)A health insurance policy issued, amended, or renewed on or after January 1, 2027, shall provide coverage for cervical cancer screening when ordered or provided by an in-network provider operating within their permitted scope of practice and consistent with any relevant recommendations published pursuant to Section 120164 of the Health and Safety Code.
(2)The coverage for a cervical cancer screening test provided pursuant to this subdivision shall include the conventional Pap test, a human papillomavirus screening test that is approved by the United States Food and Drug Administration (FDA), including FDA-authorized or cleared self-collected cervical screening kits that allow patients to self-collect samples at a location outside of a clinical setting, and the option of any cervical cancer screening test approved by the FDA that is ordered or provided by the patients health care provider.
(3)This subdivision does not require an individual or group policy to cover treatment or surgery for cervical cancer or to prevent application of deductible or copayment provisions contained in the policy or certificate, and does not require that coverage under an individual or group policy be extended to any other procedures.
(b)A health insurance policy issued, amended, or renewed on or after January 1, 2024, that provides coverage for hospital, medical, or surgical benefits shall provide coverage for the human papillomavirus vaccine for insureds for whom the vaccine is approved by the FDA.
(c)A health insurance policy shall not impose a deductible, coinsurance, copayment, or any other cost-sharing requirement on the coverage provided pursuant to this section.
(d)The cost-sharing requirements described in subdivision (c) shall only apply to a health savings account-eligible health insurance policy to the extent it does not fail to be treated as a high deductible health plan under Section 223 of Title 26 of the United States Code.
(e)This section does not apply to a vision-only, dental-only, or Medicare supplement insurance policy.
(f)This section does not limit the application of Section 10112.2.
SEC. 3.Section 14132.17 of the Welfare and Institutions Code is amended to read:14132.17.(a)Cervical cancer tests for screening that are ordered by a patients health care provider and consistent with any relevant recommendations published pursuant to Section 120164 of the Health and Safety Code are a covered benefit under this chapter, on or after January 1, 2027, subject to medical necessity and utilization management controls, to the extent required or permitted by federal law.
(b)(1)Cervical cancer home test kits for screening that allow patients to self-collect samples and are United States Food and Drug Administration-authorized or cleared are a covered benefit under this chapter, on or after January 1, 2027, subject to medical necessity and utilization management controls, to the extent required or permitted by federal law.
(2)A test described in paragraph (1) shall be ordered or provided by a patients health care provider and shall be consistent with both of the following:
(A)Any relevant recommendations published pursuant to Section 120164 of the Health and Safety Code.
(B)Medi-Cal policies.
(3)Reimbursement for a test described in paragraph (1) shall use a clinically appropriate Current Procedural Terminology or Healthcare Common Procedure Coding System billing code in order to comply with Health Insurance Portability and Accountability Act requirements.
(4)A Medi-Cal beneficiary is not subject to any cost sharing, including, but not limited to, a share of cost or spend down of excess income as described in Section 14054 for the benefit described in this subdivision.
(5)This subdivision applies to both the fee-for-service delivery system and the managed care delivery system under the Medi-Cal program.
(6)The coverage described in this subdivision is a covered benefit only to the extent that federal financial participation is available and not otherwise jeopardized and any necessary federal approvals have been obtained.
(7)Notwithstanding any other law, the department, without taking any further regulatory action, may implement, interpret, or make specific this subdivision by means of all-county letters, plan letters, plan or provider bulletins, or similar instructions.
SEC. 4.No reimbursement is required by this act pursuant to Section 6 of Article XIIIB of the California Constitution because the only costs that may be incurred by a local agency or school district will be incurred because this act creates a new crime or infraction, eliminates a crime or infraction, or changes the penalty for a crime or infraction, within the meaning of Section 17556 of the Government Code, or changes the definition of a crime within the meaning of Section 6 of Article XIIIB of the California Constitution.
(a)(1)A individual or group health care service plan contract, except for a specialized health care service plan, issued, amended, or renewed on or after January 1, 2027, shall provide coverage for cervical cancer screening when ordered or provided by an in-network provider operating within their permitted scope of practice and consistent with nationally recognized clinical guidelines. any relevant recommendations published pursuant to Section 120164.
(2)The coverage for a cervical cancer screening test provided pursuant to this subdivision shall include the conventional Pap test, a human papillomavirus screening test that is approved by the United States Food and Drug Administration (FDA), including FDA-authorized or cleared self-collected cervical screening kits that allow patients to self-collect samples at a location outside of a clinical setting, and the option of any cervical cancer screening test approved by the FDA that is ordered or provided by the patients health care provider.
(b)A health care service plan contract, except for a specialized health care service plan, issued, amended, or renewed on or after January 1, 2024, shall provide coverage for the human papillomavirus vaccine for enrollees for whom the vaccine is approved by the FDA.
(c)A health care service plan contract shall not impose a deductible, coinsurance, copayment, or any other cost-sharing requirement on the coverage provided pursuant to this section.
(d)The cost-sharing requirements described in subdivision (c) shall only apply to a health savings account-eligible health care service plan to the extent the plan does not fail to be treated as a high deductible health plan under Section 223 of Title 26 of the United States Code.
(e)This section does not apply to a vision-only, dental-only, or Medicare supplement health care service plan contract.
(e)(f)This section does not limit the application of Section 1367.002.
(g)This section does not apply to Medi-Cal managed care plan contracts with the State Department of Health Care Services pursuant to Chapter 7 (commencing with Section 14000), Chapter 8 (commencing with Section 14200), or Chapter 8.75 (commencing with Section 14591) of Part 3 of Division 9 of the Welfare and Institutions Code.
SEC. 2.Section 10123.18 of the Insurance Code is amended to read:10123.18.(a)(1)A health insurance policy issued, amended, or renewed on or after January 1, 2027, shall provide coverage for cervical cancer screening when ordered or provided by an in-network provider operating within their permitted scope of practice and consistent with nationally recognized clinical guidelines. any relevant recommendations published pursuant to Section 120164 of the Health and Safety Code.
(2)The coverage for a cervical cancer screening test provided pursuant to this subdivision shall include the conventional Pap test, a human papillomavirus screening test that is approved by the United States Food and Drug Administration (FDA), including FDA-authorized or cleared self-collected cervical screening kits that allow patients to self-collect samples at a location outside of a clinical setting, and the option of any cervical cancer screening test approved by the FDA that is ordered or provided by the patients health care provider.
(3)This subdivision does not require an individual or group policy to cover treatment or surgery for cervical cancer or to prevent application of deductible or copayment provisions contained in the policy or certificate, and does not require that coverage under an individual or group policy be extended to any other procedures.
(b)A health insurance policy issued, amended, or renewed on or after January 1, 2024, that provides coverage for hospital, medical, or surgical benefits shall provide coverage for the human papillomavirus vaccine for insureds for whom the vaccine is approved by the FDA.
(c)A health insurance policy shall not impose a deductible, coinsurance, copayment, or any other cost-sharing requirement on the coverage provided pursuant to this section.
(d)The cost-sharing requirements described in subdivision (c) shall only apply to a health savings account-eligible health insurance policy to the extent it does not fail to be treated as a high deductible health plan under Section 223 of Title 26 of the United States Code.
(e)This section does not apply to a vision-only, dental-only, or Medicare supplement insurance policy.
(e)(f)This section does not limit the application of Section 10112.2.
SEC. 3.Section 14132 of the Welfare and Institutions Code is amended to read:14132.The following is the schedule of benefits under this chapter:(a)Outpatient services are covered as follows:Physician, hospital or clinic outpatient, surgical center, respiratory care, optometric, chiropractic, psychology, podiatric, occupational therapy, physical therapy, speech therapy, audiology, acupuncture to the extent federal matching funds are provided for acupuncture, and services of persons rendering treatment by prayer or healing by spiritual means in the practice of any church or religious denomination insofar as these can be encompassed by federal participation under an approved plan, subject to utilization controls.(b)(1)Inpatient hospital services, including, but not limited to, physician and podiatric services, physical therapy, and occupational therapy, are covered subject to utilization controls.(2)For a Medi-Cal fee-for-service beneficiary, emergency services and care that are necessary for the treatment of an emergency medical condition and medical care directly related to the emergency medical condition. This paragraph does not change the obligation of Medi-Cal managed care plans to provide emergency services and care. For the purposes of this paragraph, emergency services and care and emergency medical condition have the same meanings as those terms are defined in Section 1317.1 of the Health and Safety Code.(c)Nursing facility services, subacute care services, and services provided by any category of intermediate care facility for the developmentally disabled, including podiatry, physician, nurse practitioner services, and prescribed drugs, as described in subdivision (d), are covered subject to utilization controls. Respiratory care, physical therapy, occupational therapy, speech therapy, and audiology services for patients in nursing facilities and any category of intermediate care facility for persons with developmental disabilities are covered subject to utilization controls.(d)(1)Purchase of prescribed drugs is covered subject to the Medi-Cal List of Contract Drugs and utilization controls.(2)Purchase of drugs used to treat erectile dysfunction or any off-label uses of those drugs are covered only to the extent that federal financial participation is available.(3)(A)To the extent required by federal law, the purchase of outpatient prescribed drugs, for which the prescription is executed by a prescriber in written, nonelectronic form on or after April 1, 2008, is covered only when executed on a tamper-resistant prescription form. The implementation of this paragraph shall conform to the guidance issued by the federal Centers for Medicare and Medicaid Services, but shall not conflict with state statutes on the characteristics of tamper-resistant prescriptions for controlled substances, including Section 11162.1 of the Health and Safety Code. The department shall provide providers and beneficiaries with as much flexibility in implementing these rules as allowed by the federal government. The department shall notify and consult with appropriate stakeholders in implementing, interpreting, or making specific this paragraph.(B)Notwithstanding Chapter 3.5 (commencing with Section 11340) of Part 1 of Division 3 of Title 2 of the Government Code, the department may take the actions specified in subparagraph (A) by means of a provider bulletin or notice, policy letter, or other similar instructions without taking regulatory action.(4)(A)(i)For the purposes of this paragraph, nonlegend has the same meaning as defined in subdivision (a) of Section 14105.45.(ii)Nonlegend acetaminophen-containing products, including childrens acetaminophen-containing products, selected by the department are covered benefits.(iii)Nonlegend cough and cold products selected by the department are covered benefits.(B)Notwithstanding Chapter 3.5 (commencing with Section 11340) of Part 1 of Division 3 of Title 2 of the Government Code, the department may take the actions specified in subparagraph (A) by means of a provider bulletin or notice, policy letter, or other similar instruction without taking regulatory action.(e)Outpatient dialysis services and home hemodialysis services, including physician services, medical supplies, drugs, and equipment required for dialysis, are covered, subject to utilization controls.(f)Anesthesiologist services when provided as part of an outpatient medical procedure, nurse anesthetist services when rendered in an inpatient or outpatient setting under conditions set forth by the director, outpatient laboratory services, and x-ray services are covered, subject to utilization controls. This subdivision does not require prior authorization for anesthesiologist services provided as part of an outpatient medical procedure or for portable x-ray services in a nursing facility or any category of intermediate care facility for the developmentally disabled.(g)Blood and blood derivatives are covered.(h)(1)Emergency and essential diagnostic and restorative dental services, except for orthodontic, fixed bridgework, and partial dentures that are not necessary for balance of a complete artificial denture, are covered, subject to utilization controls. The utilization controls shall allow emergency and essential diagnostic and restorative dental services and prostheses that are necessary to prevent a significant disability or to replace previously furnished prostheses that are lost or destroyed due to circumstances beyond the beneficiarys control. Notwithstanding the foregoing, the director may by regulation provide for certain fixed artificial dentures necessary for obtaining employment or for medical conditions that preclude the use of removable dental prostheses, and for orthodontic services in cleft palate deformities administered by the departments California Childrens Services program.(2)For persons 21 years of age or older, the services specified in paragraph (1) shall be provided subject to the following conditions:(A)Periodontal treatment is not a benefit.(B)Endodontic therapy is not a benefit except for vital pulpotomy.(C)Laboratory processed crowns are not a benefit.(D)Removable prosthetics shall be a benefit only for patients as a requirement for employment.(E)The director may, by regulation, provide for the provision of fixed artificial dentures that are necessary for medical conditions that preclude the use of removable dental prostheses.(F)Notwithstanding the conditions specified in subparagraphs (A) to (E), inclusive, the department may approve services for persons with special medical disorders subject to utilization review.(3)Paragraph (2) shall become inoperative on July 1, 1995.(i)Medical transportation is covered, subject to utilization controls.(j)Home health care services are covered, subject to utilization controls.(k)(1)Prosthetic and orthotic devices and eyeglasses are covered, subject to utilization controls. Utilization controls shall allow replacement of prosthetic and orthotic devices and eyeglasses necessary because of loss or destruction due to circumstances beyond the beneficiarys control. Frame styles for eyeglasses replaced pursuant to this subdivision shall not change more than once every two years, unless the department so directs.(2)Orthopedic and conventional shoes are covered when provided by a prosthetic and orthotic supplier on the prescription of a physician and when at least one of the shoes will be attached to a prosthesis or brace, subject to utilization controls. Modification of stock conventional or orthopedic shoes when medically indicated is covered, subject to utilization controls. If there is a clearly established medical need that cannot be satisfied by the modification of stock conventional or orthopedic shoes, custom-made orthopedic shoes are covered, subject to utilization controls.(3)Therapeutic shoes and inserts are covered when provided to a beneficiary with a diagnosis of diabetes, subject to utilization controls, to the extent that federal financial participation is available.(l)Hearing aids are covered, subject to utilization controls. Utilization controls shall allow replacement of hearing aids necessary because of loss or destruction due to circumstances beyond the beneficiarys control.(m)Durable medical equipment and medical supplies are covered, subject to utilization controls. The utilization controls shall allow the replacement of durable medical equipment and medical supplies when necessary because of loss or destruction due to circumstances beyond the beneficiarys control. The utilization controls shall allow authorization of durable medical equipment needed to assist a disabled beneficiary in caring for a child for whom the disabled beneficiary is a parent, stepparent, foster parent, or legal guardian, subject to the availability of federal financial participation. The department shall adopt emergency regulations to define and establish criteria for assistive durable medical equipment in accordance with the rulemaking provisions of the Administrative Procedure Act (Chapter 3.5 (commencing with Section 11340) of Part 1 of Division 3 of Title 2 of the Government Code).(n)Family planning services are covered, subject to utilization controls. However, for Medi-Cal managed care plans, utilization controls shall be subject to Section 1367.25 of the Health and Safety Code.(o)Inpatient intensive rehabilitation hospital services, including respiratory rehabilitation services, in a general acute care hospital are covered, subject to utilization controls, when either of the following criteria are met:(1)A patient with a permanent disability or severe impairment requires an inpatient intensive rehabilitation hospital program as described in Section 14064 to develop function beyond the limited amount that would occur in the normal course of recovery.(2)A patient with a chronic or progressive disease requires an inpatient intensive rehabilitation hospital program as described in Section 14064 to maintain the patients present functional level as long as possible.(p)(1)Adult day health care is covered in accordance with Chapter 8.7 (commencing with Section 14520).(2)Commencing 30 days after the effective date of the act that added this paragraph, and notwithstanding the number of days previously approved through a treatment authorization request, adult day health care is covered for a maximum of 3 days per week.(3)As provided in accordance with paragraph (4), adult day health care is covered for a maximum of five days per week.(4)As of the date that the director makes the declaration described in subdivision (g) of Section 14525.1, paragraph (2) shall become inoperative and paragraph (3) shall become operative.(q)(1)Application of fluoride, or other appropriate fluoride treatment as defined by the department, and other prophylaxis treatment for children 17 years of age or under are covered.(2)All dental hygiene services provided by a registered dental hygienist, registered dental hygienist in extended functions, and registered dental hygienist in alternative practice licensed pursuant to Sections 1753, 1917, 1918, and 1922 of the Business and Professions Code may be covered as long as they are within the scope of Denti-Cal benefits and they are necessary services provided by a registered dental hygienist, registered dental hygienist in extended functions, or registered dental hygienist in alternative practice.(r)(1)Paramedic services performed by a city, county, or special district, or pursuant to a contract with a city, county, or special district, and pursuant to a program established under former Article 3 (commencing with Section 1480) of Chapter 2.5 of Division 2 of the Health and Safety Code by a paramedic certified pursuant to that article, and consisting of defibrillation and those services specified in subdivision (3) of former Section 1482 of the article.(2)A provider enrolled under this subdivision shall satisfy all applicable statutory and regulatory requirements for becoming a Medi-Cal provider.(3)This subdivision shall be implemented only to the extent funding is available under Section 14106.6.(s)(1)In-home medical care services are covered when medically appropriate and subject to utilization controls, for a beneficiary who would otherwise require care for an extended period of time in an acute care hospital at a cost higher than in-home medical care services. The director shall have the authority under this section to contract with organizations qualified to provide in-home medical care services to those persons. These services may be provided to a patient placed in a shared or congregate living arrangement, if a home setting is not medically appropriate or available to the beneficiary.(2)As used in this subdivision, in-home medical care service includes utility bills directly attributable to continuous, 24-hour operation of life-sustaining medical equipment, to the extent that federal financial participation is available.(3)As used in this subdivision, in-home medical care services include, but are not limited to:(A)Level-of-care and cost-of-care evaluations.(B)Expenses, directly attributable to home care activities, for materials.(C)Physician fees for home visits.(D)Expenses directly attributable to home care activities for shelter and modification to shelter.(E)Expenses directly attributable to additional costs of special diets, including tube feeding.(F)Medically related personal services.(G)Home nursing education.(H)Emergency maintenance repair.(I)Home health agency personnel benefits that permit coverage of care during periods when regular personnel are on vacation or using sick leave.(J)All services needed to maintain antiseptic conditions at stoma or shunt sites on the body.(K)Emergency and nonemergency medical transportation.(L)Medical supplies.(M)Medical equipment, including, but not limited to, scales, gurneys, and equipment racks suitable for paralyzed patients.(N)Utility use directly attributable to the requirements of home care activities that are in addition to normal utility use.(O)Special drugs and medications.(P)Home health agency supervision of visiting staff that is medically necessary, but not included in the home health agency rate.(Q)Therapy services.(R)Household appliances and household utensil costs directly attributable to home care activities.(S)Modification of medical equipment for home use.(T)Training and orientation for use of life-support systems, including, but not limited to, support of respiratory functions.(U)Respiratory care practitioner services as defined in Sections 3702 and 3703 of the Business and Professions Code, subject to prescription by a physician and surgeon.(4)A beneficiary receiving in-home medical care services is entitled to the full range of services within the Medi-Cal scope of benefits as defined by this section, subject to medical necessity and applicable utilization control. Services provided pursuant to this subdivision, which are not otherwise included in the Medi-Cal schedule of benefits, shall be available only to the extent that federal financial participation for these services is available in accordance with a home- and community-based services waiver.(t)Home- and community-based services approved by the United States Department of Health and Human Services are covered to the extent that federal financial participation is available for those services under the state plan or waivers granted in accordance with Section 1315 or 1396n of Title 42 of the United States Code. The director may seek waivers for any or all home- and community-based services approvable under Section 1315 or 1396n of Title 42 of the United States Code. Coverage for those services shall be limited by the terms, conditions, and duration of the federal waivers.(u)Comprehensive perinatal services, as provided through an agreement with a health care provider designated in Section 14134.5 and meeting the standards developed by the department pursuant to Section 14134.5, subject to utilization controls.The department shall seek any federal waivers necessary to implement the provisions of this subdivision. The provisions for which appropriate federal waivers cannot be obtained shall not be implemented. Provisions for which waivers are obtained or for which waivers are not required shall be implemented notwithstanding any inability to obtain federal waivers for the other provisions. No provision of this subdivision shall be implemented unless matching funds from Subchapter XIX (commencing with Section 1396) of Chapter 7 of Title 42 of the United States Code are available.(v)Early and periodic screening, diagnosis, and treatment for any individual under 21 years of age is covered, consistent with the requirements of Subchapter XIX (commencing with Section 1396) of Chapter 7 of Title 42 of the United States Code.(w)(1)Hospice services are covered, in accordance with Medicare requirements, and are subject to utilization controls. Coverage shall be available only to the extent that no additional net program costs are incurred.(2)This subdivision shall be implemented only to the extent that federal financial participation is available and not otherwise jeopardized, and any necessary federal approvals have been obtained.(3)Notwithstanding any other law, the department, without taking any further regulatory action, may implement, interpret, or make specific this subdivision by means of all-county letters, plan letters, plan or provider bulletins, or similar instructions.(x)When a claim for treatment provided to a beneficiary includes both services that are authorized and reimbursable under this chapter and services that are not reimbursable under this chapter, that portion of the claim for the treatment and services authorized and reimbursable under this chapter shall be payable.(y)Home- and community-based services approved by the United States Department of Health and Human Services for a beneficiary with a diagnosis of Acquired Immune Deficiency Syndrome (AIDS) or AIDS-related complex, who requires intermediate care or a higher level of care.Services provided pursuant to a waiver obtained from the Secretary of the United States Department of Health and Human Services pursuant to this subdivision, and that are not otherwise included in the Medi-Cal schedule of benefits, shall be available only to the extent that federal financial participation for these services is available in accordance with the waiver, and subject to the terms, conditions, and duration of the waiver. These services shall be provided to a beneficiary in accordance with the clients needs as identified in the plan of care, and subject to medical necessity and applicable utilization control.The director may, under this section, contract with organizations qualified to provide, directly or by subcontract, services provided for in this subdivision to an eligible beneficiary. Contracts or agreements entered into pursuant to this division shall not be subject to the Public Contract Code.(z)Respiratory care when provided in organized health care systems as defined in Section 3701 of the Business and Professions Code, and as an in-home medical service as outlined in subdivision (s).(aa)(1)There is hereby established in the department a program to provide comprehensive clinical family planning services to any person who has a family income at or below 200 percent of the federal poverty level, as revised annually, and who is eligible to receive these services pursuant to the waiver identified in paragraph (2). This program shall be known as the Family Planning, Access, Care, and Treatment (Family PACT) Program.(2)The department shall seek a waiver in accordance with Section 1315 of Title 42 of the United States Code, or a state plan amendment adopted in accordance with Section 1396a(a)(10)(A)(ii)(XXI) of Title 42 of the United States Code, which was added to Section 1396a of Title 42 of the United States Code by Section 2303(a)(2) of the federal Patient Protection and Affordable Care Act (PPACA) (Public Law 111-148), for a program to provide comprehensive clinical family planning services as described in paragraph (8). Under the waiver, the program shall be operated only in accordance with the waiver and the statutes and regulations in paragraph (4) and subject to the terms, conditions, and duration of the waiver. Under the state plan amendment, which shall replace the waiver and shall be known as the Family PACT successor state plan amendment, the program shall be operated only in accordance with this subdivision and the statutes and regulations in paragraph (4). The state shall use the standards and processes imposed by the state on January 1, 2007, including the application of an eligibility discount factor to the extent required by the federal Centers for Medicare and Medicaid Services, for purposes of determining eligibility as permitted under Section 1396a(a)(10)(A)(ii)(XXI) of Title 42 of the United States Code. To the extent that federal financial participation is available, the program shall continue to conduct education, outreach, enrollment, service delivery, and evaluation services as specified under the waiver. The services shall be provided under the program only if the waiver and, when applicable, the successor state plan amendment are approved by the federal Centers for Medicare and Medicaid Services and only to the extent that federal financial participation is available for the services. This section does not prohibit the department from seeking the Family PACT successor state plan amendment during the operation of the waiver.(3)Solely for the purposes of the waiver or Family PACT successor state plan amendment and notwithstanding any other law, the collection and use of an individuals social security number shall be necessary only to the extent required by federal law.(4)Sections 14105.3 to 14105.39, inclusive, 14107.11, 24005, and 24013, and any regulations adopted under these statutes shall apply to the program provided for under this subdivision. No other law under the Medi-Cal program or the State-Only Family Planning Program shall apply to the program provided for under this subdivision.(5)Notwithstanding Chapter 3.5 (commencing with Section 11340) of Part 1 of Division 3 of Title 2 of the Government Code, the department may implement, without taking regulatory action, the provisions of the waiver after its approval by the federal Centers for Medicare and Medicaid Services and the provisions of this section by means of an all-county letter or similar instruction to providers. Thereafter, the department shall adopt regulations to implement this section and the approved waiver in accordance with the requirements of Chapter 3.5 (commencing with Section 11340) of Part 1 of Division 3 of Title 2 of the Government Code. Beginning six months after the effective date of the act adding this subdivision, the department shall provide a status report to the Legislature on a semiannual basis until regulations have been adopted.(6)If the Department of Finance determines that the program operated under the authority of the waiver described in paragraph (2) or the Family PACT successor state plan amendment is no longer cost effective, this subdivision shall become inoperative on the first day of the first month following the issuance of a 30-day notification of that determination in writing by the Department of Finance to the chairperson in each house that considers appropriations, the chairpersons of the committees, and the appropriate subcommittees in each house that considers the State Budget, and the Chairperson of the Joint Legislative Budget Committee.(7)If this subdivision ceases to be operative, all persons who have received or are eligible to receive comprehensive clinical family planning services pursuant to the waiver described in paragraph (2) shall receive family planning services under the Medi-Cal program pursuant to subdivision (n) if they are otherwise eligible for Medi-Cal with no spend down of excess income, or shall receive comprehensive clinical family planning services under the program established in Division 24 (commencing with Section 24000) either if they are eligible for Medi-Cal with a spend down of excess income or if they are otherwise eligible under Section 24003.(8)For purposes of this subdivision, comprehensive clinical family planning services means the process of establishing objectives for the number and spacing of children, and selecting the means by which those objectives may be achieved. These means include a broad range of acceptable and effective methods and services to limit or enhance fertility, including contraceptive methods, federal Food and Drug Administration-approved contraceptive drugs, devices, and supplies, natural family planning, abstinence methods, and basic, limited fertility management. Comprehensive clinical family planning services include, but are not limited to, preconception counseling, maternal and fetal health counseling, general reproductive health care, including diagnosis and treatment of infections and conditions, including cancer, that threaten reproductive capability, medical family planning treatment and procedures, including supplies and followup, and informational, counseling, and educational services. Comprehensive clinical family planning services shall not include abortion, pregnancy testing solely for the purposes of referral for abortion or services ancillary to abortions, or pregnancy care that is not incident to the diagnosis of pregnancy. Comprehensive clinical family planning services shall be subject to utilization control and include all of the following:(A)Family planning-related services and male and female sterilization. Family planning services for men and women shall include emergency services and services for complications directly related to the contraceptive method, federal Food and Drug Administration-approved contraceptive drugs, devices, and supplies, and followup, consultation, and referral services, as indicated, which may require treatment authorization requests.(B)All United States Department of Agriculture, federal Food and Drug Administration-approved contraceptive drugs, devices, and supplies that are in keeping with current standards of practice and from which the individual may choose.(C)Culturally and linguistically appropriate health education and counseling services, including informed consent, that include all of the following:(i)Psychosocial and medical aspects of contraception.(ii)Sexuality.(iii)Fertility.(iv)Pregnancy.(v)Parenthood.(vi)Infertility.(vii)Reproductive health care.(viii)Preconception and nutrition counseling.(ix)Prevention and treatment of sexually transmitted infection.(x)Use of contraceptive methods, federal Food and Drug Administration-approved contraceptive drugs, devices, and supplies.(xi)Possible contraceptive consequences and followup.(xii)Interpersonal communication and negotiation of relationships to assist individuals and couples in effective contraceptive method use and planning families.(D)A comprehensive health history, updated at the next periodic visit (between 11 and 24 months after initial examination) that includes a complete obstetrical history, gynecological history, contraceptive history, personal medical history, health risk factors, and family health history, including genetic or hereditary conditions.(E)A complete physical examination on initial and subsequent periodic visits.(F)Services, drugs, devices, and supplies deemed by the federal Centers for Medicare and Medicaid Services to be appropriate for inclusion in the program.(G)(i)Home test kits for sexually transmitted diseases, including any laboratory costs of processing the kit, that are deemed medically necessary or appropriate and ordered directly by an enrolled Medi-Cal or Family PACT clinician or furnished through a standing order for patient use based on clinical guidelines and individual patient health needs.(ii)For purposes of this subparagraph, home test kit means a product used for a test recommended by the federal Centers for Disease Control and Prevention guidelines or the United States Preventive Services Task Force that has been CLIA-waived, FDA-cleared or -approved, or developed by a laboratory in accordance with established regulations and quality standards, to allow individuals to self-collect specimens for STDs, including HIV, remotely at a location outside of a clinical setting.(iii)The home test kit shall be sent by the enrolled Family PACT provider to a Medi-Cal-enrolled laboratory with fee based on Medicare Clinical Diagnostic Laboratory Tests Payment System Final Rule.(9)In order to maximize the availability of federal financial participation under this subdivision, the director shall have the discretion to implement the Family PACT successor state plan amendment retroactively to July 1, 2010.(ab)(1)Purchase of prescribed enteral nutrition products is covered, subject to the Medi-Cal list of enteral nutrition products and utilization controls.(2)Purchase of enteral nutrition products is limited to those products to be administered through a feeding tube, including, but not limited to, a gastric, nasogastric, or jejunostomy tube. A beneficiary under the Early and Periodic Screening, Diagnostic, and Treatment Program shall be exempt from this paragraph.(3)Notwithstanding paragraph (2), the department may deem an enteral nutrition product, not administered through a feeding tube, including, but not limited to, a gastric, nasogastric, or jejunostomy tube, a benefit for patients with diagnoses, including, but not limited to, malabsorption and inborn errors of metabolism, if the product has been shown to be neither investigational nor experimental when used as part of a therapeutic regimen to prevent serious disability or death.(4)Notwithstanding Chapter 3.5 (commencing with Section 11340) of Part 1 of Division 3 of Title 2 of the Government Code, the department may implement the amendments to this subdivision made by the act that added this paragraph by means of all-county letters, provider bulletins, or similar instructions, without taking regulatory action.(5)The amendments made to this subdivision by the act that added this paragraph shall be implemented June 1, 2011, or on the first day of the first calendar month following 60 days after the date the department secures all necessary federal approvals to implement this section, whichever is later.(ac)Diabetic testing supplies are covered when provided by a pharmacy, subject to utilization controls.(ad)(1)Nonmedical transportation is covered, subject to utilization controls and permissible time and distance standards, for a beneficiary to obtain covered Medi-Cal services.(2)(A)(i)Nonmedical transportation includes, at a minimum, round trip transportation for a beneficiary to obtain covered Medi-Cal services by passenger car, taxicab, or any other form of public or private conveyance, and mileage reimbursement when conveyance is in a private vehicle arranged by the beneficiary and not through a transportation broker, bus passes, taxi vouchers, or train tickets.(ii)Nonmedical transportation does not include the transportation of a sick, injured, invalid, convalescent, infirm, or otherwise incapacitated beneficiary by ambulance, litter van, or wheelchair van licensed, operated, and equipped in accordance with state and local statutes, ordinances, or regulations.(B)Nonmedical transportation shall be provided for a beneficiary who can attest in a manner to be specified by the department that other currently available resources have been reasonably exhausted. For a beneficiary enrolled in a managed care plan, nonmedical transportation shall be provided by the beneficiarys managed care plan. For a Medi-Cal fee-for-service beneficiary, the department shall provide nonmedical transportation when those services are not available to the beneficiary under Sections 14132.44 and 14132.47.(3)Nonmedical transportation shall be provided in a form and manner that is accessible, in terms of physical and geographic accessibility, for the beneficiary and consistent with applicable state and federal disability rights laws.(4)It is the intent of the Legislature in enacting this subdivision to affirm the requirement under Section 431.53 of Title 42 of the Code of Federal Regulations, in which the department is required to provide necessary transportation, including nonmedical transportation, for recipients to and from covered services. This subdivision shall not be interpreted to add a new benefit to the Medi-Cal program.(5)The department shall seek any federal approvals that may be required to implement this subdivision, including, but not limited to, approval of revisions to the existing state plan that the department determines are necessary to implement this subdivision.(6)This subdivision shall be implemented only to the extent that federal financial participation is available and not otherwise jeopardized and any necessary federal approvals have been obtained.(7)Prior to the effective date of any necessary federal approvals, nonmedical transportation was not a Medi-Cal managed care benefit with the exception of when provided as an Early and Periodic Screening, Diagnostic, and Treatment service.(8)Notwithstanding Chapter 3.5 (commencing with Section 11340) of Part 1 of Division 3 of Title 2 of the Government Code, the department, without taking any further regulatory action, shall implement, interpret, or make specific this subdivision by means of all-county letters, plan letters, plan or provider bulletins, or similar instructions until the time regulations are adopted. By July 1, 2018, the department shall adopt regulations in accordance with the requirements of Chapter 3.5 (commencing with Section 11340) of Part 1 of Division 3 of Title 2 of the Government Code. Commencing January 1, 2018, and notwithstanding Section 10231.5 of the Government Code, the department shall provide a status report to the Legislature on a semiannual basis, in compliance with Section 9795 of the Government Code, until regulations have been adopted.(9)This subdivision shall not be implemented until July 1, 2017.(ae)(1)No sooner than January 1, 2022, Rapid Whole Genome Sequencing, including individual sequencing, trio sequencing for a parent or parents and their baby, and ultra-rapid sequencing, is a covered benefit for any Medi-Cal beneficiary who is one year of age or younger and is receiving inpatient hospital services in an intensive care unit.(2)Notwithstanding Chapter 3.5 (commencing with Section 11340) of Part 1 of Division 3 of Title 2 of the Government Code, the department, without taking any further regulatory action, shall implement, interpret, or make specific this subdivision by means of all-county letters, plan letters, plan or provider bulletins, or similar instructions until the time regulations are adopted.(3)This subdivision shall be implemented only to the extent that any necessary federal approvals are obtained, and federal financial participation is available and not otherwise jeopardized.(af)(1)Home test kits for sexually transmitted diseases that are deemed medically necessary or appropriate and ordered directly by an enrolled Medi-Cal clinician or furnished through a standing order for patient use based on clinical guidelines and individual patient health needs.(2)For purposes of this subdivision, home test kit means a product used for a test recommended by the federal Centers for Disease Control and Prevention guidelines or the United States Preventive Services Task Force that has been CLIA-waived, FDA-cleared or -approved, or developed by a laboratory in accordance with established regulations and quality standards, to allow individuals to self-collect specimens for STDs, including HIV, remotely at a location outside of a clinical setting.(3)The home test kit shall be sent by the enrolled Medi-Cal provider to a Medi-Cal-enrolled laboratory with fee based on Medicare Clinical Diagnostic Laboratory Tests Payment System Final Rule.(4)This subdivision shall be implemented only to the extent that federal financial participation is available and not otherwise jeopardized, and any necessary federal approvals have been obtained.(5)Notwithstanding Chapter 3.5 (commencing with Section 11340) of Part 1 of Division 3 of Title 2 of the Government Code, the State Department of Health Care Services may implement this subdivision by means of all-county letters, plan letters, plan or provider bulletins, or similar instructions, without taking any further regulatory action.(ag)(1)Violence prevention services are covered, subject to medical necessity and utilization controls.(2)Notwithstanding Chapter 3.5 (commencing with Section 11340) of Part 1 of Division 3 of Title 2 of the Government Code, the department, without taking any further regulatory action, may implement, interpret, or make specific this subdivision by means of all-county letters, plan letters, plan or provider bulletins, or similar instructions until the time regulations are adopted.(3)This subdivision shall be implemented only to the extent that any necessary federal approvals are obtained, and federal financial participation is available and not otherwise jeopardized.(4)The department shall post on its internet website the date upon which violence prevention services may be provided and billed pursuant to this subdivision.(5)Violence prevention services means evidence-based, trauma-informed, and culturally responsive preventive services provided to reduce the incidence of violent injury or reinjury, trauma, and related harms and promote trauma recovery, stabilization, and improved health outcomes.SEC. 4.SEC. 3.Section 14132.17 of the Welfare and Institutions Code is amended to read:14132.17.(a)Cervical cancer tests for screening that are ordered by a patients health care provider and consistent with nationally recognized clinical guidelines any relevant recommendations published pursuant to Section 120164 of the Health and Safety Code are a covered benefit under this chapter, on or after January 1, 2027, subject to medical necessity and utilization management controls, to the extent required or permitted by federal law.
(b)(1)The United States Food and Drug Administration-authorized or cleared cervical Cervical cancer home test kits for screening that are ordered by a patients health care provider and consistent with nationally recognized clinical guidelines allow patients to self-collect samples and are United States Food and Drug Administration-authorized or cleared are a covered benefit under this chapter, on or after January 1, 2027, subject to medical necessity and utilization management controls, to the extent required or permitted by federal law.
(2)A test described in paragraph (1) shall be ordered or provided by a patients health care provider and shall be consistent with both of the following:
(A)Any relevant recommendations published pursuant to Section 120164 of the Health and Safety Code.
(B)Medi-Cal policies.
(3)Reimbursement for a test described in paragraph (1) shall use a clinically appropriate Current Procedural Terminology or Healthcare Common Procedure Coding System billing code in order to comply with Health Insurance Portability and Accountability Act requirements.
(2)(4)A Medi-Cal beneficiary is not subject to any cost sharing, including, but not limited to, a share of cost or spend down of excess income as described in Section 14054 for the benefit described in this subdivision.
(3)(5)This subdivision applies to both the fee-for-service delivery system and the managed care delivery system under the Medi-Cal program.
(6)The coverage described in this subdivision is a covered benefit only to the extent that federal financial participation is available and not otherwise jeopardized and any necessary federal approvals have been obtained.
(7)Notwithstanding any other law, the department, without taking any further regulatory action, may implement, interpret, or make specific this subdivision by means of all-county letters, plan letters, plan or provider bulletins, or similar instructions.
SEC. 5.Section 24007 of the Welfare and Institutions Code is amended to read:24007.(a)The department shall determine the scope of benefits for the program, which shall include, but is not limited to, the following:(1)Family planning-related services and male and female sterilization. Family planning services for men and women include emergency and complication services directly related to the contraceptive method and followup, consultation, and referral services, as indicated, that may require treatment authorization requests.(2)All United States Department of Health and Human Services, Federal Drug Administration-approved birth control methods, devices, and supplies that are in keeping with current standards of practice and from which the individual may choose.(3)Culturally and linguistically appropriate health education and counseling services, including informed consent; psychosocial and medical aspects of contraception, sexuality, fertility, pregnancy, and parenthood; infertility; reproductive health care; preconceptual and nutrition counseling; prevention and treatment of sexually transmitted infection; use of contraceptive methods, devices, and supplies; possible contraceptive consequences and followup; interpersonal communication and negotiation of relationships to assist individuals and couples in effective contraceptive method use and planning families.(4)A comprehensive health history, updated at the next periodic visit (between 11 and 24 months after initial examination) that includes a complete obstetrical history, gynecological history, contraceptive history, personal medical history, health risk factors, and family health history, including genetic or hereditary conditions.(5)A complete physical examination on initial and subsequent periodic visits.(6)(A)Home test kits for sexually transmitted diseases, including any laboratory costs of processing the kit, that are deemed medically necessary or appropriate and ordered directly by an enrolled Family PACT clinician or furnished through a standing order for patient use based on clinical guidelines and individual patient health needs.(B)For purposes of this paragraph, home test kit means a product used for a test recommended by the federal Centers for Disease Control and Prevention guidelines or the United States Preventive Services Task Force that has been CLIA-waived, FDA-cleared or -approved, or developed by a laboratory in accordance with established regulations and quality standards, to allow individuals to self-collect specimens for STDs, including HIV, remotely at a location outside of a clinical setting.(C)The home test kit shall be sent by the enrolled Family PACT provider to a Medi-Cal-enrolled laboratory with fee based on Medicare Clinical Diagnostic Laboratory Tests Payment System Final Rule.(D)This paragraph shall be implemented only to the extent that federal financial participation is available and not otherwise jeopardized, and any necessary federal approvals have been obtained.(b)Benefits under this program shall be effective in 30 days after notice to providers, but not sooner than January 1, 1997.SEC. 6.SEC. 4.No reimbursement is required by this act pursuant to Section 6 of Article XIIIB of the California Constitution because the only costs that may be incurred by a local agency or school district will be incurred because this act creates a new crime or infraction, eliminates a crime or infraction, or changes the penalty for a crime or infraction, within the meaning of Section 17556 of the Government Code, or changes the definition of a crime within the meaning of Section 6 of Article XIIIB of the California Constitution.
(a)(1)A individual or group health care service plan contract, except for a specialized health care service plan, issued, amended, or renewed on or after January 1, 2002, shall provide coverage for an annual cervical cancer screening test upon the referral of the patients physician and surgeon, a nurse practitioner, or a certified nurse-midwife, providing care to the patient and operating within the scope of practice otherwise permitted for the licensee. 2027, shall provide coverage for cervical cancer screening when ordered or provided by an in-network provider operating within their permitted scope of practice and consistent with nationally recognized clinical guidelines.
(2)A health care service plan contract, except for a specialized health care service plan, issued, amended, or renewed on or after January 1, 2027, shall provide coverage for an annual cervical cancer screening home test kit upon the referral of the patients health care provider. A health care service plan contract shall not impose a deductible, coinsurance, copayment, or any other cost-sharing requirement on the coverage provided pursuant to this paragraph.(3)(2)The coverage for an annual a cervical cancer screening test provided pursuant to this subdivision shall include the conventional Pap test, a human papillomavirus screening test that is approved by the United States Food and Drug Administration (FDA), and the option of any cervical cancer screening test approved by the FDA, upon the referral of the patients health care provider. including FDA-authorized or cleared self-collected cervical screening kits that allow patients to self-collect samples at a location outside of a clinical setting, and the option of any cervical cancer screening test approved by the FDA that is ordered or provided by the patients health care provider.
(4)This subdivision does not establish a new mandated benefit or prevent application of deductible or copayment provisions in an existing plan contract. The Legislature intends in this section to provide that cervical cancer screening services are deemed to be covered if the plan contract includes coverage for cervical cancer treatment or surgery.(b)A health care service plan contract, except for a specialized health care service plan, issued, amended, or renewed on or after January 1, 2024, shall provide coverage for the human papillomavirus vaccine for enrollees for whom the vaccine is approved by the FDA. A health care service plan contract shall not impose a deductible, coinsurance, copayment, or any other cost-sharing requirement on the coverage provided pursuant to this subdivision.
(c)A health care service plan contract shall not impose a deductible, coinsurance, copayment, or any other cost-sharing requirement on the coverage provided pursuant to this section.
(d)The cost-sharing requirements described in subdivision (c) shall only apply to a health savings account-eligible health care service plan to the extent the plan does not fail to be treated as a high deductible health plan under Section 223 of Title 26 of the United States Code.
(e)This section does not limit the application of Section 1367.002.
SEC. 2.Section 10123.18 of the Insurance Code is amended to read:10123.18.(a)(1)A disability insurance policy issued, amended, or renewed on or after January 1, 2024, and that provides coverage for hospital, medical, or surgical benefits shall provide coverage, upon the referral of a patients physician and surgeon, a nurse practitioner, or a certified nurse-midwife, providing care to the patient and operating within the scope of practice otherwise permitted for the licensee, for an annual cervical cancer screening test.(2)A disability insurance policy issued, amended, or renewed on or after January 1, 2027, shall provide coverage for an annual cervical cancer screening home test kit upon the referral of a patients health care provider. A health insurance policy shall not impose a deductible, coinsurance, copayment, or any other cost-sharing requirement on the coverage provided pursuant to this paragraph.10123.18.(a)(1)A health insurance policy issued, amended, or renewed on or after January 1, 2027, shall provide coverage for cervical cancer screening when ordered or provided by an in-network provider operating within their permitted scope of practice and consistent with nationally recognized clinical guidelines.
(3)(2)The coverage for an annual a cervical cancer screening test provided pursuant to this subdivision shall include the conventional Pap test, a human papillomavirus screening test that is approved by the United States Food and Drug Administration (FDA) and the option of any cervical cancer screening test approved by the FDA, upon the referral of the patients health care provider. (FDA), including FDA-authorized or cleared self-collected cervical screening kits that allow patients to self-collect samples at a location outside of a clinical setting, and the option of any cervical cancer screening test approved by the FDA that is ordered or provided by the patients health care provider.
(4)(3)This subdivision does not require an individual or group policy to cover treatment or surgery for cervical cancer or to prevent application of deductible or copayment provisions contained in the policy or certificate, and does not require that coverage under an individual or group policy be extended to any other procedures.
(b)A disability health insurance policy issued, amended, or renewed on or after January 1, 2024, that provides coverage for hospital, medical, or surgical benefits shall provide coverage for the human papillomavirus vaccine for insureds for whom the vaccine is approved by the FDA. The policy shall not impose a deductible, coinsurance, copayment, or any other cost-sharing requirement on the coverage provided pursuant to this subdivision.
(c)This section shall not apply to vision-only, dental-only, accident-only, specified disease, hospital indemnity, Medicare supplement, CHAMPUS supplement, long-term care, or disability income insurance. For accident-only, hospital indemnity, or specified disease insurance, coverage for benefits under this section shall apply only to the extent that the benefits are covered under the general terms and conditions that apply to all other benefits under the policy or certificate. This section does not impose a new benefit mandate on accident-only, hospital indemnity, or specified disease insurance.(c)A health insurance policy shall not impose a deductible, coinsurance, copayment, or any other cost-sharing requirement on the coverage provided pursuant to this section.
(d)The cost-sharing requirements described in subdivision (c) shall only apply to a health savings account-eligible health insurance policy to the extent it does not fail to be treated as a high deductible health plan under Section 223 of Title 26 of the United States Code.
(e)This section does not limit the application of Section 10112.2.
SEC. 3.Section 14132 of the Welfare and Institutions Code is amended to read:14132.The following is the schedule of benefits under this chapter:
(a)Outpatient services are covered as follows:
Physician, hospital or clinic outpatient, surgical center, respiratory care, optometric, chiropractic, psychology, podiatric, occupational therapy, physical therapy, speech therapy, audiology, acupuncture to the extent federal matching funds are provided for acupuncture, and services of persons rendering treatment by prayer or healing by spiritual means in the practice of any church or religious denomination insofar as these can be encompassed by federal participation under an approved plan, subject to utilization controls.
(b)(1)Inpatient hospital services, including, but not limited to, physician and podiatric services, physical therapy, and occupational therapy, are covered subject to utilization controls.
(2)For a Medi-Cal fee-for-service beneficiary, emergency services and care that are necessary for the treatment of an emergency medical condition and medical care directly related to the emergency medical condition. This paragraph does not change the obligation of Medi-Cal managed care plans to provide emergency services and care. For the purposes of this paragraph, emergency services and care and emergency medical condition have the same meanings as those terms are defined in Section 1317.1 of the Health and Safety Code.
(c)Nursing facility services, subacute care services, and services provided by any category of intermediate care facility for the developmentally disabled, including podiatry, physician, nurse practitioner services, and prescribed drugs, as described in subdivision (d), are covered subject to utilization controls. Respiratory care, physical therapy, occupational therapy, speech therapy, and audiology services for patients in nursing facilities and any category of intermediate care facility for persons with developmental disabilities are covered subject to utilization controls.
(d)(1)Purchase of prescribed drugs is covered subject to the Medi-Cal List of Contract Drugs and utilization controls.
(2)Purchase of drugs used to treat erectile dysfunction or any off-label uses of those drugs are covered only to the extent that federal financial participation is available.
(3)(A)To the extent required by federal law, the purchase of outpatient prescribed drugs, for which the prescription is executed by a prescriber in written, nonelectronic form on or after April 1, 2008, is covered only when executed on a tamper resistant tamper-resistant prescription form. The implementation of this paragraph shall conform to the guidance issued by the federal Centers for Medicare and Medicaid Services, but shall not conflict with state statutes on the characteristics of tamper resistant tamper-resistant prescriptions for controlled substances, including Section 11162.1 of the Health and Safety Code. The department shall provide providers and beneficiaries with as much flexibility in implementing these rules as allowed by the federal government. The department shall notify and consult with appropriate stakeholders in implementing, interpreting, or making specific this paragraph.
(B)Notwithstanding Chapter 3.5 (commencing with Section 11340) of Part 1 of Division 3 of Title 2 of the Government Code, the department may take the actions specified in subparagraph (A) by means of a provider bulletin or notice, policy letter, or other similar instructions without taking regulatory action.
(4)(A)(i)For the purposes of this paragraph, nonlegend nonlegend has the same meaning as defined in subdivision (a) of Section 14105.45.
(ii)Nonlegend acetaminophen-containing products, including childrens acetaminophen-containing products, selected by the department are covered benefits.
(iii)Nonlegend cough and cold products selected by the department are covered benefits.
(B)Notwithstanding Chapter 3.5 (commencing with Section 11340) of Part 1 of Division 3 of Title 2 of the Government Code, the department may take the actions specified in subparagraph (A) by means of a provider bulletin or notice, policy letter, or other similar instruction without taking regulatory action.
(e)Outpatient dialysis services and home hemodialysis services, including physician services, medical supplies, drugs, and equipment required for dialysis, are covered, subject to utilization controls.
(f)Anesthesiologist services when provided as part of an outpatient medical procedure, nurse anesthetist services when rendered in an inpatient or outpatient setting under conditions set forth by the director, outpatient laboratory services, and x-ray services are covered, subject to utilization controls. This subdivision does not require prior authorization for anesthesiologist services provided as part of an outpatient medical procedure or for portable x-ray services in a nursing facility or any category of intermediate care facility for the developmentally disabled.
(g)Blood and blood derivatives are covered.
(h)(1)Emergency and essential diagnostic and restorative dental services, except for orthodontic, fixed bridgework, and partial dentures that are not necessary for balance of a complete artificial denture, are covered, subject to utilization controls. The utilization controls shall allow emergency and essential diagnostic and restorative dental services and prostheses that are necessary to prevent a significant disability or to replace previously furnished prostheses that are lost or destroyed due to circumstances beyond the beneficiarys control. Notwithstanding the foregoing, the director may by regulation provide for certain fixed artificial dentures necessary for obtaining employment or for medical conditions that preclude the use of removable dental prostheses, and for orthodontic services in cleft palate deformities administered by the departments California Childrens Services program.
(2)For persons 21 years of age or older, the services specified in paragraph (1) shall be provided subject to the following conditions:
(A)Periodontal treatment is not a benefit.
(B)Endodontic therapy is not a benefit except for vital pulpotomy.
(C)Laboratory processed crowns are not a benefit.
(D)Removable prosthetics shall be a benefit only for patients as a requirement for employment.
(E)The director may, by regulation, provide for the provision of fixed artificial dentures that are necessary for medical conditions that preclude the use of removable dental prostheses.
(F)Notwithstanding the conditions specified in subparagraphs (A) to (E), inclusive, the department may approve services for persons with special medical disorders subject to utilization review.
(3)Paragraph (2) shall become inoperative on July 1, 1995.
(i)Medical transportation is covered, subject to utilization controls.
(j)Home health care services are covered, subject to utilization controls.
(k)(1)Prosthetic and orthotic devices and eyeglasses are covered, subject to utilization controls. Utilization controls shall allow replacement of prosthetic and orthotic devices and eyeglasses necessary because of loss or destruction due to circumstances beyond the beneficiarys control. Frame styles for eyeglasses replaced pursuant to this subdivision shall not change more than once every two years, unless the department so directs.
(2)Orthopedic and conventional shoes are covered when provided by a prosthetic and orthotic supplier on the prescription of a physician and when at least one of the shoes will be attached to a prosthesis or brace, subject to utilization controls. Modification of stock conventional or orthopedic shoes when medically indicated is covered, subject to utilization controls. If there is a clearly established medical need that cannot be satisfied by the modification of stock conventional or orthopedic shoes, custom-made orthopedic shoes are covered, subject to utilization controls.
(3)Therapeutic shoes and inserts are covered when provided to a beneficiary with a diagnosis of diabetes, subject to utilization controls, to the extent that federal financial participation is available.
(l)Hearing aids are covered, subject to utilization controls. Utilization controls shall allow replacement of hearing aids necessary because of loss or destruction due to circumstances beyond the beneficiarys control.
(m)Durable medical equipment and medical supplies are covered, subject to utilization controls. The utilization controls shall allow the replacement of durable medical equipment and medical supplies when necessary because of loss or destruction due to circumstances beyond the beneficiarys control. The utilization controls shall allow authorization of durable medical equipment needed to assist a disabled beneficiary in caring for a child for whom the disabled beneficiary is a parent, stepparent, foster parent, or legal guardian, subject to the availability of federal financial participation. The department shall adopt emergency regulations to define and establish criteria for assistive durable medical equipment in accordance with the rulemaking provisions of the Administrative Procedure Act (Chapter 3.5 (commencing with Section 11340) of Part 1 of Division 3 of Title 2 of the Government Code).
(n)Family planning services are covered, subject to utilization controls. However, for Medi-Cal managed care plans, utilization controls shall be subject to Section 1367.25 of the Health and Safety Code.
(o)Inpatient intensive rehabilitation hospital services, including respiratory rehabilitation services, in a general acute care hospital are covered, subject to utilization controls, when either of the following criteria are met:
(1)A patient with a permanent disability or severe impairment requires an inpatient intensive rehabilitation hospital program as described in Section 14064 to develop function beyond the limited amount that would occur in the normal course of recovery.
(2)A patient with a chronic or progressive disease requires an inpatient intensive rehabilitation hospital program as described in Section 14064 to maintain the patients present functional level as long as possible.
(p)(1)Adult day health care is covered in accordance with Chapter 8.7 (commencing with Section 14520).
(2)Commencing 30 days after the effective date of the act that added this paragraph, and notwithstanding the number of days previously approved through a treatment authorization request, adult day health care is covered for a maximum of three 3 days per week.
(3)As provided in accordance with paragraph (4), adult day health care is covered for a maximum of five days per week.
(4)As of the date that the director makes the declaration described in subdivision (g) of Section 14525.1, paragraph (2) shall become inoperative and paragraph (3) shall become operative.
(q)(1)Application of fluoride, or other appropriate fluoride treatment as defined by the department, and other prophylaxis treatment for children 17 years of age and or under are covered.
(2)All dental hygiene services provided by a registered dental hygienist, registered dental hygienist in extended functions, and registered dental hygienist in alternative practice licensed pursuant to Sections 1753, 1917, 1918, and 1922 of the Business and Professions Code may be covered as long as they are within the scope of Denti-Cal benefits and they are necessary services provided by a registered dental hygienist, registered dental hygienist in extended functions, or registered dental hygienist in alternative practice.
(r)(1)Paramedic services performed by a city, county, or special district, or pursuant to a contract with a city, county, or special district, and pursuant to a program established under former Article 3 (commencing with Section 1480) of Chapter 2.5 of Division 2 of the Health and Safety Code by a paramedic certified pursuant to that article, and consisting of defibrillation and those services specified in subdivision (3) of former Section 1482 of the article.
(2)A provider enrolled under this subdivision shall satisfy all applicable statutory and regulatory requirements for becoming a Medi-Cal provider.
(3)This subdivision shall be implemented only to the extent funding is available under Section 14106.6.
(s)(1)In-home medical care services are covered when medically appropriate and subject to utilization controls, for a beneficiary who would otherwise require care for an extended period of time in an acute care hospital at a cost higher than in-home medical care services. The director shall have the authority under this section to contract with organizations qualified to provide in-home medical care services to those persons. These services may be provided to a patient placed in a shared or congregate living arrangement, if a home setting is not medically appropriate or available to the beneficiary.
(2)As used in this subdivision, in-home medical care service includes utility bills directly attributable to continuous, 24-hour operation of life-sustaining medical equipment, to the extent that federal financial participation is available.
(3)As used in this subdivision, in-home medical care services include, but are not limited to:
(A)Level-of-care and cost-of-care evaluations.
(B)Expenses, directly attributable to home care activities, for materials.
(C)Physician fees for home visits.
(D)Expenses directly attributable to home care activities for shelter and modification to shelter.
(E)Expenses directly attributable to additional costs of special diets, including tube feeding.
(F)Medically related personal services.
(G)Home nursing education.
(H)Emergency maintenance repair.
(I)Home health agency personnel benefits that permit coverage of care during periods when regular personnel are on vacation or using sick leave.
(J)All services needed to maintain antiseptic conditions at stoma or shunt sites on the body.
(K)Emergency and nonemergency medical transportation.
(L)Medical supplies.
(M)Medical equipment, including, but not limited to, scales, gurneys, and equipment racks suitable for paralyzed patients.
(N)Utility use directly attributable to the requirements of home care activities that are in addition to normal utility use.
(O)Special drugs and medications.
(P)Home health agency supervision of visiting staff that is medically necessary, but not included in the home health agency rate.
(Q)Therapy services.
(R)Household appliances and household utensil costs directly attributable to home care activities.
(S)Modification of medical equipment for home use.
(T)Training and orientation for use of life-support systems, including, but not limited to, support of respiratory functions.
(U)Respiratory care practitioner services as defined in Sections 3702 and 3703 of the Business and Professions Code, subject to prescription by a physician and surgeon.
(4)A beneficiary receiving in-home medical care services is entitled to the full range of services within the Medi-Cal scope of benefits as defined by this section, subject to medical necessity and applicable utilization control. Services provided pursuant to this subdivision, which are not otherwise included in the Medi-Cal schedule of benefits, shall be available only to the extent that federal financial participation for these services is available in accordance with a home- and community-based services waiver.
(t)Home- and community-based services approved by the United States Department of Health and Human Services are covered to the extent that federal financial participation is available for those services under the state plan or waivers granted in accordance with Section 1315 or 1396n of Title 42 of the United States Code. The director may seek waivers for any or all home- and community-based services approvable under Section 1315 or 1396n of Title 42 of the United States Code. Coverage for those services shall be limited by the terms, conditions, and duration of the federal waivers.
(u)Comprehensive perinatal services, as provided through an agreement with a health care provider designated in Section 14134.5 and meeting the standards developed by the department pursuant to Section 14134.5, subject to utilization controls.
The department shall seek any federal waivers necessary to implement the provisions of this subdivision. The provisions for which appropriate federal waivers cannot be obtained shall not be implemented. Provisions for which waivers are obtained or for which waivers are not required shall be implemented notwithstanding any inability to obtain federal waivers for the other provisions. No provision of this subdivision shall be implemented unless matching funds from Subchapter XIX (commencing with Section 1396) of Chapter 7 of Title 42 of the United States Code are available.
(v)Early and periodic screening, diagnosis, and treatment for any individual under 21 years of age is covered, consistent with the requirements of Subchapter XIX (commencing with Section 1396) of Chapter 7 of Title 42 of the United States Code.
(w)(1)Hospice services are covered, in accordance with Medicare requirements, and are subject to utilization controls. Coverage shall be available only to the extent that no additional net program costs are incurred.
(2)This subdivision shall be implemented only to the extent that federal financial participation is available and not otherwise jeopardized, and any necessary federal approvals have been obtained.
(3)Notwithstanding any other law, the department, without taking any further regulatory action, may implement, interpret, or make specific this subdivision by means of all-county letters, plan letters, plan or provider bulletins, or similar instructions.
(x)When a claim for treatment provided to a beneficiary includes both services that are authorized and reimbursable under this chapter and services that are not reimbursable under this chapter, that portion of the claim for the treatment and services authorized and reimbursable under this chapter shall be payable.
(y)Home- and community-based services approved by the United States Department of Health and Human Services for a beneficiary with a diagnosis of Acquired Immune Deficiency Syndrome (AIDS) or AIDS-related complex, who requires intermediate care or a higher level of care.
Services provided pursuant to a waiver obtained from the Secretary of the United States Department of Health and Human Services pursuant to this subdivision, and that are not otherwise included in the Medi-Cal schedule of benefits, shall be available only to the extent that federal financial participation for these services is available in accordance with the waiver, and subject to the terms, conditions, and duration of the waiver. These services shall be provided to a beneficiary in accordance with the clients needs as identified in the plan of care, and subject to medical necessity and applicable utilization control.
The director may, under this section, contract with organizations qualified to provide, directly or by subcontract, services provided for in this subdivision to an eligible beneficiary. Contracts or agreements entered into pursuant to this division shall not be subject to the Public Contract Code.
(z)Respiratory care when provided in organized health care systems as defined in Section 3701 of the Business and Professions Code, and as an in-home medical service as outlined in subdivision (s).
(aa)(1)There is hereby established in the department a program to provide comprehensive clinical family planning services to any person who has a family income at or below 200 percent of the federal poverty level, as revised annually, and who is eligible to receive these services pursuant to the waiver identified in paragraph (2). This program shall be known as the Family Planning, Access, Care, and Treatment (Family PACT) Program.
(2)The department shall seek a waiver in accordance with Section 1315 of Title 42 of the United States Code, or a state plan amendment adopted in accordance with Section 1396a(a)(10)(A)(ii)(XXI) of Title 42 of the United States Code, which was added to Section 1396a of Title 42 of the United States Code by Section 2303(a)(2) of the federal Patient Protection and Affordable Care Act (PPACA) (Public Law 111-148), for a program to provide comprehensive clinical family planning services as described in paragraph (8). Under the waiver, the program shall be operated only in accordance with the waiver and the statutes and regulations in paragraph (4) and subject to the terms, conditions, and duration of the waiver. Under the state plan amendment, which shall replace the waiver and shall be known as the Family PACT successor state plan amendment, the program shall be operated only in accordance with this subdivision and the statutes and regulations in paragraph (4). The state shall use the standards and processes imposed by the state on January 1, 2007, including the application of an eligibility discount factor to the extent required by the federal Centers for Medicare and Medicaid Services, for purposes of determining eligibility as permitted under Section 1396a(a)(10)(A)(ii)(XXI) of Title 42 of the United States Code. To the extent that federal financial participation is available, the program shall continue to conduct education, outreach, enrollment, service delivery, and evaluation services as specified under the waiver. The services shall be provided under the program only if the waiver and, when applicable, the successor state plan amendment are approved by the federal Centers for Medicare and Medicaid Services and only to the extent that federal financial participation is available for the services. This section does not prohibit the department from seeking the Family PACT successor state plan amendment during the operation of the waiver.
(3)Solely for the purposes of the waiver or Family PACT successor state plan amendment and notwithstanding any other law, the collection and use of an individuals social security number shall be necessary only to the extent required by federal law.
(4)Sections 14105.3 to 14105.39, inclusive, 14107.11, 24005, and 24013, and any regulations adopted under these statutes shall apply to the program provided for under this subdivision. No other law under the Medi-Cal program or the State-Only Family Planning Program shall apply to the program provided for under this subdivision.
(5)Notwithstanding Chapter 3.5 (commencing with Section 11340) of Part 1 of Division 3 of Title 2 of the Government Code, the department may implement, without taking regulatory action, the provisions of the waiver after its approval by the federal Centers for Medicare and Medicaid Services and the provisions of this section by means of an all-county letter or similar instruction to providers. Thereafter, the department shall adopt regulations to implement this section and the approved waiver in accordance with the requirements of Chapter 3.5 (commencing with Section 11340) of Part 1 of Division 3 of Title 2 of the Government Code. Beginning six months after the effective date of the act adding this subdivision, the department shall provide a status report to the Legislature on a semiannual basis until regulations have been adopted.
(6)If the Department of Finance determines that the program operated under the authority of the waiver described in paragraph (2) or the Family PACT successor state plan amendment is no longer cost effective, this subdivision shall become inoperative on the first day of the first month following the issuance of a 30-day notification of that determination in writing by the Department of Finance to the chairperson in each house that considers appropriations, the chairpersons of the committees, and the appropriate subcommittees in each house that considers the State Budget, and the Chairperson of the Joint Legislative Budget Committee.
(7)If this subdivision ceases to be operative, all persons who have received or are eligible to receive comprehensive clinical family planning services pursuant to the waiver described in paragraph (2) shall receive family planning services under the Medi-Cal program pursuant to subdivision (n) if they are otherwise eligible for Medi-Cal with no spend down of excess income, or shall receive comprehensive clinical family planning services under the program established in Division 24 (commencing with Section 24000) either if they are eligible for Medi-Cal with a spend down of excess income or if they are otherwise eligible under Section 24003.
(8)For purposes of this subdivision, comprehensive clinical family planning services means the process of establishing objectives for the number and spacing of children, and selecting the means by which those objectives may be achieved. These means include a broad range of acceptable and effective methods and services to limit or enhance fertility, including contraceptive methods, federal Food and Drug Administration-approved contraceptive drugs, devices, and supplies, natural family planning, abstinence methods, and basic, limited fertility management. Comprehensive clinical family planning services include, but are not limited to, preconception counseling, maternal and fetal health counseling, general reproductive health care, including diagnosis and treatment of infections and conditions, including cancer, that threaten reproductive capability, medical family planning treatment and procedures, including supplies and followup, and informational, counseling, and educational services. Comprehensive clinical family planning services shall not include abortion, pregnancy testing solely for the purposes of referral for abortion or services ancillary to abortions, or pregnancy care that is not incident to the diagnosis of pregnancy. Comprehensive clinical family planning services shall be subject to utilization control and include all of the following:
(A)Family planning-related services and male and female sterilization. Family planning services for men and women shall include emergency services and services for complications directly related to the contraceptive method, federal Food and Drug Administration-approved contraceptive drugs, devices, and supplies, and followup, consultation, and referral services, as indicated, which may require treatment authorization requests.
(B)All United States Department of Agriculture, federal Food and Drug Administration-approved contraceptive drugs, devices, and supplies that are in keeping with current standards of practice and from which the individual may choose.
(C)Culturally and linguistically appropriate health education and counseling services, including informed consent, that include all of the following:
(i)Psychosocial and medical aspects of contraception.
(ii)Sexuality.
(iii)Fertility.
(iv)Pregnancy.
(v)Parenthood.
(vi)Infertility.
(vii)Reproductive health care.
(viii)Preconception and nutrition counseling.
(ix)Prevention and treatment of sexually transmitted infection.
(x)Use of contraceptive methods, federal Food and Drug Administration-approved contraceptive drugs, devices, and supplies.
(xi)Possible contraceptive consequences and followup.
(xii)Interpersonal communication and negotiation of relationships to assist individuals and couples in effective contraceptive method use and planning families.
(D)A comprehensive health history, updated at the next periodic visit (between 11 and 24 months after initial examination) that includes a complete obstetrical history, gynecological history, contraceptive history, personal medical history, health risk factors, and family health history, including genetic or hereditary conditions.
(E)A complete physical examination on initial and subsequent periodic visits.
(F)Services, drugs, devices, and supplies deemed by the federal Centers for Medicare and Medicaid Services to be appropriate for inclusion in the program.
(G)(i)Home test kits for sexually transmitted diseases, including any laboratory costs of processing the kit, that are deemed medically necessary or appropriate and ordered directly by an enrolled Medi-Cal or Family PACT clinician or furnished through a standing order for patient use based on clinical guidelines and individual patient health needs.
(ii)For purposes of this subparagraph, home test kit means a product used for a test recommended by the federal Centers for Disease Control and Prevention guidelines or the United States Preventive Services Task Force that has been CLIA-waived, FDA-cleared or -approved, or developed by a laboratory in accordance with established regulations and quality standards, to allow individuals to self-collect specimens for STDs, including HIV, remotely at a location outside of a clinical setting.
(iii)The home test kit shall be sent by the enrolled Family PACT provider to a Medi-Cal-enrolled laboratory with fee based on Medicare Clinical Diagnostic Laboratory Tests Payment System Final Rule.
(9)In order to maximize the availability of federal financial participation under this subdivision, the director shall have the discretion to implement the Family PACT successor state plan amendment retroactively to July 1, 2010.
(ab)(1)Purchase of prescribed enteral nutrition products is covered, subject to the Medi-Cal list of enteral nutrition products and utilization controls.
(2)Purchase of enteral nutrition products is limited to those products to be administered through a feeding tube, including, but not limited to, a gastric, nasogastric, or jejunostomy tube. A beneficiary under the Early and Periodic Screening, Diagnostic, and Treatment Program shall be exempt from this paragraph.
(3)Notwithstanding paragraph (2), the department may deem an enteral nutrition product, not administered through a feeding tube, including, but not limited to, a gastric, nasogastric, or jejunostomy tube, a benefit for patients with diagnoses, including, but not limited to, malabsorption and inborn errors of metabolism, if the product has been shown to be neither investigational nor experimental when used as part of a therapeutic regimen to prevent serious disability or death.
(4)Notwithstanding Chapter 3.5 (commencing with Section 11340) of Part 1 of Division 3 of Title 2 of the Government Code, the department may implement the amendments to this subdivision made by the act that added this paragraph by means of all-county letters, provider bulletins, or similar instructions, without taking regulatory action.
(5)The amendments made to this subdivision by the act that added this paragraph shall be implemented June 1, 2011, or on the first day of the first calendar month following 60 days after the date the department secures all necessary federal approvals to implement this section, whichever is later.
(ac)Diabetic testing supplies are covered when provided by a pharmacy, subject to utilization controls.
(ad)(1)Nonmedical transportation is covered, subject to utilization controls and permissible time and distance standards, for a beneficiary to obtain covered Medi-Cal services.
(2)(A)(i)Nonmedical transportation includes, at a minimum, round trip transportation for a beneficiary to obtain covered Medi-Cal services by passenger car, taxicab, or any other form of public or private conveyance, and mileage reimbursement when conveyance is in a private vehicle arranged by the beneficiary and not through a transportation broker, bus passes, taxi vouchers, or train tickets.
(ii)Nonmedical transportation does not include the transportation of a sick, injured, invalid, convalescent, infirm, or otherwise incapacitated beneficiary by ambulance, litter van, or wheelchair van licensed, operated, and equipped in accordance with state and local statutes, ordinances, or regulations.
(B)Nonmedical transportation shall be provided for a beneficiary who can attest in a manner to be specified by the department that other currently available resources have been reasonably exhausted. For a beneficiary enrolled in a managed care plan, nonmedical transportation shall be provided by the beneficiarys managed care plan. For a Medi-Cal fee-for-service beneficiary, the department shall provide nonmedical transportation when those services are not available to the beneficiary under Sections 14132.44 and 14132.47.
(3)Nonmedical transportation shall be provided in a form and manner that is accessible, in terms of physical and geographic accessibility, for the beneficiary and consistent with applicable state and federal disability rights laws.
(4)It is the intent of the Legislature in enacting this subdivision to affirm the requirement under Section 431.53 of Title 42 of the Code of Federal Regulations, in which the department is required to provide necessary transportation, including nonmedical transportation, for recipients to and from covered services. This subdivision shall not be interpreted to add a new benefit to the Medi-Cal program.
(5)The department shall seek any federal approvals that may be required to implement this subdivision, including, but not limited to, approval of revisions to the existing state plan that the department determines are necessary to implement this subdivision.
(6)This subdivision shall be implemented only to the extent that federal financial participation is available and not otherwise jeopardized and any necessary federal approvals have been obtained.
(7)Prior to the effective date of any necessary federal approvals, nonmedical transportation was not a Medi-Cal managed care benefit with the exception of when provided as an Early and Periodic Screening, Diagnostic, and Treatment service.
(8)Notwithstanding Chapter 3.5 (commencing with Section 11340) of Part 1 of Division 3 of Title 2 of the Government Code, the department, without taking any further regulatory action, shall implement, interpret, or make specific this subdivision by means of all-county letters, plan letters, plan or provider bulletins, or similar instructions until the time regulations are adopted. By July 1, 2018, the department shall adopt regulations in accordance with the requirements of Chapter 3.5 (commencing with Section 11340) of Part 1 of Division 3 of Title 2 of the Government Code. Commencing January 1, 2018, and notwithstanding Section 10231.5 of the Government Code, the department shall provide a status report to the Legislature on a semiannual basis, in compliance with Section 9795 of the Government Code, until regulations have been adopted.
(9)This subdivision shall not be implemented until July 1, 2017.
(ae)(1)No sooner than January 1, 2022, Rapid Whole Genome Sequencing, including individual sequencing, trio sequencing for a parent or parents and their baby, and ultra-rapid sequencing, is a covered benefit for any Medi-Cal beneficiary who is one year of age or younger and is receiving inpatient hospital services in an intensive care unit.
(2)Notwithstanding Chapter 3.5 (commencing with Section 11340) of Part 1 of Division 3 of Title 2 of the Government Code, the department, without taking any further regulatory action, shall implement, interpret, or make specific this subdivision by means of all-county letters, plan letters, plan or provider bulletins, or similar instructions until the time regulations are adopted.
(3)This subdivision shall be implemented only to the extent that any necessary federal approvals are obtained, and federal financial participation is available and not otherwise jeopardized.
(af)(1)Home test kits for sexually transmitted diseases that are deemed medically necessary or appropriate and ordered directly by an enrolled Medi-Cal clinician or furnished through a standing order for patient use based on clinical guidelines and individual patient health needs.
(2)For purposes of this subdivision, home test kit means a product used for a test recommended by the federal Centers for Disease Control and Prevention guidelines or the United States Preventive Services Task Force that has been CLIA-waived, FDA-cleared or -approved, or developed by a laboratory in accordance with established regulations and quality standards, to allow individuals to self-collect specimens for STDs, including HIV, remotely at a location outside of a clinical setting.
(3)The home test kit shall be sent by the enrolled Medi-Cal provider to a Medi-Cal-enrolled laboratory with fee based on Medicare Clinical Diagnostic Laboratory Tests Payment System Final Rule.
(4)This subdivision shall be implemented only to the extent that federal financial participation is available and not otherwise jeopardized, and any necessary federal approvals have been obtained.
(5)Notwithstanding Chapter 3.5 (commencing with Section 11340) of Part 1 of Division 3 of Title 2 of the Government Code, the State Department of Health Care Services may implement this subdivision by means of all-county letters, plan letters, plan or provider bulletins, or similar instructions, without taking any further regulatory action.
(ag)(1)Violence prevention services are covered, subject to medical necessity and utilization controls.
(2)Notwithstanding Chapter 3.5 (commencing with Section 11340) of Part 1 of Division 3 of Title 2 of the Government Code, the department, without taking any further regulatory action, may implement, interpret, or make specific this subdivision by means of all-county letters, plan letters, plan or provider bulletins, or similar instructions until the time regulations are adopted.
(3)This subdivision shall be implemented only to the extent that any necessary federal approvals are obtained, and federal financial participation is available and not otherwise jeopardized.
(4)The department shall post on its internet website the date upon which violence prevention services may be provided and billed pursuant to this subdivision.
(5)Violence prevention services means evidence-based, trauma-informed, and culturally responsive preventive services provided to reduce the incidence of violent injury or reinjury, trauma, and related harms and promote trauma recovery, stabilization, and improved health outcomes.
SEC. 4.Section 14132.17 of the Welfare and Institutions Code is amended to read:14132.17.(a)Annual cervical cancer tests for screening or diagnostic purposes, upon the referral of a patients physician, is a covered benefit under this chapter, on or after January 1, 1991, to the extent required or permitted by federal law.14132.17.(a)Cervical cancer tests for screening that are ordered by a patients health care provider and consistent with nationally recognized clinical guidelines are a covered benefit under this chapter, on or after January 1, 2027, to the extent required or permitted by federal law.
(b)(1)Annual cervical cancer home test kits for screening or diagnostic purposes, upon the referral of a patients health care provider, is The United States Food and Drug Administration-authorized or cleared cervical cancer home test kits for screening that are ordered by a patients health care provider and consistent with nationally recognized clinical guidelines are a covered benefit under this chapter, on or after January 1, 2027, to the extent required or permitted by federal law.
(2)A Medi-Cal beneficiary is not subject to any cost sharing, including, but not limited to, a share of cost or spend down of excess income as described in Section 14054 for the benefit described in this subdivision.
(3)This subdivision applies to both the fee-for-service delivery system and the managed care delivery system under the Medi-Cal program.
SEC. 5.Section 24007 of the Welfare and Institutions Code is amended to read:24007.(a)The department shall determine the scope of benefits for the program, which shall include, but is not limited to, the following:
(1)Family planning-related services and male and female sterilization. Family planning services for men and women include emergency and complication services directly related to the contraceptive method and followup, consultation, and referral services, as indicated, that may require treatment authorization requests.
(2)All United States Department of Health and Human Services, Federal Drug Administration-approved birth control methods, devices, and supplies that are in keeping with current standards of practice and from which the individual may choose.
(3)Culturally and linguistically appropriate health education and counseling services, including informed consent; psychosocial and medical aspects of contraception, sexuality, fertility, pregnancy, and parenthood; infertility; reproductive health care; preconceptual and nutrition counseling; prevention and treatment of sexually transmitted infection; use of contraceptive methods, devices, and supplies; possible contraceptive consequences and followup; interpersonal communication and negotiation of relationships to assist individuals and couples in effective contraceptive method use and planning families.
(4)A comprehensive health history, updated at the next periodic visit (between 11 and 24 months after initial examination) that includes a complete obstetrical history, gynecological history, contraceptive history, personal medical history, health risk factors, and family health history, including genetic or hereditary conditions.
(5)A complete physical examination on initial and subsequent periodic visits.
(6)(A)Home test kits for sexually transmitted diseases, including any laboratory costs of processing the kit, that are deemed medically necessary or appropriate and ordered directly by an enrolled Family PACT clinician or furnished through a standing order for patient use based on clinical guidelines and individual patient health needs.
(B)For purposes of this paragraph, home test kit means a product used for a test recommended by the federal Centers for Disease Control and Prevention guidelines or the United States Preventive Services Task Force that has been CLIA-waived, FDA-cleared or -approved, or developed by a laboratory in accordance with established regulations and quality standards, to allow individuals to self-collect specimens for STDs, including HIV, remotely at a location outside of a clinical setting.
(C)The home test kit shall be sent by the enrolled Family PACT provider to a Medi-Cal-enrolled laboratory with fee based on Medicare Clinical Diagnostic Laboratory Tests Payment System Final Rule.
(D)This paragraph shall be implemented only to the extent that federal financial participation is available and not otherwise jeopardized, and any necessary federal approvals have been obtained.
(b)Benefits under this program shall be effective in 30 days after notice to providers, but not sooner than January 1, 1997.
SEC. 6.No reimbursement is required by this act pursuant to Section 6 of Article XIIIB of the California Constitution because the only costs that may be incurred by a local agency or school district will be incurred because this act creates a new crime or infraction, eliminates a crime or infraction, or changes the penalty for a crime or infraction, within the meaning of Section 17556 of the Government Code, or changes the definition of a crime within the meaning of Section 6 of Article XIIIB of the California Constitution.
(a)(1)A individual or group health care service plan contract, except for a specialized health care service plan, issued, amended, or renewed on or after January 1, 2002, shall provide coverage for an annual cervical cancer screening test upon the referral of the patients physician and surgeon, a nurse practitioner, or a certified nurse-midwife, providing care to the patient and operating within the scope of practice otherwise permitted for the licensee.
(2)A health care service plan contract, except for a specialized health care service plan, issued, amended, or renewed on or after January 1, 2027, shall provide coverage for an annual cervical cancer screening home test kit upon the referral of the patients health care provider. A health care service plan contract shall not impose a deductible, coinsurance, copayment, or any other cost-sharing requirement on the coverage provided pursuant to this paragraph.
(3)The coverage for an annual cervical cancer screening test provided pursuant to this subdivision shall include the conventional Pap test, a human papillomavirus screening test that is approved by the United States Food and Drug Administration (FDA), and the option of any cervical cancer screening test approved by the FDA, upon the referral of the patients health care provider.
(4)This subdivision does not establish a new mandated benefit or prevent application of deductible or copayment provisions in an existing plan contract. The Legislature intends in this section to provide that cervical cancer screening services are deemed to be covered if the plan contract includes coverage for cervical cancer treatment or surgery.
(b)A health care service plan contract, except for a specialized health care service plan, issued, amended, or renewed on or after January 1, 2024, shall provide coverage for the human papillomavirus vaccine for enrollees for whom the vaccine is approved by the FDA. A health care service plan contract shall not impose a deductible, coinsurance, copayment, or any other cost-sharing requirement on the coverage provided pursuant to this subdivision.
SEC. 2.Section 10123.18 of the Insurance Code is amended to read:10123.18.(a)(1)A disability insurance policy issued, amended, or renewed on or after January 1, 2024, and that provides coverage for hospital, medical, or surgical benefits shall provide coverage, upon the referral of a patients physician and surgeon, a nurse practitioner, or a certified nurse-midwife, providing care to the patient and operating within the scope of practice otherwise permitted for the licensee, for an annual cervical cancer screening test.
(2)A disability insurance policy issued, amended, or renewed on or after January 1, 2027, shall provide coverage for an annual cervical cancer screening home test kit upon the referral of a patients health care provider. A health insurance policy shall not impose a deductible, coinsurance, copayment, or any other cost-sharing requirement on the coverage provided pursuant to this paragraph.
(3)The coverage for an annual cervical cancer screening test provided pursuant to this subdivision shall include the conventional Pap test, a human papillomavirus screening test that is approved by the United States Food and Drug Administration (FDA) and the option of any cervical cancer screening test approved by the FDA, upon the referral of the patients health care provider.
(4)This subdivision does not require an individual or group policy to cover treatment or surgery for cervical cancer or to prevent application of deductible or copayment provisions contained in the policy or certificate, and does not require that coverage under an individual or group policy be extended to any other procedures.
(b)A disability insurance policy issued, amended, or renewed on or after January 1, 2024, that provides coverage for hospital, medical, or surgical benefits shall provide coverage for the human papillomavirus vaccine for insureds for whom the vaccine is approved by the FDA. The policy shall not impose a deductible, coinsurance, copayment, or any other cost-sharing requirement on the coverage provided pursuant to this subdivision.
(c)This section shall not apply to vision-only, dental-only, accident-only, specified disease, hospital indemnity, Medicare supplement, CHAMPUS supplement, long-term care, or disability income insurance. For accident-only, hospital indemnity, or specified disease insurance, coverage for benefits under this section shall apply only to the extent that the benefits are covered under the general terms and conditions that apply to all other benefits under the policy or certificate. This section does not impose a new benefit mandate on accident-only, hospital indemnity, or specified disease insurance.
SEC. 3.Section 14132 of the Welfare and Institutions Code is amended to read:14132.The following is the schedule of benefits under this chapter:
(a)Outpatient services are covered as follows:
Physician, hospital or clinic outpatient, surgical center, respiratory care, optometric, chiropractic, psychology, podiatric, occupational therapy, physical therapy, speech therapy, audiology, acupuncture to the extent federal matching funds are provided for acupuncture, and services of persons rendering treatment by prayer or healing by spiritual means in the practice of any church or religious denomination insofar as these can be encompassed by federal participation under an approved plan, subject to utilization controls.
(b)(1)Inpatient hospital services, including, but not limited to, physician and podiatric services, physical therapy, and occupational therapy, are covered subject to utilization controls.
(2)For a Medi-Cal fee-for-service beneficiary, emergency services and care that are necessary for the treatment of an emergency medical condition and medical care directly related to the emergency medical condition. This paragraph does not change the obligation of Medi-Cal managed care plans to provide emergency services and care. For the purposes of this paragraph, emergency services and care and emergency medical condition have the same meanings as those terms are defined in Section 1317.1 of the Health and Safety Code.
(c)Nursing facility services, subacute care services, and services provided by any category of intermediate care facility for the developmentally disabled, including podiatry, physician, nurse practitioner services, and prescribed drugs, as described in subdivision (d), are covered subject to utilization controls. Respiratory care, physical therapy, occupational therapy, speech therapy, and audiology services for patients in nursing facilities and any category of intermediate care facility for persons with developmental disabilities are covered subject to utilization controls.
(d)(1)Purchase of prescribed drugs is covered subject to the Medi-Cal List of Contract Drugs and utilization controls.
(2)Purchase of drugs used to treat erectile dysfunction or any off-label uses of those drugs are covered only to the extent that federal financial participation is available.
(3)(A)To the extent required by federal law, the purchase of outpatient prescribed drugs, for which the prescription is executed by a prescriber in written, nonelectronic form on or after April 1, 2008, is covered only when executed on a tamper resistant prescription form. The implementation of this paragraph shall conform to the guidance issued by the federal Centers for Medicare and Medicaid Services, but shall not conflict with state statutes on the characteristics of tamper resistant prescriptions for controlled substances, including Section 11162.1 of the Health and Safety Code. The department shall provide providers and beneficiaries with as much flexibility in implementing these rules as allowed by the federal government. The department shall notify and consult with appropriate stakeholders in implementing, interpreting, or making specific this paragraph.
(B)Notwithstanding Chapter 3.5 (commencing with Section 11340) of Part 1 of Division 3 of Title 2 of the Government Code, the department may take the actions specified in subparagraph (A) by means of a provider bulletin or notice, policy letter, or other similar instructions without taking regulatory action.
(4)(A)(i)For the purposes of this paragraph, nonlegend has the same meaning as defined in subdivision (a) of Section 14105.45.
(ii)Nonlegend acetaminophen-containing products, including childrens acetaminophen-containing products, selected by the department are covered benefits.
(iii)Nonlegend cough and cold products selected by the department are covered benefits.
(B)Notwithstanding Chapter 3.5 (commencing with Section 11340) of Part 1 of Division 3 of Title 2 of the Government Code, the department may take the actions specified in subparagraph (A) by means of a provider bulletin or notice, policy letter, or other similar instruction without taking regulatory action.
(e)Outpatient dialysis services and home hemodialysis services, including physician services, medical supplies, drugs, and equipment required for dialysis, are covered, subject to utilization controls.
(f)Anesthesiologist services when provided as part of an outpatient medical procedure, nurse anesthetist services when rendered in an inpatient or outpatient setting under conditions set forth by the director, outpatient laboratory services, and x-ray services are covered, subject to utilization controls. This subdivision does not require prior authorization for anesthesiologist services provided as part of an outpatient medical procedure or for portable x-ray services in a nursing facility or any category of intermediate care facility for the developmentally disabled.
(g)Blood and blood derivatives are covered.
(h)(1)Emergency and essential diagnostic and restorative dental services, except for orthodontic, fixed bridgework, and partial dentures that are not necessary for balance of a complete artificial denture, are covered, subject to utilization controls. The utilization controls shall allow emergency and essential diagnostic and restorative dental services and prostheses that are necessary to prevent a significant disability or to replace previously furnished prostheses that are lost or destroyed due to circumstances beyond the beneficiarys control. Notwithstanding the foregoing, the director may by regulation provide for certain fixed artificial dentures necessary for obtaining employment or for medical conditions that preclude the use of removable dental prostheses, and for orthodontic services in cleft palate deformities administered by the departments California Childrens Services program.
(2)For persons 21 years of age or older, the services specified in paragraph (1) shall be provided subject to the following conditions:
(A)Periodontal treatment is not a benefit.
(B)Endodontic therapy is not a benefit except for vital pulpotomy.
(C)Laboratory processed crowns are not a benefit.
(D)Removable prosthetics shall be a benefit only for patients as a requirement for employment.
(E)The director may, by regulation, provide for the provision of fixed artificial dentures that are necessary for medical conditions that preclude the use of removable dental prostheses.
(F)Notwithstanding the conditions specified in subparagraphs (A) to (E), inclusive, the department may approve services for persons with special medical disorders subject to utilization review.
(3)Paragraph (2) shall become inoperative on July 1, 1995.
(i)Medical transportation is covered, subject to utilization controls.
(j)Home health care services are covered, subject to utilization controls.
(k)(1)Prosthetic and orthotic devices and eyeglasses are covered, subject to utilization controls. Utilization controls shall allow replacement of prosthetic and orthotic devices and eyeglasses necessary because of loss or destruction due to circumstances beyond the beneficiarys control. Frame styles for eyeglasses replaced pursuant to this subdivision shall not change more than once every two years, unless the department so directs.
(2)Orthopedic and conventional shoes are covered when provided by a prosthetic and orthotic supplier on the prescription of a physician and when at least one of the shoes will be attached to a prosthesis or brace, subject to utilization controls. Modification of stock conventional or orthopedic shoes when medically indicated is covered, subject to utilization controls. If there is a clearly established medical need that cannot be satisfied by the modification of stock conventional or orthopedic shoes, custom-made orthopedic shoes are covered, subject to utilization controls.
(3)Therapeutic shoes and inserts are covered when provided to a beneficiary with a diagnosis of diabetes, subject to utilization controls, to the extent that federal financial participation is available.
(l)Hearing aids are covered, subject to utilization controls. Utilization controls shall allow replacement of hearing aids necessary because of loss or destruction due to circumstances beyond the beneficiarys control.
(m)Durable medical equipment and medical supplies are covered, subject to utilization controls. The utilization controls shall allow the replacement of durable medical equipment and medical supplies when necessary because of loss or destruction due to circumstances beyond the beneficiarys control. The utilization controls shall allow authorization of durable medical equipment needed to assist a disabled beneficiary in caring for a child for whom the disabled beneficiary is a parent, stepparent, foster parent, or legal guardian, subject to the availability of federal financial participation. The department shall adopt emergency regulations to define and establish criteria for assistive durable medical equipment in accordance with the rulemaking provisions of the Administrative Procedure Act (Chapter 3.5 (commencing with Section 11340) of Part 1 of Division 3 of Title 2 of the Government Code).
(n)Family planning services are covered, subject to utilization controls. However, for Medi-Cal managed care plans, utilization controls shall be subject to Section 1367.25 of the Health and Safety Code.
(o)Inpatient intensive rehabilitation hospital services, including respiratory rehabilitation services, in a general acute care hospital are covered, subject to utilization controls, when either of the following criteria are met:
(1)A patient with a permanent disability or severe impairment requires an inpatient intensive rehabilitation hospital program as described in Section 14064 to develop function beyond the limited amount that would occur in the normal course of recovery.
(2)A patient with a chronic or progressive disease requires an inpatient intensive rehabilitation hospital program as described in Section 14064 to maintain the patients present functional level as long as possible.
(p)(1)Adult day health care is covered in accordance with Chapter 8.7 (commencing with Section 14520).
(2)Commencing 30 days after the effective date of the act that added this paragraph, and notwithstanding the number of days previously approved through a treatment authorization request, adult day health care is covered for a maximum of three days per week.
(3)As provided in accordance with paragraph (4), adult day health care is covered for a maximum of five days per week.
(4)As of the date that the director makes the declaration described in subdivision (g) of Section 14525.1, paragraph (2) shall become inoperative and paragraph (3) shall become operative.
(q)(1)Application of fluoride, or other appropriate fluoride treatment as defined by the department, and other prophylaxis treatment for children 17 years of age and under are covered.
(2)All dental hygiene services provided by a registered dental hygienist, registered dental hygienist in extended functions, and registered dental hygienist in alternative practice licensed pursuant to Sections 1753, 1917, 1918, and 1922 of the Business and Professions Code may be covered as long as they are within the scope of Denti-Cal benefits and they are necessary services provided by a registered dental hygienist, registered dental hygienist in extended functions, or registered dental hygienist in alternative practice.
(r)(1)Paramedic services performed by a city, county, or special district, or pursuant to a contract with a city, county, or special district, and pursuant to a program established under former Article 3 (commencing with Section 1480) of Chapter 2.5 of Division 2 of the Health and Safety Code by a paramedic certified pursuant to that article, and consisting of defibrillation and those services specified in subdivision (3) of former Section 1482 of the article.
(2)A provider enrolled under this subdivision shall satisfy all applicable statutory and regulatory requirements for becoming a Medi-Cal provider.
(3)This subdivision shall be implemented only to the extent funding is available under Section 14106.6.
(s)(1)In-home medical care services are covered when medically appropriate and subject to utilization controls, for a beneficiary who would otherwise require care for an extended period of time in an acute care hospital at a cost higher than in-home medical care services. The director shall have the authority under this section to contract with organizations qualified to provide in-home medical care services to those persons. These services may be provided to a patient placed in a shared or congregate living arrangement, if a home setting is not medically appropriate or available to the beneficiary.
(2)As used in this subdivision, in-home medical care service includes utility bills directly attributable to continuous, 24-hour operation of life-sustaining medical equipment, to the extent that federal financial participation is available.
(3)As used in this subdivision, in-home medical care services include, but are not limited to:
(A)Level-of-care and cost-of-care evaluations.
(B)Expenses, directly attributable to home care activities, for materials.
(C)Physician fees for home visits.
(D)Expenses directly attributable to home care activities for shelter and modification to shelter.
(E)Expenses directly attributable to additional costs of special diets, including tube feeding.
(F)Medically related personal services.
(G)Home nursing education.
(H)Emergency maintenance repair.
(I)Home health agency personnel benefits that permit coverage of care during periods when regular personnel are on vacation or using sick leave.
(J)All services needed to maintain antiseptic conditions at stoma or shunt sites on the body.
(K)Emergency and nonemergency medical transportation.
(L)Medical supplies.
(M)Medical equipment, including, but not limited to, scales, gurneys, and equipment racks suitable for paralyzed patients.
(N)Utility use directly attributable to the requirements of home care activities that are in addition to normal utility use.
(O)Special drugs and medications.
(P)Home health agency supervision of visiting staff that is medically necessary, but not included in the home health agency rate.
(Q)Therapy services.
(R)Household appliances and household utensil costs directly attributable to home care activities.
(S)Modification of medical equipment for home use.
(T)Training and orientation for use of life-support systems, including, but not limited to, support of respiratory functions.
(U)Respiratory care practitioner services as defined in Sections 3702 and 3703 of the Business and Professions Code, subject to prescription by a physician and surgeon.
(4)A beneficiary receiving in-home medical care services is entitled to the full range of services within the Medi-Cal scope of benefits as defined by this section, subject to medical necessity and applicable utilization control. Services provided pursuant to this subdivision, which are not otherwise included in the Medi-Cal schedule of benefits, shall be available only to the extent that federal financial participation for these services is available in accordance with a home- and community-based services waiver.
(t)Home- and community-based services approved by the United States Department of Health and Human Services are covered to the extent that federal financial participation is available for those services under the state plan or waivers granted in accordance with Section 1315 or 1396n of Title 42 of the United States Code. The director may seek waivers for any or all home- and community-based services approvable under Section 1315 or 1396n of Title 42 of the United States Code. Coverage for those services shall be limited by the terms, conditions, and duration of the federal waivers.
(u)Comprehensive perinatal services, as provided through an agreement with a health care provider designated in Section 14134.5 and meeting the standards developed by the department pursuant to Section 14134.5, subject to utilization controls.
The department shall seek any federal waivers necessary to implement the provisions of this subdivision. The provisions for which appropriate federal waivers cannot be obtained shall not be implemented. Provisions for which waivers are obtained or for which waivers are not required shall be implemented notwithstanding any inability to obtain federal waivers for the other provisions. No provision of this subdivision shall be implemented unless matching funds from Subchapter XIX (commencing with Section 1396) of Chapter 7 of Title 42 of the United States Code are available.
(v)Early and periodic screening, diagnosis, and treatment for any individual under 21 years of age is covered, consistent with the requirements of Subchapter XIX (commencing with Section 1396) of Chapter 7 of Title 42 of the United States Code.
(w)(1)Hospice services are covered, in accordance with Medicare requirements, and are subject to utilization controls. Coverage shall be available only to the extent that no additional net program costs are incurred.
(2)This subdivision shall be implemented only to the extent that federal financial participation is available and not otherwise jeopardized, and any necessary federal approvals have been obtained.
(3)Notwithstanding any other law, the department, without taking any further regulatory action, may implement, interpret, or make specific this subdivision by means of all-county letters, plan letters, plan or provider bulletins, or similar instructions.
(x)When a claim for treatment provided to a beneficiary includes both services that are authorized and reimbursable under this chapter and services that are not reimbursable under this chapter, that portion of the claim for the treatment and services authorized and reimbursable under this chapter shall be payable.
(y)Home- and community-based services approved by the United States Department of Health and Human Services for a beneficiary with a diagnosis of Acquired Immune Deficiency Syndrome (AIDS) or AIDS-related complex, who requires intermediate care or a higher level of care.
Services provided pursuant to a waiver obtained from the Secretary of the United States Department of Health and Human Services pursuant to this subdivision, and that are not otherwise included in the Medi-Cal schedule of benefits, shall be available only to the extent that federal financial participation for these services is available in accordance with the waiver, and subject to the terms, conditions, and duration of the waiver. These services shall be provided to a beneficiary in accordance with the clients needs as identified in the plan of care, and subject to medical necessity and applicable utilization control.
The director may, under this section, contract with organizations qualified to provide, directly or by subcontract, services provided for in this subdivision to an eligible beneficiary. Contracts or agreements entered into pursuant to this division shall not be subject to the Public Contract Code.
(z)Respiratory care when provided in organized health care systems as defined in Section 3701 of the Business and Professions Code, and as an in-home medical service as outlined in subdivision (s).
(aa)(1)There is hereby established in the department a program to provide comprehensive clinical family planning services to any person who has a family income at or below 200 percent of the federal poverty level, as revised annually, and who is eligible to receive these services pursuant to the waiver identified in paragraph (2). This program shall be known as the Family Planning, Access, Care, and Treatment (Family PACT) Program.
(2)The department shall seek a waiver in accordance with Section 1315 of Title 42 of the United States Code, or a state plan amendment adopted in accordance with Section 1396a(a)(10)(A)(ii)(XXI) of Title 42 of the United States Code, which was added to Section 1396a of Title 42 of the United States Code by Section 2303(a)(2) of the federal Patient Protection and Affordable Care Act (PPACA) (Public Law 111-148), for a program to provide comprehensive clinical family planning services as described in paragraph (8). Under the waiver, the program shall be operated only in accordance with the waiver and the statutes and regulations in paragraph (4) and subject to the terms, conditions, and duration of the waiver. Under the state plan amendment, which shall replace the waiver and shall be known as the Family PACT successor state plan amendment, the program shall be operated only in accordance with this subdivision and the statutes and regulations in paragraph (4). The state shall use the standards and processes imposed by the state on January 1, 2007, including the application of an eligibility discount factor to the extent required by the federal Centers for Medicare and Medicaid Services, for purposes of determining eligibility as permitted under Section 1396a(a)(10)(A)(ii)(XXI) of Title 42 of the United States Code. To the extent that federal financial participation is available, the program shall continue to conduct education, outreach, enrollment, service delivery, and evaluation services as specified under the waiver. The services shall be provided under the program only if the waiver and, when applicable, the successor state plan amendment are approved by the federal Centers for Medicare and Medicaid Services and only to the extent that federal financial participation is available for the services. This section does not prohibit the department from seeking the Family PACT successor state plan amendment during the operation of the waiver.
(3)Solely for the purposes of the waiver or Family PACT successor state plan amendment and notwithstanding any other law, the collection and use of an individuals social security number shall be necessary only to the extent required by federal law.
(4)Sections 14105.3 to 14105.39, inclusive, 14107.11, 24005, and 24013, and any regulations adopted under these statutes shall apply to the program provided for under this subdivision. No other law under the Medi-Cal program or the State-Only Family Planning Program shall apply to the program provided for under this subdivision.
(5)Notwithstanding Chapter 3.5 (commencing with Section 11340) of Part 1 of Division 3 of Title 2 of the Government Code, the department may implement, without taking regulatory action, the provisions of the waiver after its approval by the federal Centers for Medicare and Medicaid Services and the provisions of this section by means of an all-county letter or similar instruction to providers. Thereafter, the department shall adopt regulations to implement this section and the approved waiver in accordance with the requirements of Chapter 3.5 (commencing with Section 11340) of Part 1 of Division 3 of Title 2 of the Government Code. Beginning six months after the effective date of the act adding this subdivision, the department shall provide a status report to the Legislature on a semiannual basis until regulations have been adopted.
(6)If the Department of Finance determines that the program operated under the authority of the waiver described in paragraph (2) or the Family PACT successor state plan amendment is no longer cost effective, this subdivision shall become inoperative on the first day of the first month following the issuance of a 30-day notification of that determination in writing by the Department of Finance to the chairperson in each house that considers appropriations, the chairpersons of the committees, and the appropriate subcommittees in each house that considers the State Budget, and the Chairperson of the Joint Legislative Budget Committee.
(7)If this subdivision ceases to be operative, all persons who have received or are eligible to receive comprehensive clinical family planning services pursuant to the waiver described in paragraph (2) shall receive family planning services under the Medi-Cal program pursuant to subdivision (n) if they are otherwise eligible for Medi-Cal with no spend down of excess income, or shall receive comprehensive clinical family planning services under the program established in Division 24 (commencing with Section 24000) either if they are eligible for Medi-Cal with a spend down of excess income or if they are otherwise eligible under Section 24003.
(8)For purposes of this subdivision, comprehensive clinical family planning services means the process of establishing objectives for the number and spacing of children, and selecting the means by which those objectives may be achieved. These means include a broad range of acceptable and effective methods and services to limit or enhance fertility, including contraceptive methods, federal Food and Drug Administration-approved contraceptive drugs, devices, and supplies, natural family planning, abstinence methods, and basic, limited fertility management. Comprehensive clinical family planning services include, but are not limited to, preconception counseling, maternal and fetal health counseling, general reproductive health care, including diagnosis and treatment of infections and conditions, including cancer, that threaten reproductive capability, medical family planning treatment and procedures, including supplies and followup, and informational, counseling, and educational services. Comprehensive clinical family planning services shall not include abortion, pregnancy testing solely for the purposes of referral for abortion or services ancillary to abortions, or pregnancy care that is not incident to the diagnosis of pregnancy. Comprehensive clinical family planning services shall be subject to utilization control and include all of the following:
(A)Family planning related planning-related services and male and female sterilization. Family planning services for men and women shall include emergency services and services for complications directly related to the contraceptive method, federal Food and Drug Administration-approved contraceptive drugs, devices, and supplies, and followup, consultation, and referral services, as indicated, which may require treatment authorization requests.
(B)All United States Department of Agriculture, federal Food and Drug Administration-approved contraceptive drugs, devices, and supplies that are in keeping with current standards of practice and from which the individual may choose.
(C)Culturally and linguistically appropriate health education and counseling services, including informed consent, that include all of the following:
(i)Psychosocial and medical aspects of contraception.
(ii)Sexuality.
(iii)Fertility.
(iv)Pregnancy.
(v)Parenthood.
(vi)Infertility.
(vii)Reproductive health care.
(viii)Preconception and nutrition counseling.
(ix)Prevention and treatment of sexually transmitted infection.
(x)Use of contraceptive methods, federal Food and Drug Administration-approved contraceptive drugs, devices, and supplies.
(xi)Possible contraceptive consequences and followup.
(xii)Interpersonal communication and negotiation of relationships to assist individuals and couples in effective contraceptive method use and planning families.
(D)A comprehensive health history, updated at the next periodic visit (between 11 and 24 months after initial examination) that includes a complete obstetrical history, gynecological history, contraceptive history, personal medical history, health risk factors, and family health history, including genetic or hereditary conditions.
(E)A complete physical examination on initial and subsequent periodic visits.
(F)Services, drugs, devices, and supplies deemed by the federal Centers for Medicare and Medicaid Services to be appropriate for inclusion in the program.
(G)(i)Home test kits for sexually transmitted diseases, including any laboratory costs of processing the kit, that are deemed medically necessary or appropriate and ordered directly by an enrolled Medi-Cal or Family PACT clinician or furnished through a standing order for patient use based on clinical guidelines and individual patient health needs.
(ii)For purposes of this subparagraph, home test kit means a product used for a test recommended by the federal Centers for Disease Control and Prevention guidelines or the United States Preventive Services Task Force that has been CLIA-waived, FDA-cleared or -approved, or developed by a laboratory in accordance with established regulations and quality standards, to allow individuals to self-collect specimens for STDs, including HIV, remotely at a location outside of a clinical setting.
(iii)Reimbursement under this subparagraph shall be contingent upon the addition of codes specific to home test kits in the Current Procedural Terminology or Healthcare Common Procedure Coding System to comply with Health Insurance Portability and Accountability Act requirements. The home test kit shall be sent by the enrolled Family PACT provider to a Medi-Cal-enrolled laboratory with fee based on Medicare Clinical Diagnostic Laboratory Tests Payment System Final Rule.
(9)In order to maximize the availability of federal financial participation under this subdivision, the director shall have the discretion to implement the Family PACT successor state plan amendment retroactively to July 1, 2010.
(ab)(1)Purchase of prescribed enteral nutrition products is covered, subject to the Medi-Cal list of enteral nutrition products and utilization controls.
(2)Purchase of enteral nutrition products is limited to those products to be administered through a feeding tube, including, but not limited to, a gastric, nasogastric, or jejunostomy tube. A beneficiary under the Early and Periodic Screening, Diagnostic, and Treatment Program shall be exempt from this paragraph.
(3)Notwithstanding paragraph (2), the department may deem an enteral nutrition product, not administered through a feeding tube, including, but not limited to, a gastric, nasogastric, or jejunostomy tube, a benefit for patients with diagnoses, including, but not limited to, malabsorption and inborn errors of metabolism, if the product has been shown to be neither investigational nor experimental when used as part of a therapeutic regimen to prevent serious disability or death.
(4)Notwithstanding Chapter 3.5 (commencing with Section 11340) of Part 1 of Division 3 of Title 2 of the Government Code, the department may implement the amendments to this subdivision made by the act that added this paragraph by means of all-county letters, provider bulletins, or similar instructions, without taking regulatory action.
(5)The amendments made to this subdivision by the act that added this paragraph shall be implemented June 1, 2011, or on the first day of the first calendar month following 60 days after the date the department secures all necessary federal approvals to implement this section, whichever is later.
(ac)Diabetic testing supplies are covered when provided by a pharmacy, subject to utilization controls.
(ad)(1)Nonmedical transportation is covered, subject to utilization controls and permissible time and distance standards, for a beneficiary to obtain covered Medi-Cal services.
(2)(A)(i)Nonmedical transportation includes, at a minimum, round trip transportation for a beneficiary to obtain covered Medi-Cal services by passenger car, taxicab, or any other form of public or private conveyance, and mileage reimbursement when conveyance is in a private vehicle arranged by the beneficiary and not through a transportation broker, bus passes, taxi vouchers, or train tickets.
(ii)Nonmedical transportation does not include the transportation of a sick, injured, invalid, convalescent, infirm, or otherwise incapacitated beneficiary by ambulance, litter van, or wheelchair van licensed, operated, and equipped in accordance with state and local statutes, ordinances, or regulations.
(B)Nonmedical transportation shall be provided for a beneficiary who can attest in a manner to be specified by the department that other currently available resources have been reasonably exhausted. For a beneficiary enrolled in a managed care plan, nonmedical transportation shall be provided by the beneficiarys managed care plan. For a Medi-Cal fee-for-service beneficiary, the department shall provide nonmedical transportation when those services are not available to the beneficiary under Sections 14132.44 and 14132.47.
(3)Nonmedical transportation shall be provided in a form and manner that is accessible, in terms of physical and geographic accessibility, for the beneficiary and consistent with applicable state and federal disability rights laws.
(4)It is the intent of the Legislature in enacting this subdivision to affirm the requirement under Section 431.53 of Title 42 of the Code of Federal Regulations, in which the department is required to provide necessary transportation, including nonmedical transportation, for recipients to and from covered services. This subdivision shall not be interpreted to add a new benefit to the Medi-Cal program.
(5)The department shall seek any federal approvals that may be required to implement this subdivision, including, but not limited to, approval of revisions to the existing state plan that the department determines are necessary to implement this subdivision.
(6)This subdivision shall be implemented only to the extent that federal financial participation is available and not otherwise jeopardized and any necessary federal approvals have been obtained.
(7)Prior to the effective date of any necessary federal approvals, nonmedical transportation was not a Medi-Cal managed care benefit with the exception of when provided as an Early and Periodic Screening, Diagnostic, and Treatment service.
(8)Notwithstanding Chapter 3.5 (commencing with Section 11340) of Part 1 of Division 3 of Title 2 of the Government Code, the department, without taking any further regulatory action, shall implement, interpret, or make specific this subdivision by means of all-county letters, plan letters, plan or provider bulletins, or similar instructions until the time regulations are adopted. By July 1, 2018, the department shall adopt regulations in accordance with the requirements of Chapter 3.5 (commencing with Section 11340) of Part 1 of Division 3 of Title 2 of the Government Code. Commencing January 1, 2018, and notwithstanding Section 10231.5 of the Government Code, the department shall provide a status report to the Legislature on a semiannual basis, in compliance with Section 9795 of the Government Code, until regulations have been adopted.
(9)This subdivision shall not be implemented until July 1, 2017.
(ae)(1)No sooner than January 1, 2022, Rapid Whole Genome Sequencing, including individual sequencing, trio sequencing for a parent or parents and their baby, and ultra-rapid sequencing, is a covered benefit for any Medi-Cal beneficiary who is one year of age or younger and is receiving inpatient hospital services in an intensive care unit.
(2)Notwithstanding Chapter 3.5 (commencing with Section 11340) of Part 1 of Division 3 of Title 2 of the Government Code, the department, without taking any further regulatory action, shall implement, interpret, or make specific this subdivision by means of all-county letters, plan letters, plan or provider bulletins, or similar instructions until the time regulations are adopted.
(3)This subdivision shall be implemented only to the extent that any necessary federal approvals are obtained, and federal financial participation is available and not otherwise jeopardized.
(af)(1)Home test kits for sexually transmitted diseases that are deemed medically necessary or appropriate and ordered directly by an enrolled Medi-Cal clinician or furnished through a standing order for patient use based on clinical guidelines and individual patient health needs.
(2)For purposes of this subdivision, home test kit means a product used for a test recommended by the federal Centers for Disease Control and Prevention guidelines or the United States Preventive Services Task Force that has been CLIA-waived, FDA-cleared or -approved, or developed by a laboratory in accordance with established regulations and quality standards, to allow individuals to self-collect specimens for STDs, including HIV, remotely at a location outside of a clinical setting.
(3)Reimbursement under this subparagraph shall be contingent upon the addition of codes specific to home test kits in the Current Procedural Terminology or Healthcare Common Procedure Coding System to comply with Health Insurance Portability and Accountability Act requirements. The home test kit shall be sent by the enrolled Medi-Cal provider to a Medi-Cal-enrolled laboratory with fee based on Medicare Clinical Diagnostic Laboratory Tests Payment System Final Rule.
(4)This subdivision shall be implemented only to the extent that federal financial participation is available and not otherwise jeopardized, and any necessary federal approvals have been obtained.
(5)Notwithstanding Chapter 3.5 (commencing with Section 11340) of Part 1 of Division 3 of Title 2 of the Government Code, the State Department of Health Care Services may implement this subdivision by means of all-county letters, plan letters, plan or provider bulletins, or similar instructions, without taking any further regulatory action.
(ag)(1)Violence prevention services are covered, subject to medical necessity and utilization controls.
(2)Notwithstanding Chapter 3.5 (commencing with Section 11340) of Part 1 of Division 3 of Title 2 of the Government Code, the department, without taking any further regulatory action, may implement, interpret, or make specific this subdivision by means of all-county letters, plan letters, plan or provider bulletins, or similar instructions until the time regulations are adopted.
(3)This subdivision shall be implemented only to the extent that any necessary federal approvals are obtained, and federal financial participation is available and not otherwise jeopardized.
(4)The department shall post on its internet website the date upon which violence prevention services may be provided and billed pursuant to this subdivision.
(5)Violence prevention services means evidence-based, trauma-informed, and culturally responsive preventive services provided to reduce the incidence of violent injury or reinjury, trauma, and related harms and promote trauma recovery, stabilization, and improved health outcomes.
SEC. 3.SEC. 4.Section 14132.17 of the Welfare and Institutions Code is amended to read:14132.17.(a)Annual cervical cancer tests for screening or diagnostic purposes, upon the referral of a patients physician, is a covered benefit under this chapter, on or after January 1, 1991, to the extent required or permitted by federal law.
(b)(1)Annual cervical cancer home test kits for screening or diagnostic purposes, upon the referral of a patients health care provider, is a covered benefit under this chapter, on or after January 1, 2027, to the extent required or permitted by federal law.
(2)A Medi-Cal beneficiary is not subject to any cost sharing, including, but not limited to, a share of cost or spend down of excess income as described in Section 14054 for the benefit described in this subdivision.
(3)This subdivision applies to both the fee-for-service delivery system and the managed care delivery system under the Medi-Cal program.
SEC. 5.Section 24007 of the Welfare and Institutions Code is amended to read:24007.(a)The department shall determine the scope of benefits for the program, which shall include, but is not limited to, the following:
(1)Family planning related planning-related services and male and female sterilization. Family planning services for men and women include emergency and complication services directly related to the contraceptive method and followup, consultation, and referral services, as indicated, that may require treatment authorization requests.
(2)All United States Department of Health and Human Services, Federal Drug Administration-approved birth control methods, devices, and supplies that are in keeping with current standards of practice and from which the individual may choose.
(3)Culturally and linguistically appropriate health education and counseling services, including informed consent; psychosocial and medical aspects of contraception, sexuality, fertility, pregnancy, and parenthood; infertility; reproductive health care; preconceptual and nutrition counseling; prevention and treatment of sexually transmitted infection; use of contraceptive methods, devices, and supplies; possible contraceptive consequences and followup; interpersonal communication and negotiation of relationships to assist individuals and couples in effective contraceptive method use and planning families.
(4)A comprehensive health history, updated at the next periodic visit (between 11 and 24 months after initial examination) that includes a complete obstetrical history, gynecological history, contraceptive history, personal medical history, health risk factors, and family health history, including genetic or hereditary conditions.
(5)A complete physical examination on initial and subsequent periodic visits.
(6)(A)Home test kits for sexually transmitted diseases, including any laboratory costs of processing the kit, that are deemed medically necessary or appropriate and ordered directly by an enrolled Family PACT clinician or furnished through a standing order for patient use based on clinical guidelines and individual patient health needs.
(B)For purposes of this paragraph, home test kit means a product used for a test recommended by the federal Centers for Disease Control and Prevention guidelines or the United States Preventive Services Task Force that has been CLIA-waived, FDA-cleared or -approved, or developed by a laboratory in accordance with established regulations and quality standards, to allow individuals to self-collect specimens for STDs, including HIV, remotely at a location outside of a clinical setting.
(C)Reimbursement under this subparagraph shall be contingent upon the addition of codes specific to home test kits in the Current Procedural Terminology or Healthcare Common Procedure Coding System to comply with Health Insurance Portability and Accountability Act requirements. The home test kit shall be sent by the enrolled Family PACT provider to a Medi-Cal-enrolled laboratory with fee based on Medicare Clinical Diagnostic Laboratory Tests Payment System Final Rule.
(D)This paragraph shall be implemented only to the extent that federal financial participation is available and not otherwise jeopardized, and any necessary federal approvals have been obtained.
(b)Benefits under this program shall be effective in 30 days after notice to providers, but not sooner than January 1, 1997.
SEC. 4.SEC. 6.No reimbursement is required by this act pursuant to Section 6 of Article XIIIB of the California Constitution because the only costs that may be incurred by a local agency or school district will be incurred because this act creates a new crime or infraction, eliminates a crime or infraction, or changes the penalty for a crime or infraction, within the meaning of Section 17556 of the Government Code, or changes the definition of a crime within the meaning of Section 6 of Article XIIIB of the California Constitution.
(a)Every (1)A individual or group health care service plan contract, except for a specialized health care service plan, issued, amended, or renewed on or after January 1, 2002, shall provide coverage for an annual cervical cancer screening test upon the referral of the patients physician and surgeon, a nurse practitioner, or a certified nurse-midwife, providing care to the patient and operating within the scope of practice otherwise permitted for the licensee.
(2)A health care service plan contract, except for a specialized health care service plan, issued, amended, or renewed on or after January 1, 2027, shall provide coverage for an annual cervical cancer screening home test kit upon the referral of the patients health care provider. A health care service plan contract shall not impose a deductible, coinsurance, copayment, or any other cost-sharing requirement on the coverage provided pursuant to this paragraph.
(1)(3)The coverage for an annual cervical cancer screening test provided pursuant to this section subdivision shall include the conventional Pap test, a human papillomavirus screening test that is approved by the United States Food and Drug Administration (FDA), and the option of any cervical cancer screening test approved by the FDA, upon the referral of the patients health care provider.
(2)(4)This subdivision does not establish a new mandated benefit or prevent application of deductible or copayment provisions in an existing plan contract. The Legislature intends in this section to provide that cervical cancer screening services are deemed to be covered if the plan contract includes coverage for cervical cancer treatment or surgery.
(b)A health care service plan contract, except for a specialized health care service plan, issued, amended, or renewed on or after January 1, 2024, shall provide coverage for the human papillomavirus vaccine for enrollees for whom the vaccine is approved by the FDA. A health care service plan contract shall not impose a deductible, coinsurance, copayment, or any other cost-sharing requirement on the coverage provided pursuant to this subdivision.
SEC. 2.Section 10123.18 of the Insurance Code is amended to read:10123.18.(a)(1)A disability insurance policy issued, amended, or renewed on or after January 1, 2024, and that provides coverage for hospital, medical, or surgical benefits shall provide coverage, upon the referral of a patients physician and surgeon, a nurse practitioner, or a certified nurse-midwife, providing care to the patient and operating within the scope of practice otherwise permitted for the licensee, for an annual cervical cancer screening test.
(2)A disability insurance policy issued, amended, or renewed on or after January 1, 2027, shall provide coverage for an annual cervical cancer screening home test kit upon the referral of a patients health care provider. A health insurance policy shall not impose a deductible, coinsurance, copayment, or any other cost-sharing requirement on the coverage provided pursuant to this paragraph.
(1)(3)The coverage for an annual cervical cancer screening test provided pursuant to this section subdivision shall include the conventional Pap test, a human papillomavirus screening test that is approved by the United States Food and Drug Administration (FDA) and the option of any cervical cancer screening test approved by the FDA, upon the referral of the patients health care provider.
(2)(4)This subdivision does not require an individual or group policy to cover treatment or surgery for cervical cancer or to prevent application of deductible or copayment provisions contained in the policy or certificate, and does not require that coverage under an individual or group policy be extended to any other procedures.
(b)A disability insurance policy issued, amended, or renewed on or after January 1, 2024, that provides coverage for hospital, medical, or surgical benefits shall provide coverage for the human papillomavirus vaccine for insureds for whom the vaccine is approved by the FDA. The policy shall not impose a deductible, coinsurance, copayment, or any other cost-sharing requirement on the coverage provided pursuant to this subdivision.
(c)This section shall not apply to vision-only, dental-only, accident-only, specified disease, hospital indemnity, Medicare supplement, CHAMPUS supplement, long-term care, or disability income insurance. For accident-only, hospital indemnity, or specified disease insurance, coverage for benefits under this section shall apply only to the extent that the benefits are covered under the general terms and conditions that apply to all other benefits under the policy or certificate. This section does not impose a new benefit mandate on accident-only, hospital indemnity, or specified disease insurance.
SEC. 3.Section 14132.17 of the Welfare and Institutions Code is amended to read:14132.17.(a)Annual cervical cancer tests for screening or diagnostic purposes, upon the referral of a patients physician, is a covered benefit under this chapter, on or after January 1, 1991, to the extent required or permitted by federal law.
(b)(1)Annual cervical cancer home test kits for screening or diagnostic purposes, upon the referral of a patients health care provider, is a covered benefit under this chapter, on or after January 1, 2027, to the extent required or permitted by federal law.
(2)A Medi-Cal beneficiary is not subject to any cost sharing, including, but not limited to, a share of cost or spend down of excess income as described in Section 14054 for the benefit described in this subdivision.
(3)This subdivision applies to both the fee-for-service delivery system and the managed care delivery system under the Medi-Cal program.
SEC. 4.No reimbursement is required by this act pursuant to Section 6 of Article XIIIB of the California Constitution because the only costs that may be incurred by a local agency or school district will be incurred because this act creates a new crime or infraction, eliminates a crime or infraction, or changes the penalty for a crime or infraction, within the meaning of Section 17556 of the Government Code, or changes the definition of a crime within the meaning of Section 6 of Article XIIIB of the California Constitution.
|
Date
|
Status
|
|---|---|
| Sep 27, 2026 | Chaptered by Secretary of State - Chapter 560, Statutes of 2026. |
| Sep 27, 2026 | Approved by the Governor. |
| Sep 8, 2026 | Enrolled and presented to the Governor at 3:30 p.m. |
| Aug 28, 2026 | Senate amendments concurred in. To Engrossing and Enrolling. (Ayes 78. Noes 0. Page 6799.). |
| Aug 28, 2026 | Senate amendments concurred in. To Engrossing and Enrolling. (Ayes 78. Noes 0.). |
| Aug 27, 2026 | In Assembly. Concurrence in Senate amendments pending. |
| Aug 27, 2026 | Read third time. Passed. Ordered to the Assembly. (Ayes 40. Noes 0. Page 5992.). |
| Aug 27, 2026 | Read third time. Passed. Ordered to the Assembly. (Ayes 40. Noes 0.). |
| Aug 24, 2026 | Read second time. Ordered to third reading. |
| Aug 21, 2026 | Read third time and amended. Ordered to second reading. |
| Aug 13, 2026 | Read second time. Ordered to third reading. |
| Aug 13, 2026 | From committee: Do pass. (Ayes 7. Noes 0.) (August 13). |
| Jun 29, 2026 | In committee: Referred to APPR. suspense file. |
| Jun 22, 2026 | Read second time and amended. Re-referred to Com. on APPR. |
| Jun 18, 2026 | From committee: Amend, and do pass as amended and re-refer to Com. on APPR. (Ayes 11. Noes 0.) (June 17). |
| Jun 8, 2026 | From committee chair, with author's amendments: Amend, and re-refer to committee. Read second time, amended, and re-referred to Com. on HEALTH. |
| Jun 3, 2026 | Referred to Com. on HEALTH. |
| May 21, 2026 | In Senate. Read first time. To Com. on RLS. for assignment. |
| May 21, 2026 | Read third time. Passed. Ordered to the Senate. (Ayes 73. Noes 0. Page 5202.) |
| May 21, 2026 | Read third time. Passed. Ordered to the Senate. (Ayes 73. Noes 0.) |
| May 18, 2026 | Read second time. Ordered to third reading. |
| May 14, 2026 | Joint Rule 62(a), file notice suspended. (Page 5030.) |
| May 14, 2026 | From committee: Do pass. (Ayes 14. Noes 0.) (May 14). |
| May 14, 2026 | Joint Rule 62(a), file notice suspended. |
| May 13, 2026 | In committee: Set, first hearing. Referred to APPR. suspense file. |
| Apr 22, 2026 | From committee: Do pass and re-refer to Com. on APPR. (Ayes 16. Noes 0.) (April 21). Re-referred to Com. on APPR. |
| Mar 2, 2026 | Referred to Com. on HEALTH. |
| Feb 13, 2026 | From printer. May be heard in committee March 15. |
| Feb 12, 2026 | Read first time. To print. |
|
Date
|
Description
|
Location
|
Votes
|
|
|---|---|---|---|---|
| Aug 28, 2026 | AB 1906 Aguiar-Curry Concurrence in Senate Amendments | Assembly Floor |
Passed |
|
| Aug 27, 2026 | Assembly 3rd Reading AB1906 Aguiar-Curry By Pérez | Senate Floor |
Passed |
|
| Aug 13, 2026 | Do pass | Senate Standing Committee on Appropriations |
Passed |
|
| Jun 29, 2026 | Placed on suspense file | Senate Standing Committee on Appropriations |
Passed |
|
| Jun 17, 2026 | Do pass as amended, but first amend, and re-refer to the Committee on [Appropriations] | Senate Standing Committee on Health |
Passed |
|
| May 21, 2026 | AB 1906 Aguiar-Curry Assembly Third Reading | Assembly Floor |
Passed |
|
| May 14, 2026 | Do pass. | Assembly Standing Committee on Appropriations |
Passed |
|
| Apr 21, 2026 | Do pass and be re-referred to the Committee on [Appropriations] | Assembly Standing Committee on Health |
Passed |
This list shows positions taken on this bill by organizations on the date displayed, which is linked to the original source.
Positions by individuals are not included.
|
Organization
|
Position
|
Date
|
|---|---|---|
| American Association Of University Women - California | ** Support | |
| American Association of University Women - San Jose Branch | ** Support | |
| AMERICAN COLLEGE OF OBSTETRICIANS & GYNECOLOGISTS - DISTRICT IX | ** Support | |
| American College of Surgeons, Southern California Chapter | ** Support | |
| America’s Health Insurance Plans | ** Against | |
| America'S Health Insurance Plans | ** Against | |
| Association Of California Life & Health Insurance Companies | ** Against | |
| Association of Health Insurance Plans | ** Against | |
| Association of LIfe and Health Insurance Companies | ** Against | |
| Biocom | ** Support | |
| California Association Of Health Plans | ** Against | |
| California Commission on the Status of Women and Girls | ** Support | |
| California Federation Of Teachers | ** Support | |
| California Life Sciences Association | ** Support | |
| California Pan-Ethnic Health Network | ** Support | |
| CALIFORNIA PRIMARY CARE ASSOCIATION ADVOCATES | ** Support | |
| California Retired Teachers Association | ** Support | |
| California Small Business Association | ** Against | |
| California State Retirees | ** Support | |
| Health Access California | ** Support | |
| Informed Policy Advocates | ** Support | |
| Planned Parenthood Affiliates Of California | ** Support | |
| Teal Health | ** Support | |
| Western Center on Law & Poverty, INC. | ** Support |
CONCURRENCE IN SENATE AMENDMENTS
CSA1 Bill Id:AB 1906
Author:(Aguiar-Curry)
As Amended Ver:August 21, 2026
Majority vote
SUMMARY
Requires a health plan, health insurer, and the Medi-Cal program to cover cervical cancer screening without cost-sharing, including United States Food and Drug Administration (FDA)-authorized or cleared self-collected cervical screening kits, when ordered or provided by an in-network provider and consistent with recommendations published by the California Department of Public Health (DPH) and Medi-Cal policies.
Senate Amendments
Make technical and clarifying changes, including that the screening kits are "self-collected" instead of "at home" and to align coverage with state guidelines and policies.
COMMENTS
Cervical cancer is a type of cancer that develops in the cells of the cervix, the lower, narrow end of the uterus. Persistent infection with high-risk human papillomavirus (HPV) can cause cells of the cervix to go through dysplasia, a change that causes abnormal cells called precancers to appear in the cervical tissue. These abnormal cells can become cancerous if they are not destroyed or removed. HPV is the most common sexually transmitted disease (STD) in the United States, with an estimated 13 million new cases each year, and will infect approximately 85% of the population at some point in their lifetime. Cervical cancer remains the most common HPV-related cancer. Although HPV vaccination is anticipated to lead to a 90% reduction in cervical cancer among those vaccinated during adolescence, studies have shown that the full benefits of vaccination do not occur until the vaccinated population reaches mid- to late life. As a result, cervical cancer screening remains an important preventative measure against cervical cancer. Cervical cancer screening detects precancerous changes in cervical cells so that treatment can prevent the development of invasive cancer. There are three primary methods for screening for cervical cancer: HPV testing, which checks cells for infection with high-risk HPV; Pap testing, where cervical cells are checked for abnormalities caused by HPV that may indicate precancerous or cancerous cells on the cervix; and the HPV/Pap co-test, which combines both methods to detect both high-risk HPV and cellular abnormalities.
Self-collected HPV screenings. Historically, samples for both the HPV test and Pap test have been collected from the cervix during a pelvic exam by a health care provider in a clinical setting. More recently, technology has developed to allow for HPV testing to be performed using self-collected samples. There are two ways in which self-collection can occur:
- Self-collection in a health clinic or office: Tests that are approved by the United State Food and Drug Administration (FDA) to self-collect specimens in a health care facility under the supervision of a health care provider. As of September 2025, three in-clinic self-collection tests have received FDA approval.
- Self-collection at home: Tests that are approved, authorized, or cleared by the FDA to self-collect specimens in the home or a similarly private setting. Home test kits are provided by a health care provider and mailed back by the user to a lab for processing In May 2025, the FDA authorized the first device for self-collection of cervical specimens in the home. This test – the Teal Wand – is the only one of its kind with FDA authorization on the market. This bill aims to ensure coverage, at zero cost sharing, for this type of HPV screening.
Federal and state coverage of cervical cancer screening. Both the California Preventive Services Mandate and the Federal Preventive Services Mandate require coverage of certain preventive services without cost sharing. Federal bodies, including the United States Preventive Service Task Force, Health Resources & Services Administration (HRSA), and Advisory Committee on Immunization Practices review preventive services and make recommendations on coverage. Plans are required to provide such coverage within 12 months of the recommendation's publication. On January 5, 2026, the HRSA guidelines for women's preventive services updated its recommendation for cervical cancer screening to include self-collected HPV testing as a service to be offered as an option for cervical cancer screening in women aged 30 to 65 years at average risk. As such, impacted plans will be required to cover some form of self-collected HPV tests without cost sharing by January 2027. However, at-home test kits for cervical cancer screening are only one form of patient-collected testing, impacted plans may not necessarily cover them without cost sharing as a result of this HRSA recommendation. Some patient-collected tests are performed in a clinical setting, and plans may choose to cover this form of testing without cost sharing instead.
Despite the federal government moving to mandate the coverage of self-collected HPV testing without cost sharing, coverage in California is unclear. AB 144 (Committee on Budget), Chapter 105, Statutes of 2025, froze federal preventive service recommendations as of January 1, 2025, and empowered the State Department of Public Health (DPH) to modify or supplement these recommendations going forward. At the time this analysis was finalized, DPH had not published a recommendation for self-collected HPV tests. DPH indicated that they are still evaluating the recommendation and "if the department finds credible evidence and support for recommendation and reimbursement of these tests, then the recommendation will be filed with the Office of Administrative Law and posted on our website."
California Health Benefits Review Program (CHBRP). CHBRP was created in response to AB 1996 (Thomson), Chapter 795, Statutes of 2002, which requests the University of California to assess legislation proposing a mandated benefit or service and prepare a written analysis with relevant data on the medical, economic, and public health impacts of proposed health plan and health insurance benefit mandate legislation. SB 125 (Hernandez), Chapter 9, Statutes of 2015, added an impact assessment on essential health benefits, and legislation that impacts health insurance benefit designs, cost-sharing, premiums, and other health insurance topics to CHBRP's purview. CHBRP reviewed this bill and included the following impact estimates in their analysis:
- Premium increases & enrollee out-of-pocket decreases. Premiums paid by employers and enrollees would increase upon enaction of this bill by an estimated $1,580,000 annually, impacting market segments differently at a range of $0.00002-$0.0111 per member per month. This bill would expand coverage without cost sharing for at-home HPV kits to 60% of enrollees who currently lack it.
- Increased utilization of care. This bill would result in 6,798 enrollees using at-home HPV test kits, an increase of 5,753 new users. CHBRP estimates that 13% of women enrolled in state-regulated commercial plans and 8% of women enrolled in state-regulated Medi-Cal plans aged 30 to 65 years currently use cervical cancer screening services annually, with 1% of those screenings conducted using at-home test kits. CHBRP attributes the increases in utilization to the expansion of coverage for those who don't have it, the removal of cost sharing for those who currently have it, and increased awareness and convenience of the at-home screening option.
- Public health impacts. CHRBP determined that this bill would produce no measurable short-term public health impact. However, over time, home test kits may address disparities in screening rates by reducing certain barriers to screening, including structural, individual, and cultural barriers.
Office of Health Care Affordability (OHCA) cost targets. OHCA was established in 2022 in response to widespread cost-related access challenges across California. According to the California Health Care Foundation (CHCF), over half of Californians say they skip or delay health care due to costs. OHCA collects, analyzes, and publicly reports data on total health care expenditures and enforces spending targets. OHCA's spending targets are intended to reduce excess spending and slow health care spending growth. In April of 2024, OHCA approved a statewide cost growth target of 3.5% starting in 2025 and phasing down to 3% by 2029. Health care entities, including health plans and insurers, are subject to the statewide spending target and are subject to progressive enforcement if the entity's costs exceed the target. Some entities have raised concerns that new legislative insurance mandates will make it difficult for them to meet the established cost growth target.
Current law does not explicitly require OHCA to adjust the cost growth targets based on changes to state policy, such as insurance mandates, that may increase spending. However, it does require OHCA to consider state benefit mandates in its development and enforcement of cost growth targets. Specifically, when establishing cost growth target methodology, OHCA is required to review relevant state policy changes impacting covered benefits, provider reimbursement, and costs, among other factors. In addition, in enforcing cost growth targets, OHCA is required to consider factors that contribute to spending in excess of the applicable target, and the extent to which each entity has control over the applicable components of its cost target.
According to the Author
Cervical cancer is the fourth most common cancer among women and is almost always caused by HPV. The author continues that if caught early, it's highly treatable—but too many Californians, especially those in rural communities and Black and Native populations, face deadly late-stage diagnoses. The author notes that cervical cancer screenings have cut deaths by about 70% since 1950, but many people still do not get tested because they lack coverage or cannot easily access a clinic. The author continues that recent federal guidance has confirmed the importance of expanding access to cervical cancer screenings by requiring private health plans to cover at-home test kits beginning in 2027. The author states that DPH has not yet adopted these federal guidelines, leaving Californians without this life-saving care. The author continues that this bill will require coverage of at-home cervical cancer tests at no cost to patients, making preventive care affordable, promoting early detection, and reducing health disparities. The author concludes that this bill also offers significant long-term cost savings for the state, health systems, and insurers by reducing the need for in-person visits and preventing costly late-stage cancer treatments.
Arguments in Support
Planned Parenthood Affiliates of California (PPAC) support this bill, stating that cervical cancer is the fourth most common cancer among women globally, with about 99.7% of cases caused by persistent HPV infection. PPAC notes that cervical cancer has a five-year survival rate of about 91% which drops to about 20% for late-stage diagnoses. PPAC continues that disparities exist with rural women 25% more likely to be diagnosed and 42% more likely to die, while Black and Native women experience mortality rates about 55% and 80% higher than white women. PPAC cites the Centers for Disease Control and Prevention (CDC), which found that widespread screening has reduced cervical cancer incidence and mortality by about 70% since the 1950s. PPAC continues that CDC research also shows that at-home HPV test kits can more than double screening participation and reduce costs for health systems and insurers by eliminating the need for in-office visits and clinician time. PPAC notes this is particularly helpful for people already facing barriers to in-person care. PPAC concludes that this bill expands access to critical preventive care that will save lives, especially for rural and working Californians facing barriers to in-person cervical cancer screening.
Arguments in Opposition
The Association of Health Insurance Plans (AHIP) writes that this is one of ten health insurance mandate bills that will increase costs, reduce choice and competition, and further incent some employers and individuals to avoid state regulated coverage by seeking alternative coverage options, and that state mandates increase premium costs for families and individuals and small business owners who cannot or do not wish to self-insure. AHIP continues that large employers, unions, small businesses, and hard-working families value their ability to shop for the right health plan – at the right price – that best fits their needs. AHIP argues that benefit mandates impose a one-size-fits-all approach to medical care and benefit design without consideration for consumer choice.
FISCAL COMMENTS
According to the Senate Appropriations Committee, unknown costs, potentially hundreds of thousands to low millions, in the Medi-Cal program due to increased utilization of cervical cancer screenings (General Fund and federal funds). Unknown costs for Department of Managed Health Care for state administration (Managed Care Fund). The California Department of Insurance estimates costs of $7,000 in 2026-27 and $19,000 in 2027-28 for state administration (Insurance Fund). Unknown ongoing General Fund costs, likely minor, due to increased California Public Employees' Retirement System plan premiums.
VOTES:
ASM HEALTH: 16-0-0
YES: Bonta, Chen, Addis, Aguiar-Curry, Ahrens, Caloza, Carrillo, Mark González, Johnson, Patel, Patterson, Rogers, Sanchez, Schiavo, Sharp-Collins, Stefani
ASM APPROPRIATIONS: 14-0-1
YES: Wicks, Hoover, Aguiar-Curry, Calderon, Caloza, Dixon, Fong, Mark González, Krell, Pacheco, Pellerin, Sharp-Collins, Solache, Ta
ABS, ABST OR NV: Tangipa
ASSEMBLY FLOOR: 73-0-7
YES: Addis, Aguiar-Curry, Ahrens, Alanis, Alvarez, Ávila Farías, Bains, Bauer-Kahan, Bennett, Berman, Boerner, Bonta, Bryan, Calderon, Caloza, Carrillo, Castillo, Connolly, Davies, DeMaio, Dixon, Elhawary, Ellis, Flora, Fong, Gabriel, Gallagher, Gipson, Jeff Gonzalez, Mark González, Hadwick, Haney, Harabedian, Hart, Hoover, Irwin, Jackson, Johnson, Kalra, Krell, Lee, Lowenthal, Macedo, McKinnor, Muratsuchi, Nguyen, Ortega, Pacheco, Papan, Patel, Patterson, Pellerin, Petrie-Norris, Quirk-Silva, Ransom, Michelle Rodriguez, Rogers, Blanca Rubio, Sanchez, Schiavo, Schultz, Sharp-Collins, Solache, Soria, Stefani, Ta, Valencia, Wallis, Ward, Wicks, Wilson, Zbur, Rivas
ABS, ABST OR NV: Arambula, Chen, Garcia, Lackey, Ramos, Celeste Rodriguez, Tangipa
UPDATED
VERSION: June 22, 2026
CONSULTANT: Riana King / HEALTH / (916) 319-2097 FN: 0004114
SENATE RULES COMMITTEE Office of Senate Floor Analyses (916) 651-4171 | AB 1906 |
THIRD READING
Bill No: AB 1906
Author: Aguiar-Curry (D)
Amended: 8/21/26 in Senate
Vote: 21
SENATE HEALTH COMMITTEE: 11-0, 6/17/26
AYES: Weber Pierson, Valladares, Caballero, Durazo, Gonzalez, Grove, Menjivar, Padilla, Pérez, Rubio, Smallwood-Cuevas
SENATE APPROPRIATIONS COMMITTEE: 7-0, 8/13/26
AYES: Cervantes, Seyarto, Cabaldon, Dahle, Grayson, Richardson, Wahab
ASSEMBLY FLOOR: 73-0, 5/21/26 - See last page for vote
SUBJECT: Health care coverage: home test kits
SOURCE: Author
DIGEST:
This bill requires health plans, insurers, and Medi-Cal to provide coverage without cost-sharing for cervical cancer screening when ordered or provided by an in-network provider consistent with nationally recognized clinical guidelines, instead of annually, and includes coverage for cervical cancer screening test kits that allow patients to self-collect at a location outside of a clinical setting that is ordered by the patient’s health care provider .
Senate Floor Amendments of 8/21/26 replace “nationally recognized clinical guidelines” with any relevant recommendations published by the California Department of Public Health (CDPH), as specified. Exempt vision-only, dental-only, or Medicare supplement health plan contracts and insurance policies, as well as Medi-Cal managed care plan contracts, as specified. Remove provisions from this bill regarding billing codes home test kits for sexually transmitted diseases. Make cervical cancer screening tests under Medi-Cal subject to medical necessity and utilization management controls, to the extent required or permitted by federal law. Make cervical cancer screening test kits for screening that allow patients to self-collect samples covered subject to medical necessity and utilization management controls. Require cervical cancer screening test kits covered under Medi-Cal to be ordered or provided by a patient’s health care provider and to be consistent with recommendations published by CDPH, and Medi-Cal policies. Require Medi-Cal reimbursement for a cervical cancer screening test kit to use a clinically appropriate Current Procedural Terminology or Healthcare Common Procedure Coding System billing code in order to comply with Health Insurance Portability and Accountability Act requirements. Indicate Medi-Cal coverage for cervical cancer screening test kits is a covered benefit only to the extent that federal financial participation is available and not otherwise jeopardized and any necessary federal approvals have been obtained. Permit DHCS to implement, interpret, or make specific this coverage by means of all-county letters, plan letters, plan or provider bulletins, or similar instructions.
ANALYSIS:
Existing law:
- Establishes the Department of Managed Health Care (DMHC) to regulate health plans under the Knox-Keene Health Care Service Plan Act of 1975 (Knox-Keene Act) and the California Department of Insurance (CDI) to regulate health insurance. [Health and Safety Code (HSC) §1340, et seq. and Insurance Code (INS) §106, et seq.]
- Requires every individual and group health plan contract, except specialized health plans, and a disability insurance policy that covers hospital, medical, or surgical benefits to provide coverage for an annual cervical cancer screening test (includes conventional Pap test, federal Food and Drug Administration (FDA)-approved human papillomavirus (HPV) screening test, and the option of any cervical cancer screening test approved by the FDA) upon the referral of the patient’s physician and surgeon, a nurse practitioner, or a certified nurse-midwife, providing care to the patient and operating withing the scope of practice otherwise permitted for the licensee. Permits application of a deductible or copayment in an existing plan contract. [HSC §1367.66 and INS §10123.18]
- Establishes the Medi-Cal program, administered by the Department of Health Care Services (DHCS), under which qualified low-income individuals receive health care services. [Welfare and Institutions Code (WIC) §14000, et seq.]
- Establishes a schedule of benefits under the Medi-Cal program, which includes benefits required under federal law and benefits provided at the state’s option, both of which are funded with federal and state dollars. The schedule of benefits includes annual cervical cancer tests for screening or diagnostic purposes, upon the referral of a patient’s physician, to the extent required or permitted by federal law, and home test kits for STDs, including any laboratory costs of processing the kit, that are deemed medically necessary or appropriate and ordered directly by an enrolled provider or furnished through a standing order for patient use based on clinical guidelines and individual patient needs. [WIC §14132 and §14132.17]
- Requires a group or individual non-grandfathered (plans after the federal Affordable Care Act (ACA)) health plan contract or health insurance policy to, at a minimum, provide coverage without cost-sharing for the following (this is based on the ACA preventive services requirements):
- Evidence-based items or services that had in effect on January 1, 2025, a rating of “A” or “B” in United States Preventative Services Task Force (USPSTF) recommendations, as periodically updated or any modification or supplement to that recommendation adopted by the California Department of Public Health (CDPH), as specified;
- Additional preventive care and screenings for women not described in a) above as provided for in comprehensive guidelines supported by the Health Resources and Services Administration (HRSA), as specified, in effect on January 1, 2025, or any modification or supplement to that recommendation adopted by CDPH; and,
- Current USPSTF recommendations regarding breast cancer screening, mammography, and prevention in effect on January 1, 2025, or any modification or supplement to that recommendation adopted by CDPH. [HSC §1367.002 and INS §10112.2]
- Permits CDPH to modify or supplement baseline recommendations from entities described above that were in effect on January 1, 2025, and requires CDPH to publish any modifications or supplement and filed with the Secretary of State and published in the California Code of Regulations. [HSC §120164]
This bill:
- Requires a health plan contract, except a specialized health plan, and a disability insurance policy issued, amended, or renewed on or after January 1, 2027, to provide coverage for cervical cancer screening when ordered or provided by an in-network provider operating within their permitted scope of practice and consistent any relevant recommendations published by CDPH, including FDA-authorized or cleared self-collected cervical cancer screening kits that allow patients to self-collect samples a location outside of a clinical setting.
- Prohibits a health plan contract and disability insurance policy from imposing a deductible, coinsurance, copayment, or any other cost-sharing requirement on the coverage provided pursuant to this bill, to the extent the plan does not fail to be treated as a high deductible health plan, under federal law, as specified.
- Exempts vision-only, dental-only, Medicare supplement health plan contracts or insurance policies, and Medi-Cal managed care plans from 1) and 2) directly above.
- Requires Medi-Cal to cover cervical cancer tests for screening that are ordered by a patient’s health care provider and consistent with any relevant recommendations published by CDPH to the extent required or permitted by federal law, including FDA-authorized or cleared cervical cancer home test kits for screening that are ordered by a patient’s health care provider and consistent with Medi-Cal policies and any relevant recommendations published by CDPH. Subjects home test kits for screening to medical necessity and utilization management.
- Deletes the coverage requirement for annual cervical cancer screening.
Background
According to the author:
Cervical cancer is the fourth most common cancer among women and is almost always caused by HPV. If caught early, it’s highly treatable—but too many Californians, especially those in rural communities and Black and Native populations, face deadly late-stage diagnoses. Cervical cancer screenings have cut deaths by about 70% since 1950, but many people still do not get tested because they lack coverage or cannot easily access a clinic. Recent federal guidance has confirmed the importance of expanding access to cervical cancer screenings by requiring private health plans to cover at-home test kits beginning in 2027. CDPH has not yet adopted these federal guidelines, leaving Californians without this life-saving care. This bill will require coverage of at-home cervical cancer tests at no cost to patients, making preventive care affordable, promoting early detection, and reducing health disparities. This bill also offers significant long-term cost savings for the state, health systems, and insurers by reducing the need for in-person visits and preventing costly late-stage cancer treatments.
USPSTF recommendation. The USPSTF, with an A rating, recommends screening for cervical cancer every three years with cervical cytology alone in women ages 21 to 29 years and then every five years with clinician- or patient-collected high-risk HPV primary screening in women ages 30 to 65 years. As an alternative to HPV primary screening for women ages 30 to 65 years, the USPSTF recommends continued screening every three years with cervical cytology (Pap test) alone or screening every five years with high-risk HPV testing in combination with cytology (cotesting).
HRSA recommendation. HRSA adopted the Women’s Preventive Services Initiative recommendation for cervical cancer screening for average-risk women aged 21 to 65 years. For women aged 21 to 29 years, cervical cancer screening using Pap test (cytology) every three years is recommended. Co-testing with cytology and high-risk HPV testing is not recommended for women younger than 30 years. Women aged 30 to 65 years should be screened with primary high-risk HPV testing every five years or cytology and high-risk HPV testing every five years. If high risk HPV testing is not available, continue screening with cytology alone every three years. Women who are at average risk should not be screened more than once every three years. Patient-collected high risk HPV testing is an appropriate method and should be offered as an option for cervical cancer screening in women aged 30 to 65 years at average risk. Additional testing may be required to complete the screening process and follow-up findings on the initial screening. If additional testing (e.g., cytology, biopsy, colposcopy, extended genotyping, dual stain) and pathologic evaluation are indicated, these services also are recommended to complete the screening process for malignancies. Non-grandfathered group health plans and health insurance issuers offering group or individual health insurance coverage must cover without cost-sharing the services and screenings listed on the updated Women’s Preventive Services Guidelines for plan/policy years that begin one year after this date.
CDPH. CDPH endorses the recommendations of the USPSTF as they stood on January 1, 2025, and HRSA published updates regarding cervical cancer screening for average-risk people on January 5, 2026, with a clarifying addition to align with the American Cancer Society. The CDPH endorsed recommendations are described below and will be published (with potential updates) by CDPH before February 1, 2027. California regulated health plans and insurers are expected to cover these services without cost-sharing by February 1, 2027:
- Age 21-29 years - Cervical cytology every 3 years.
- Age 30-65 years - Primary high-risk Human Papillomavirus (hrHPV) testing is preferred.
- Clinician collected hrHPV or co-testing (hrHPV plus cervical cytology) every five years.
- If hrHPV testing is not available, cervical cytology (alone) every three years.
- Self-collected hrHPV testing should be offered as an alternative to clinician collected hrHPV testing in order to increase screening rates and improve health equity.
- Screening after a negative self-collected hrHPV test should be repeated in three years (American Cancer Society 2025).
- Additional testing that may be required to complete the screening process and follow-up screening findings are recommended and should be covered without cost-sharing.
- Implementation, systems and infrastructure support for self-collection screening and follow-up testing outside of the clinical setting should be considered.
California Health Benefits Review Program (CHBRP) report. Key findings include:
- Cervical cancer screening. Cervical cancer screening detects precancerous changes in cervical cells so that treatment can prevent the development of invasive cancer. The three primary methods of testing are: 1) HPV testing which checks cells for infection with high-risk HPV types of cells; 2) Cytology or Pap testing, where cervical cells are checked for abnormalities caused by HPV. Pap testing does not detect high risk HPV; and, 3) HPV/Pap co-test which tests for both abnormal cells and high-risk HPV infection. There are three FDA approved tests for self-collection in a clinic or office, and two self-collection tests for home: one is FDA authorized, and one is FDA cleared. CHBRP reports 25% of women in the U.S. are under screened and 2% require more frequent screening due to abnormal results or immunosuppression. Studies have also found 41% of women screened with Pap tests, 51% with co-testing, and 9% with HPV testing were over-screened.
- Coverage impacts and enrollees covered. CHBRP indicates that 40% of enrollees in state regulated health insurance have coverage without cost-sharing for home test kits.
- Medical effectiveness. According to CHBRP, the scientific consensus and pooled data indicate very strong evidence that, when instructions are properly followed, self-samples provide accurate, stable, and clinically valid HPV detection suitable for future widespread home-based screening. Currently, the Teal Wand is the only FDA-authorized home test kit for cervical cancer screening for use at the time of the CHBRP report. The Teal Wand can be requested online through the Teal Health website. Ordering the kit requires attending a virtual visit with a Teal provider to review the patient’s screening history and discuss the at-home screening steps. The test kit is mailed and returned once the sample is collected. Virtual consultation to discuss follow-up care is available through Teal Health. A second product has been cleared by the FDA, BD Onclarity HPV Assay, in April 2026. CHBRP also indicates that some health systems in California are planning their own self-collection screening programs outside of the Teal mechanism, using their own laboratories and mailing infrastructure.
FISCAL EFFECT: Appropriation: No Fiscal Com.: Yes Local: Yes
According to the Senate Appropriations Committee, unknown costs, potentially hundreds of thousands to low millions, in the Medi-Cal program due to increased utilization of cervical cancer screenings (General Fund and federal funds).
Unknown costs for DMHC for state administration (Managed Care Fund).
CDI estimates costs of $7,000 in 2026-27 and $19,000 in 2027-28 for state administration (Insurance Fund).
Unknown ongoing General Fund costs, likely minor, due to increased California Public Employees' Retirement System plan premiums.
SUPPORT: (Verified 8/21/26)
American Association of University Women - California
American Association of University Women - San Jose Branch
American College of Obstetricians & Gynecologists - District IX
American College of Surgeons, Southern California Chapter
Biocom
California Commission on the Status of Women and Girls
California Federation of Teachers
California Life Sciences Association
California Pan-Ethnic Health Network
California Primary Care Association Advocates
California Retired Teachers Association
California State Retirees
Health Access California
Informed Policy Advocates
Planned Parenthood Affiliates of California
Teal Health
Western Center on Law & Poverty, Inc.
OPPOSITION: (Verified 8/21/26)
America's Health Insurance Plans
ARGUMENTS IN SUPPORT: American College of Obstetricians & Gynecologists (ACOG) writes this bill addresses barriers by ensuring coverage of clinician-referred home screening options, which can increase screening uptake, particularly among underserved and hard-to-reach populations. According to ACOG, by requiring coverage without cost-sharing across both commercial markets and Medi-Cal, this bill promotes equitable access to lifesaving preventive care, and early detection of cervical cancer and precancerous conditions significantly improve outcomes, reduces the need for more invasive treatment, and lowers long-term health care costs. ACOG writes this bill maintains the role of the patient’s health care provider in recommending and guiding appropriate screening, ensuring continuity and quality of care.
ARGUMENTS IN OPPOSITION: The Association of Health Insurance Plans writes that this is one of ten health insurance mandate bills that will increase costs, reduce choice and competition, and further incent some employers and individuals to avoid state regulated coverage by seeking alternative coverage options.
ASSEMBLY FLOOR: 73-0, 5/21/26
AYES: Addis, Aguiar-Curry, Ahrens, Alanis, Alvarez, Ávila Farías, Bains, Bauer-Kahan, Bennett, Berman, Boerner, Bonta, Bryan, Calderon, Caloza, Carrillo, Castillo, Connolly, Davies, DeMaio, Dixon, Elhawary, Ellis, Flora, Fong, Gabriel, Gallagher, Gipson, Jeff Gonzalez, Mark González, Hadwick, Haney, Harabedian, Hart, Hoover, Irwin, Jackson, Johnson, Kalra, Krell, Lee, Lowenthal, Macedo, McKinnor, Muratsuchi, Nguyen, Ortega, Pacheco, Papan, Patel, Patterson, Pellerin, Petrie-Norris, Quirk-Silva, Ransom, Michelle Rodriguez, Rogers, Blanca Rubio, Sanchez, Schiavo, Schultz, Sharp-Collins, Solache, Soria, Stefani, Ta, Valencia, Wallis, Ward, Wicks, Wilson, Zbur, Rivas
NO VOTE RECORDED: Arambula, Chen, Garcia, Lackey, Ramos, Celeste Rodriguez, Tangipa
Prepared by: Teri Boughton / HEALTH / (916) 651-4111
8/24/26 14:07:54
**** END ****
SENATE RULES COMMITTEE Office of Senate Floor Analyses (916) 651-4171 | AB 1906 |
THIRD READING
Bill No: AB 1906
Author: Aguiar-Curry (D)
Amended: 6/22/26 in Senate
Vote: 21
SENATE HEALTH COMMITTEE: 11-0, 6/17/26
AYES: Weber Pierson, Valladares, Caballero, Durazo, Gonzalez, Grove, Menjivar, Padilla, Pérez, Rubio, Smallwood-Cuevas
SENATE APPROPRIATIONS COMMITTEE: 7-0, 8/13/26
AYES: Cervantes, Seyarto, Cabaldon, Dahle, Grayson, Richardson, Wahab
ASSEMBLY FLOOR: 73-0, 5/21/26 - See last page for vote
SUBJECT: Health care coverage: home test kits
SOURCE: Author
DIGEST:
This bill requires health plans, insurers, and Medi-Cal to provide coverage without cost-sharing for cervical cancer screening when ordered or provided by an in-network provider consistent with nationally recognized clinical guidelines, instead of annually, and includes coverage for cervical cancer screening test kits that allow patients to self-collect at a location outside of a clinical setting that is ordered by the patient’s health care provider. Eliminates a Medi-Cal and Family Planning, Access, Care, and Treatment (PACT) reimbursement requirement for home test kits for sexually transmitted diseases that is contingent upon the addition of billing codes specific to home test kits.
ANALYSIS:
Existing law:
- Establishes the Department of Managed Health Care (DMHC) to regulate health plans under the Knox-Keene Health Care Service Plan Act of 1975 (Knox-Keene Act) and the California Department of Insurance (CDI) to regulate health insurance. [Health and Safety Code (HSC) §1340, et seq. and Insurance Code (INS) §106, et seq.]
- Requires every individual and group health plan contract, except specialized health plans, and a disability insurance policy that covers hospital, medical, or surgical benefits to provide coverage for an annual cervical cancer screening test (includes conventional Pap test, federal Food and Drug Administration (FDA)-approved human papillomavirus (HPV) screening test, and the option of any cervical cancer screening test approved by the FDA) upon the referral of the patient’s physician and surgeon, a nurse practitioner, or a certified nurse-midwife, providing care to the patient and operating withing the scope of practice otherwise permitted for the licensee. Permits application of a deductible or copayment in an existing plan contract. [HSC §1367.66 and INS §10123.18]
- Requires a health plan or insurance policy to provide coverage for the HPV vaccine for enrollees for whom the vaccine is approved by the FDA. Prohibits a plan contract from imposing a deductible, coinsurance, copayment, or any other cost-sharing requirement on this coverage. [HSC §1367.66 and INS §10123.18]
- Requires every health plan contract and insurance policy to provide coverage for home test kits for sexually transmitted diseases (STDs), including any laboratory costs of processing the kit, that are deemed medically necessary or appropriate and ordered directly by a clinician or furnished through a standing order for patient use based on clinical guidelines and individual patient health needs. Requires health plan and insurer coverage when ordered by an in-network provider. [HSC §1367.34 and INS §10123.208]
- Establishes the Medi-Cal program, administered by the Department of Health Care Services (DHCS), under which qualified low-income individuals receive health care services. [Welfare and Institutions Code (WIC) §14000, et seq.]
- Establishes a schedule of benefits under the Medi-Cal program, which includes benefits required under federal law and benefits provided at the state’s option, both of which are funded with federal and state dollars. The schedule of benefits includes annual cervical cancer tests for screening or diagnostic purposes, upon the referral of a patient’s physician, to the extent required or permitted by federal law, and home test kits for STDs, including any laboratory costs of processing the kit, that are deemed medically necessary or appropriate and ordered directly by an enrolled provider or furnished through a standing order for patient use based on clinical guidelines and individual patient needs. [WIC §14132 and §14132.17]
- Defines “home test kit” as a product used for a test recommended by the federal Centers for Disease Control and Prevention (CDC) guidelines or the U.S. Preventive Services Task Force (USPSTF) that have been Clinical Laboratory Improvement Act-waived, FDA-cleared or -approved, or developed by a laboratory in accordance with regulations and quality standards to allow individuals to self-collect specimens for STDs, including HIV, remotely at a location outside of a clinical setting. [WIC §14132, §14132.17, §24007, HSC §1367.34 and INS §10123.208]
- Makes Medi-Cal and State-only family planning reimbursement under 6) and 7) above contingent upon the addition of codes specific to home test kits in the Current Procedural Terminology (CPT) or Healthcare Common Procedure Coding System (HCPCS). Requires the home test kit to be sent by the enrolled provider to a Medi-Cal-enrolled laboratory with fees based on Medicare Clinical Diagnostic Laboratory Test Payment System Final Rule. [WIC §14132, §14132.17 and §24007]
- Requires a group or individual nongrandfathered (plans after the federal Affordable Care Act (ACA)) health plan contract or health insurance policy to, at a minimum, provide coverage without cost-sharing for all of the following (this is based on the ACA preventive services requirements):
- Evidence-based items or services that had in effect on January 1, 2025, a rating of “A” or “B” in USPSTF recommendations, as periodically updated or any modification or supplement to that recommendation adopted by the California Department of Public Health (CDPH), as specified;
- Immunizations that had in effect on January 1, 2025, a recommendation, as periodically updated, from the Advisory Committee on Immunization Practices (ACIP) of the CDC or any modification or supplement to that recommendation adopted by CDPH, as specified;
- Evidence-informed preventive care and screening with respect to infants, children, and adolescents provided in the comprehensive guidelines, as periodically updated, supported by the Health Resources and Services Administration (HRSA) in effect on January 1, 2025, or any modification or supplement to that recommendation adopted by CDPH;
- Additional preventive care and screenings for women not described in a) above as provided for in comprehensive guidelines supported by HRSA, as specified, in effect on January 1, 2025, or any modification or supplement to that recommendation adopted by CDPH; and,
- Current USPSTF recommendations regarding breast cancer screening, mammography, and prevention in effect on January 1, 2025, or any modification or supplement to that recommendation adopted by CDPH. [HSC §1367.002 and INS §10112.2]
- Requires, notwithstanding Existing Law 9a) above, health plan contracts and insurance policies to cover items and services in accordance with any applicable requirement of specified law, including, but not limited to, prophylaxis of HIV infection, home test kits for sexually transmitted diseases, cervical cancer screening, and colorectal cancer screening. [HSC §1367.002 and INS §10112.2]
This bill:
- Requires a health plan contract, except a specialized health plan, and a disability insurance policy issued, amended, or renewed on or after January 1, 2027, to provide coverage for cervical cancer screening when ordered or provided by an in-network provider operating within their permitted scope of practice and consistent with nationally recognized clinical guidelines, including FDA-authorized or cleared self-collected cervical cancer screening kits that allow patients to self-collect samples a location outside of a clinical setting.
- Prohibits a health plan contract and disability insurance policy from imposing a deductible, coinsurance, copayment, or any other cost-sharing requirement on the coverage provided pursuant to this bill, to the extent the plan does not fail to be treated as a high deductible health plan, under federal law, as specified.
- Requires Medi-Cal to cover cervical cancer tests for screening that are ordered by a patient’s health care provider and consistent with nationally recognized clinical guidelines to the extent required or permitted by federal law, including FDA-authorized or cleared cervical cancer home test kits for screening that are ordered by a patient’s health care provider and consistent with nationally recognized guidelines. Indicates a Medi-Cal beneficiary is not subject to any cost-sharing, including but not limited to, a share of cost or spend down of excess income, as specified. Applies this requirement to fee-for-service and the managed care delivery system.
- Eliminates a Medi-Cal and Family PACT requirement for STD home test kits, including HIV tests, that reimbursement is contingent upon the addition of codes specific to home test kits in the CPT or HCPCS to comply with HIPAA requirements.
- Deletes the coverage requirement for annual cervical cancer screening.
Comments
According to the author:
Cervical cancer is the fourth most common cancer among women and is almost always caused by HPV. If caught early, it’s highly treatable—but too many Californians, especially those in rural communities and Black and Native populations, face deadly late-stage diagnoses. Cervical cancer screenings have cut deaths by about 70% since 1950, but many people still do not get tested because they lack coverage or cannot easily access a clinic. Recent federal guidance has confirmed the importance of expanding access to cervical cancer screenings by requiring private health plans to cover at-home test kits beginning in 2027. CDPH has not yet adopted these federal guidelines, leaving Californians without this life-saving care. This bill will require coverage of at-home cervical cancer tests at no cost to patients, making preventive care affordable, promoting early detection, and reducing health disparities. This bill also offers significant long-term cost savings for the state, health systems, and insurers by reducing the need for in-person visits and preventing costly late-stage cancer treatments.
Background
USPSTF recommendation. The USPSTF, with an A rating, recommends screening for cervical cancer every three years with cervical cytology alone in women ages 21 to 29 years and then every five years with clinician- or patient-collected high-risk HPV primary screening in women ages 30 to 65 years. As an alternative to HPV primary screening for women ages 30 to 65 years, the USPSTF recommends continued screening every three years with cervical cytology (Pap test) alone or screening every five years with high-risk HPV testing in combination with cytology (cotesting).
HRSA recommendation. HRSA adopted the Women’s Preventive Services Initiative recommendation for cervical cancer screening for average-risk women aged 21 to 65 years. For women aged 21 to 29 years, cervical cancer screening using Pap test (cytology) every three years is recommended. Co-testing with cytology and high-risk HPV testing is not recommended for women younger than 30 years. Women aged 30 to 65 years should be screened with primary high-risk HPV testing every five years or cytology and high-risk HPV testing every five years. If high risk HPV testing is not available, continue screening with cytology alone every three years. Women who are at average risk should not be screened more than once every three years. Patient-collected high risk HPV testing is an appropriate method and should be offered as an option for cervical cancer screening in women aged 30 to 65 years at average risk. Additional testing may be required to complete the screening process and follow-up findings on the initial screening. If additional testing (e.g., cytology, biopsy, colposcopy, extended genotyping, dual stain) and pathologic evaluation are indicated, these services also are recommended to complete the screening process for malignancies. Non-grandfathered group health plans and health insurance issuers offering group or individual health insurance coverage must cover without cost-sharing the services and screenings listed on the updated Women’s Preventive Services Guidelines for plan/policy years that begin one year after this date.
CDPH. CDPH endorses the recommendations of the USPSTF as they stood on January 1, 2025, and HRSA published updates regarding cervical cancer screening for average-risk people on January 5, 2026, with a clarifying addition to align with the American Cancer Society. The CDPH endorsed recommendations are described below and will be published (with potential updates) by CDPH before February 1, 2027. California regulated health plans and insurers are expected to cover these services without cost-sharing by February 1, 2027:
- Age 21-29 years - Cervical cytology every 3 years.
- Age 30-65 years - Primary high-risk Human Papillomavirus (hrHPV) testing is preferred.
- Clinician collected hrHPV or co-testing (hrHPV plus cervical cytology) every five years.
- If hrHPV testing is not available, cervical cytology (alone) every three years.
- Self-collected hrHPV testing should be offered as an alternative to clinician collected hrHPV testing in order to increase screening rates and improve health equity.
- Screening after a negative self-collected hrHPV test should be repeated in three years (American Cancer Society 2025).
- Additional testing that may be required to complete the screening process and follow-up screening findings are recommended and should be covered without cost-sharing.
- Implementation, systems and infrastructure support for self-collection screening and follow-up testing outside of the clinical setting should be considered.
California Health Benefits Review Program (CHBRP) report. Key findings include:
- Cervical cancer screening. HPV is the most common sexually transmitted infection in the U.S., with an estimated 13 million new cases each year. Cervical cancer is the most common HPV-related cancer. HPV vaccination is anticipated to lead to a 90% reduction in cervical cancer among those vaccinated during adolescence. However, the full benefits do not occur until the vaccinated population reaches mid- to late life. Cervical cancer screening detects precancerous changes in cervical cells so that treatment can prevent the development of invasive cancer. The three primary methods of testing are: 1) HPV testing which checks cells for infection with high-risk HPV types of cells; 2) Cytology or Pap testing, where cervical cells are checked for abnormalities caused by HPV. Pap testing does not detect high risk HPV; and, 3) HPV/Pap co-test which tests for both abnormal cells and high-risk HPV infection. There are three FDA approved tests for self-collection in a clinic or office, and two self-collection tests for home: one is FDA authorized, and one is FDA cleared. CHBRP reports 25% of women in the U.S. are under screened and 2% require more frequent screening due to abnormal results or immunosuppression. Studies have also found 41% of women screened with Pap tests, 51% with co-testing, and 9% with HPV testing were over-screened.
- Coverage impacts and enrollees covered. CHBRP indicates that 40% of enrollees in state regulated health insurance have coverage without cost-sharing for home test kits.
- Medical effectiveness. According to CHBRP, the scientific consensus and pooled data indicate very strong evidence that, when instructions are properly followed, self-samples provide accurate, stable, and clinically valid HPV detection suitable for future widespread home-based screening. Currently, the Teal Wand is the only FDA-authorized home test kit for cervical cancer screening for use at the time of the CHBRP report. The Teal Wand can be requested online through the Teal Health website. Ordering the kit requires attending a virtual visit with a Teal provider to review the patient’s screening history and discuss the at-home screening steps. The test kit is mailed and returned once the sample is collected. Virtual consultation to discuss follow-up care is available through Teal Health. A second product has been cleared by the FDA, BD Onclarity HPV Assay, in April 2026. CHBRP also indicates that some health systems in California are planning their own self-collection screening programs outside of the Teal mechanism, using their own laboratories and mailing infrastructure.
FISCAL EFFECT: Appropriation: No Fiscal Com.: Yes Local: Yes
According to the Senate Appropriations Committee, unknown costs, potentially hundreds of thousands to low millions, in the Medi-Cal program due to increased utilization of cervical cancer screenings (General Fund and federal funds).
Unknown costs for DMHC for state administration (Managed Care Fund).
CDI estimates costs of $7,000 in 2026-27 and $19,000 in 2027-28 for state administration (Insurance Fund).
Unknown ongoing General Fund costs, likely minor, due to increased California Public Employees' Retirement System plan premiums.
SUPPORT: (Verified 8/14/26)
American Association of University Women - California
American Association of University Women - San Jose Branch
American College of Obstetricians & Gynecologists - District IX
American College of Surgeons, Southern California Chapter
Biocom
California Commission on the Status of Women and Girls
California Federation of Teachers
California Life Sciences Association
California Pan-Ethnic Health Network
California Primary Care Association Advocates
California Retired Teachers Association
California State Retirees
Health Access California
Informed Policy Advocates
Planned Parenthood Affiliates of California
Teal Health
Western Center on Law & Poverty, Inc.
OPPOSITION: (Verified 8/14/26)
America's Health Insurance Plans
ARGUMENTS IN SUPPORT: ACOG writes this bill addresses barriers by ensuring coverage of clinician-referred home screening options, which can increase screening uptake, particularly among underserved and hard-to-reach populations. According to ACOG, by requiring coverage without cost-sharing across both commercial markets and Medi-Cal, this bill promotes equitable access to lifesaving preventive care, and early detection of cervical cancer and precancerous conditions significantly improve outcomes, reduces the need for more invasive treatment, and lowers long-term health care costs. ACOG writes this bill maintains the role of the patient’s health care provider in recommending and guiding appropriate screening, ensuring continuity and quality of care. Planned Parenthood Affiliates of California (PPAC) writes this bill also helps increase access to other STD home test kits for Medi-Cal patients by making technical changes to existing law to ensure that both HPV tests and other STD tests can be reimbursed in Medi-Cal. According to PPAC, this bill would create billing parity between commercial and Medi-Cal plans by removing the contingent application of coverage in Medi-Cal, which will allow Medi-Cal providers to use existing CPT and HCPCS codes for clinical laboratory tests, regardless of whether the collection of a lab sample occurs in a clinic or using a home test kit.
ARGUMENTS IN OPPOSITION: The Association of Health Insurance Plans (AHIP) writes that this is one of ten health insurance mandate bills that will increase costs, reduce choice and competition, and further incent some employers and individuals to avoid state regulated coverage by seeking alternative coverage options, and “state mandates increase premium costs for families and individuals and small business owners who cannot or do not wish to self-insure. Large employers, unions, small businesses, and hard-working families value their ability to shop for the right health plan – at the right price – that best fits their needs. Benefit mandates impose a one-size-fits-all approach to medical care and benefit design without consideration for consumer choice.”
ASSEMBLY FLOOR: 73-0, 5/21/26
AYES: Addis, Aguiar-Curry, Ahrens, Alanis, Alvarez, Ávila Farías, Bains, Bauer-Kahan, Bennett, Berman, Boerner, Bonta, Bryan, Calderon, Caloza, Carrillo, Castillo, Connolly, Davies, DeMaio, Dixon, Elhawary, Ellis, Flora, Fong, Gabriel, Gallagher, Gipson, Jeff Gonzalez, Mark González, Hadwick, Haney, Harabedian, Hart, Hoover, Irwin, Jackson, Johnson, Kalra, Krell, Lee, Lowenthal, Macedo, McKinnor, Muratsuchi, Nguyen, Ortega, Pacheco, Papan, Patel, Patterson, Pellerin, Petrie-Norris, Quirk-Silva, Ransom, Michelle Rodriguez, Rogers, Blanca Rubio, Sanchez, Schiavo, Schultz, Sharp-Collins, Solache, Soria, Stefani, Ta, Valencia, Wallis, Ward, Wicks, Wilson, Zbur, Rivas
NO VOTE RECORDED: Arambula, Chen, Garcia, Lackey, Ramos, Celeste Rodriguez, Tangipa
Prepared by: Teri Boughton / HEALTH / (916) 651-4111
8/15/26 15:19:07
**** END ****
SENATE COMMITTEE ON
Senator Sabrina Cervantes, Chair
2025 - 2026 Regular Session
AB 1906 (Aguiar-Curry) - Health care coverage: home test kits
Version: | Policy Vote: |
Urgency: | Mandate: |
Hearing Date: | Consultant: |
Bill Summary:
AB 1906 would require health coverage of cervical cancer home test kits, as specified.
Fiscal Impact:
- Unknown costs, potentially hundreds of thousands to low millions, in the Medi-Cal program due to increased utilization of cervical cancer screenings (General Fund and federal funds).
- Unknown costs for the Department of Managed Health Care (DMHC) for state administration (Managed Care Fund).
- The California Department of Insurance (CDI) estimates costs of $7,000 in 2026-27 and $19,000 in 2027-28 for state administration (Insurance Fund).
- Unknown ongoing General Fund costs, likely minor, due to increased CalPERS plan premiums.
Background:
Health Plan and Insurer Coverage of Cervical Cancer Screening. Current law requires health plans and insurers to provide coverage for an annual cervical cancer screening test upon the referral of the patient’s physician and surgeon, a nurse practitioner, or a certified nurse-midwife, providing care to the patient and operating within the scope of practice otherwise permitted for the licensee. The coverage for an annual cervical cancer screening test provided must include the conventional Pap test, a human papillomavirus screening test that is approved by the United States Food and Drug Administration (FDA), and the option of any cervical cancer screening test approved by the FDA, upon the referral of the patient’s health care provider. Current law allows the application of deductible or copayment provisions, as specified.
Medi-Cal Coverage of Cervical Cancer Screening. The Medi-Cal program provides health care services to qualified low-income individuals. Current law establishes a schedule of benefits under the Medi-Cal program. Medi-Cal covers annual cervical cancer tests for screening or diagnostic purposes, upon the referral of a patient’s physician, to the extent required or permitted by federal law.
Home Test Kits for Cervical Cancer Screening. According to the California Health Benefits Review Program (CHBRP), samples for a cervical cancer test have historically been collected from the cervix during a pelvic exam in a clinical setting. More recently, there have been developments to allow for some testing to be performed using self-collected samples, where a speculum or pelvic exam is not required. This can occur at home or in a health clinic or office, depending on the test used. Currently, there is only one U.S. Food and Drug Administration (FDA)-authorized home test kit for cervical cancer screening available for use (approved May 2025).
The CHBRP indicates that on January 5, 2026, the federal Health Resources and Services Administration (HRSA)-supported health plan coverage guidelines for women’s preventive services updated its recommendation for cervical cancer screening to include that patient-collected hrHPV testing is an appropriate method and should be offered as an option for cervical cancer screening in women aged 30 to 65 years at average risk. As such, impacted plans will be required to cover some form of patient-collected hrHPV tests without cost sharing by January 2027. However, as home test kits for cervical cancer screening are only one form of patient-collected testing, impacted plans may not necessarily cover them without cost sharing as a result of this HRSA recommendation. Some patient-collected tests are performed in a clinical setting, and plans may choose to cover this form of testing without cost sharing instead. In addition, the U. S. Preventive Services Task Force (USPSTF) has published a draft recommendation for patient-collected hrHPV testing and sought public comment. The USPTF guidelines will also have implications for determining plan coverage of these services.
Medi-Cal, Family PACT, and State-Only Family Planning Program Coverage of Home Test Kits for Sexually Transmitted Diseases (STDs). The Family PACT program and the State-Only Family Planning program provide comprehensive family planning and reproductive health services at no cost to eligible low-income Californians. The Medi-Cal, Family PACT, and State-Only Family Planning programs cover home test kits for sexually transmitted diseases that are deemed medically necessary or appropriate and ordered directly by an enrolled Medi-Cal or Family PACT clinician or furnished through a standing order for patient use based on clinical guidelines and individual patient health needs. Current law requires reimbursement for these home test kits to be contingent upon the addition of codes specific to home test kits in the Current Procedural Terminology or Healthcare Common Procedure Coding System to comply with federal Health Insurance Portability and Accountability Act (HIPAA) requirements.
Proposed Law:
Specific provisions of the bill would:
- Require health plans and insurers to provide coverage for cervical cancer screening that includes FDA-authorized or cleared self-collected cervical screening kits that allow patients to self-collect samples at a location outside of a clinical setting; and prohibit health plans and insurers from imposing a deductible, coinsurance, copayment, or any other cost-sharing requirement for cervical cancer screening.
- Require the Medi-Cal program to additionally cover as a benefit, FDA-authorized or cleared cervical cancer home test kits for screening that are ordered by a patient’s health care provider and consistent with nationally recognized clinical guidelines; and prohibit a Medi-Cal beneficiary from being subjected to any cost sharing, as specified.
- Delete the existing requirement that reimbursement for STD home test kits in the Medi-Cal, Family PACT, and State-Only Family Planning programs be contingent upon the addition of specified billing codes.
Staff Comments:
According to the CHBRP analysis of AB 1906 (introduced version), for DMHC-regulated plans and CDI-regulated policies, total premiums paid by employers and enrollees would increase by approximately $1,580,000. This includes an increase in CalPERS employer premiums of $69,000 and an increase in Medi-Cal premiums of $2,000.
-- END --
SENATE COMMITTEE ON HEALTH
Senator Akilah Weber Pierson, Chair
BILL NO: AB 1906
AUTHOR: | Aguiar-Curry | ||
VERSION: | June 8, 2026 | ||
HEARING DATE: | June 17, 2026 | ||
CONSULTANT: | Teri Boughton | ||
SUBJECT: Health care coverage: home test kits
SUMMARY:
- Requires health plans, insurers, and Medi-Cal to provide coverage without cost-sharing for an annual cervical cancer screening home test kit upon the referral of the patient’s health care provider. Eliminates a Medi-Cal and Family PACT reimbursement requirement for home test kits for sexually transmitted diseases that is contingent upon the addition of billing codes specific to home test kits.
Existing law:
- Establishes the Department of Managed Health Care (DMHC) to regulate health plans under the Knox-Keene Health Care Service Plan Act of 1975 (Knox-Keene Act) and the California Department of Insurance (CDI) to regulate health insurance. [HSC §1340, et seq. and INS §106, et seq.]
- Requires every individual and group health plan contract, except specialized health plans, and a disability insurance policy that covers hospital, medical, or surgical benefits to provide coverage for an annual cervical cancer screening test (includes conventional Pap test, federal Food and Drug Administration (FDA)-approved human papillomavirus (HPV) screening test, and the option of any cervical cancer screening test approved by the FDA) upon the referral of the patient’s physician and surgeon, a nurse practitioner, or a certified nurse-midwife, providing care to the patient and operating withing the scope of practice otherwise permitted for the licensee. Permits application of a deductible or copayment in an existing plan contract. [HSC §1367.66 and INS §10123.18]
- Requires a health plan or insurance policy to provide coverage for the HPV vaccine for enrollees for whom the vaccine is approved by the FDA. Prohibits a plan contract from imposing a deductible, coinsurance, copayment, or any other cost-sharing requirement on this coverage. [HSC §1367.66 and INS §10123.18]
- Requires every health plan contract and insurance policy to provide coverage for home test kits for sexually transmitted diseases (STDs), including any laboratory costs of processing the kit, that are deemed medically necessary or appropriate and ordered directly by a clinician or furnished through a standing order for patient use based on clinical guidelines and individual patient health needs. Requires health plan coverage when ordered by an in-network provider. [HSC §1367.34 and INS §10123.208]
- Establishes the Medi-Cal program, administered by the Department of Health Care Services (DHCS), under which qualified low-income individuals receive health care services. [WIC §14000, et seq.]
- Establishes a schedule of benefits under the Medi-Cal program, which includes benefits required under federal law and benefits provided at the state’s option, both of which are funded with federal and state dollars. The schedule of benefits includes annual cervical cancer tests for screening or diagnostic purposes, upon the referral of a patient’s physician, to the extent required or permitted by federal law, and home test kits for STDs, including any laboratory costs of processing the kit, that are deemed medically necessary or appropriate and ordered directly by an enrolled provider or furnished through a standing order for patient use based on clinical guidelines and individual patient needs. [WIC §14132 and §14132.17]
- Defines “home test kit” as a product used for a test recommended by the federal Centers for Disease Control and Prevention (CDC) guidelines or the U.S. Preventive Services Task Force (USPSTF) that have been Clinical Laboratory Improvement Act-waived, FDA-cleared or -approved, or developed by a laboratory in accordance with regulations and quality standards to allow individuals to self-collect specimens for STDs, including HIV, remotely at a location outside of a clinical setting. [WIC §14132, §14132.17, §24007, HSC §1367.34 and INS §10123.208]
- Makes Medi-Cal and State-only family planning reimbursement under 6) and 7) above contingent upon the addition of codes specific to home test kits in the Current Procedural Terminology (CPT) or Healthcare Common Procedure Coding System (HCPCS) to comply with Health Insurance Portability and Accountability Act requirements (HIPAA). Requires the home test kit to be sent by the enrolled provider to a Medi-Cal-enrolled laboratory with fees based on Medicare Clinical Diagnostic Laboratory Test Payment System Final Rule. [WIC §14132, §14132.17 and §24007]
- Requires a group or individual nongrandfathered (plans after the federal Affordable Care Act (ACA)) health plan contract or health insurance policy to, at a minimum, provide coverage without cost-sharing for all of the following (this is based on the ACA preventive services requirements):
- Evidence-based items or services that had in effect on January 1, 2025, a rating of “A” or “B” in USPSTF recommendations, as periodically updated or any modification or supplement to that recommendation adopted by the California Department of Public Health (CDPH), as specified;
- Immunizations that had in effect on January 1, 2025, a recommendation, as periodically updated, from the Advisory Committee on Immunization Practices (ACIP) of the CDC or any modification or supplement to that recommendation adopted by CDPH, as specified;
- Evidence-informed preventive care and screening with respect to infants, children, and adolescents provided in the comprehensive guidelines, as periodically updated, supported by the Health Resources and Services Administration (HRSA) in effect on January 1, 2025, or any modification or supplement to that recommendation adopted by CDPH;
- Additional preventive care and screenings for women not described in a) above as provided for in comprehensive guidelines supported by HRSA, as specified, in effect on January 1, 2025, or any modification or supplement to that recommendation adopted by CDPH; and,
- Current USPSTF recommendations regarding breast cancer screening, mammography, and prevention in effect on January 1, 2025, or any modification or supplement to that recommendation adopted by CDPH. [HSC §1367.002 and INS §10112.2]
- Requires, notwithstanding Existing Law 9a) above, health plan contracts and insurance policies to cover items and services in accordance with any applicable requirement of specified law, including, but not limited to, prophylaxis of HIV infection, home test kits for sexually transmitted diseases, cervical cancer screening, and colorectal cancer screening. [HSC §1367.002 and INS §10112.2]
This bill:
- Requires a health plan contract, except a specialized health plan, and a disability insurance policy issued, amended, or renewed on or after January 1, 2027, to provide coverage for an annual cervical cancer screening home test kit upon the referral of the patient’s health care provider.
- Prohibits a health plan contract and disability insurance policy from imposing a deductible, coinsurance, copayment, or any other cost-sharing requirement on the coverage provided pursuant to this bill.
- Requires Medi-Cal to cover annual cervical cancer home test kits for screening or diagnostic purposes, upon the referral of a patient’s health care provider, to the extent required or permitted by federal law. Indicates a Medi-Cal beneficiary is not subject to any cost-sharing, including but not limited to, a share of cost or spend down of excess income, as specified. Applies this requirement to fee-for-service and the managed care delivery system.
- Eliminates a Medi-Cal and Family PACT requirement for STD home test kits, including HIV tests, that reimbursement is contingent upon the addition of codes specific to home test kits in the CPT or HCPCS to comply with HIPAA requirements.
FISCAL EFFECT:
According to the Assembly Appropriations Committee (this analysis did not include an estimate related to the STD home test kit provisions):
- CHBRP estimates this bill will increase premiums in health plans and insurance policies offered though the California Public Employees Retirement System (CalPERS) by $69,000 for DMHC-regulated plans, of which the state's share would be around $30,000 (General Fund (GF)). There would also be increases to CalPERS premiums for health insurance policies regulated by CDI, the state's share of which would likely be less than $30,000 (GF).
- Minor and absorbable costs to DMHC.
- CDI estimates costs of $7,000 in fiscal year (FY) 2026-27 and $19,000 in FY 2027-28 (Insurance Fund).
- CHBRP estimates the bill could increase costs to the Medi-Cal program by $2,000 (GF, federal funds (FF)). However, DHCS states this bill could increase Medi-Cal expenditures in the range of low hundreds of thousands to low millions of dollars (GF, FF) due to indeterminate increased utilization that may result from requiring broad-based coverage of home cervical cancer screening kits versus case-by-case, individual medical necessity determinations. Actual expenditures may vary from this estimate based on the clinical guidelines ultimately adopted by the USPSTF and uptake of the new at-home cervical cancer screening kits by Medi-Cal members. DHCS notes that it may be required to cover these increased costs using 100% GF if the federal Centers for Medicare and Medicaid Services (CMS) determines the intended use is not medically necessary.
PRIOR VOTES:
Assembly Floor: | 73 - 0 |
Assembly Appropriations Committee: | 14 - 0 |
Assembly Health Committee: | 16 - 0 |
COMMENTS:
- Author’s statement. According to the author, cervical cancer is the fourth most common cancer among women and is almost always caused by HPV. If caught early, it’s highly treatable—but too many Californians, especially those in rural communities and Black and Native populations, face deadly late-stage diagnoses. Cervical cancer screenings have cut deaths by about 70% since 1950, but many people still do not get tested because they lack coverage or cannot easily access a clinic. Recent federal guidance has confirmed the importance of expanding access to cervical cancer screenings by requiring private health plans to cover at-home test kits beginning in 2027. CDPH has not yet adopted these federal guidelines, leaving Californians without this life-saving care. This bill will require coverage of at-home cervical cancer tests at no cost to patients, making preventive care affordable, promoting early detection, and reducing health disparities. This bill also offers significant long-term cost savings for the state, health systems, and insurers by reducing the need for in-person visits and preventing costly late-stage cancer treatments.
- USPSTF recommendation. The USPSTF, with an A rating, recommends screening for cervical cancer every three years with cervical cytology alone in women ages 21 to 29 years and then every five years with clinician- or patient-collected high-risk HPV primary screening in women ages 30 to 65 years. As an alternative to HPV primary screening for women ages 30 to 65 years, the USPSTF recommends continued screening every three years with cervical cytology (Pap test) alone or screening every five years with high-risk HPV testing in combination with cytology (cotesting).
- HRSA recommendation. HRSA adopted the Women’s Preventive Services Initiative recommendation for cervical cancer screening for average-risk women aged 21 to 65 years. For women aged 21 to 29 years, cervical cancer screening using Pap test (cytology) every three years is recommended. Co-testing with cytology and high-risk HPV testing is not recommended for women younger than 30 years. Women aged 30 to 65 years should be screened with primary high-risk HPV testing every five years or cytology and high-risk HPV testing every five years. If high risk HPV testing is not available, continue screening with cytology alone every three years. Women who are at average risk should not be screened more than once every three years. Patient-collected high risk HPV testing is an appropriate method and should be offered as an option for cervical cancer screening in women aged 30 to 65 years at average risk. Additional testing may be required to complete the screening process and follow-up findings on the initial screening. If additional testing (e.g., cytology, biopsy, colposcopy, extended genotyping, dual stain) and pathologic evaluation are indicated, these services also are recommended to complete the screening process for malignancies. Non-grandfathered group health plans and health insurance issuers offering group or individual health insurance coverage must cover without cost-sharing the services and screenings listed on the updated Women’s Preventive Services Guidelines for plan/policy years that begin one year after this date.
- California Health Benefits Review Program (CHBRP) report. AB 1996 (Thomson, Chapter 795, Statutes of 2002) requests the University of California to assess legislation proposing a mandated benefit or service and prepare a written analysis with relevant data on the medical, economic, and public health impacts of proposed health plan and health insurance benefit mandate legislation. CHBRP was created in response to AB 1996 and reviewed this bill. Key findings include:
- Cervical cancer screening. HPV is the most common sexually transmitted infection in the U.S., with an estimated 13 million new cases each year. Cervical cancer is the most common HPV-related cancer. HPV vaccination is anticipated to lead to a 90% reduction in cervical cancer among those vaccinated during adolescence. However, the full benefits do not occur until the vaccinated population reaches mid- to late life. Cervical cancer screening detects precancerous changes in cervical cells so that treatment can prevent the development of invasive cancer. The three primary methods of testing are: 1) HPV testing which checks cells for infection with high-risk HPV types of cells; 2) Cytology or Pap testing, where cervical cells are checked for abnormalities caused by HPV. Pap testing does not detect high risk HPV; and, 3) HPV/Pap co-test which tests for both abnormal cells and high-risk HPV infection. There are three FDA approved tests for self-collection in a clinic or office, and two self-collection tests for home: one is FDA authorized, and one is FDA cleared. CHBRP reports 25% of women in the U.S. are under screened and 2% require more frequent screening due to abnormal results or immunosuppression. Studies have also found 41% of women screened with Pap tests, 51% with co-testing, and 9% with HPV testing were over-screened.
- Coverage impacts and enrollees covered. CHBRP indicates that 40% of enrollees in state regulated health insurance have coverage without cost-sharing for home test kits.
- Medical effectiveness. According to CHBRP, the scientific consensus and pooled data indicate very strong evidence that, when instructions are properly followed, self-samples provide accurate, stable, and clinically valid HPV detection suitable for future widespread home-based screening. Currently, the Teal Wand is the only FDA-authorized home test kit for cervical cancer screening for use at the time of the CHBRP report. The Teal Wand can be requested online through the Teal Health website. Ordering the kit requires attending a virtual visit with a Teal provider to review the patient’s screening history and discuss the at-home screening steps. The test kit is mailed and returned once the sample is collected. Virtual consultation to discuss follow-up care is available through Teal Health. A second product has been cleared by the FDA, BD Onclarity HPV Assay, in April 2026. CHBRP also indicates that some health systems in California are planning their own self-collection screening programs outside of the Teal mechanism, using their own laboratories and mailing infrastructure.
- Utilization. CHBRP estimates an increase of 5,753 enrollees using home test kits for cervical cancer. CHBRP estimated average per unit costs of $223.71.
- Medi-Cal. $2,000 increase in Medi-Cal premiums reflects the marginal awareness-driven utilization among beneficiaries who already have baseline coverage without cost-sharing at a lower reimbursement rate ($77.19 per kit). Additionally, CHBRP indicates that although Medi-Cal plans report covering home test kits, access is limited by the Teal Wand’s current distribution model. CHBRP also reports that the Every Woman Counts program covers self-collected HPV testing for cervical cancer screening using current CPT codes for HPV testing.
- Impact on expenditures. Premiums would increase by just over $1 million (employers), $315,000 (employees), $262,000 (individual purchasers), and $2,000 (Medi-Cal managed care plans). This represents commercial insurance premium impacts per member per month of $.0094-.0099, Covered California $.0105-0111, and $.0074 for CalPERS.
- Public health. Long-term, this bill could modify the effects of the social drivers of health on cervical cancer screening by reducing barriers to screening over time.
- Essential health benefits (EHBs). No impact on EHBs.
- Billing Codes. A fact sheet published by CDPH on SB 306 (Pan, Chapter 486, Statutes of 2021) indicates that before STD home screening tests will be covered by Medi-Cal and Family PACT, there must be the addition of CPT or HCPCS codes specific to at home STD test kits. CPT Codes are developed by the American Medical Association and HCPCS Codes are developed by CMS. It is unknown if or when these specific codes will be established. Additionally, the kits must be sent by the enrolled provider to a Medi-Cal enrolled laboratory with a fee based on the Medicare Clinical Diagnostic Laboratory Test Payment System Final Rule. Lastly, reimbursement will also only be covered if “any necessary federal approvals” have been obtained. The fact sheet also says that some at home STD testing companies have already begun to bill commercial insurance for their services, although Medi-Cal reimbursement may currently only cover the cost of laboratory processing the test specimen and not the cost of the kit itself or shipping and handling until additional billing codes are established.
- Prior legislation. AB 144 (Committee on Budget, Chapter 105, Statutes of 2025), among other provisions, establishes baseline recommendations for preventive services, items, and immunizations recommended, as of January 1, 2025, by the USPSTF, the ACIP, and HRSA. Authorizes CDPH to modify or supplement the baseline recommendations, taking into consideration guidance and recommendations from additional medical and scientific organizations, including, but not limited to, the American Academy of Pediatrics, the American College of Obstetricians and Gynecologists (ACOG), and the American Academy of Family Physicians. Authorizes CDPH to incorporate subsequent evidence-based recommendations from USPSTF, ACIP, or HRSA, to the extent the department determines them to promote public health. Requires CDPH to publish the baseline recommendations, including any modification or supplement, and that any updates, modifications, or supplements are deemed effective on the date of publication. Replaces references to USPSTF, ACIP, or HRSA for coverage preventive services and items, and for the administration of vaccines by various health professionals and other personnel and entities, with references to these federal recommendations as they existed on January 1, 2025, as modified or supplemented by CDPH pursuant to its authority under the baseline recommendations. Until January 1, 2030, extends protection of liability for any injury caused by an act or omission in prescribing, dispensing, ordering, furnishing, or in the administration of vaccines or other immunizing agents if required by state law or administered in accordance with guidance from CDPH according to its baseline recommendations, unless the act or omission constitutes willful misconduct or gross negligence.
SB 306 (Pan, Chapter 486, Statutes of 2021) among other provisions, requires public and commercial health coverage of home STD test kits, specifically for Medi-Cal coverage the benefit is contingent upon the addition of codes specific to home test kits in the CPT or HCPCS to comply with HIPAA requirements.
- Support. ACOG writes this bill addresses barriers by ensuring coverage of clinician-referred home screening options, which can increase screening uptake, particularly among underserved and hard-to-reach populations. According to ACOG, by requiring coverage without cost-sharing across both commercial markets and Medi-Cal, this bill promotes equitable access to lifesaving preventive care, and early detection of cervical cancer and precancerous conditions significantly improve outcomes, reduces the need for more invasive treatment, and lowers long-term health care costs. ACOG writes this bill maintains the role of the patient’s health care provider in recommending and guiding appropriate screening, ensuring continuity and quality of care. Planned Parenthood Affiliates of California (PPAC) writes this bill also helps increase access to other STD home test kits for Medi-Cal patients by making technical changes to existing law to ensure that both HPV tests and other STD tests can be reimbursed in Medi-Cal. According to PPAC, this bill would create billing parity between commercial and Medi-Cal plans by removing the contingent application of coverage in Medi-Cal, which will allow Medi-Cal providers to use existing CPT and HCPCS codes for clinical laboratory tests, regardless of whether the collection of a lab sample occurs in a clinic or using a home test kit.
- Opposition. The California Association of Health Plans and the Association of California Life and Health Insurance Companies write that this is one of ten health insurance mandate bills that will increase costs, reduce choice and competition, and further incent some employers and individuals to avoid state regulated coverage by seeking alternative coverage options. Opponents write “state mandates increase premium costs for families and individuals and small business owners who cannot or do not wish to self-insure. Large employers, unions, small businesses, and hard-working families value their ability to shop for the right health plan – at the right price – that best fits their needs. Benefit mandates impose a one-size-fits-all approach to medical care and benefit design without consideration for consumer choice.”
- Policy comments.
- The existing cervical cancer screening requirement, which is being amended by this bill, was enacted in 2001, long before the enactment of the ACA preventive services requirements and other related policies. Clean up and modernization of the code may be useful.
- Cervical cancer screening coverage without cost-sharing should be consistent with Nationally recognized clinical care guidelines. Coverage for annual screening appears to be outdated.
- Nongrandfathered health plans and insurers may already be required to cover at home HPV screening tests without cost-sharing under the preventive services requirements of the ACA beginning in 2027. Because of the passage of AB 144, state enforcement of the federal requirement may be on hold until CDPH makes a determination if the state supports the new recommendations. It is unknown when CDPH will make their determination and what is their process and timeline.
SUPPORT AND OPPOSITION:
Support: American Association of University Women - California
American Association of University Women - San Jose Branch
American College of Obstetricians & Gynecologists - District IX
American College of Surgeons, Southern California Chapter
Biocom
California Commission on the Status of Women and Girls
California Federation of Teachers
California Life Sciences Association
California Primary Care Association Advocates
California Retired Teachers Association
Health Access California
Planned Parenthood Affiliates of California
Teal Health
Western Center on Law & Poverty, Inc.
Oppose: America's Health Insurance Plans
Association of California Life & Health Insurance Companies
California Association of Health Plans
-- END --
ASSEMBLY THIRD READING
ATR Bill Id:AB 1906
Author:(Aguiar-Curry)
As Introduced Ver:February 12, 2026
Majority vote
SUMMARY
Requires a health plan, health insurer, and the Medi-Cal program to cover cervical cancer screening home kits at zero cost sharing, upon referral of a patient's health care provider.
Major Provisions
COMMENTS
Cervical cancer is a type of cancer that develops in the cells of the cervix, the lower, narrow end of the uterus. Persistent infection with high-risk human papillomavirus (HPV) can cause cells of the cervix to go through dysplasia, a change that causes abnormal cells called precancers to appear in the cervical tissue. These abnormal cells can become cancerous if they are not destroyed or removed. HPV is the most common sexually transmitted disease (STD) in the United States, with an estimated 13 million new cases each year, and will infect approximately 85% of the population at some point in their lifetime. Cervical cancer remains the most common HPV-related cancer. Although HPV vaccination is anticipated to lead to a 90% reduction in cervical cancer among those vaccinated during adolescence, studies have shown that the full benefits of vaccination do not occur until the vaccinated population reaches mid- to late life. As a result, cervical cancer screening remains an important preventative measure against cervical cancer. Cervical cancer screening detects precancerous changes in cervical cells so that treatment can prevent the development of invasive cancer. There are three primary methods for screening for cervical cancer: HPV testing, which checks cells for infection with high-risk HPV; Pap testing, where cervical cells are checked for abnormalities caused by HPV that may indicate precancerous or cancerous cells on the cervix; and the HPV/Pap co-test, which combines both methods to detect both high-risk HPV and cellular abnormalities.
Self-collected HPV screenings. Historically, samples for both the HPV test and Pap test have been collected from the cervix during a pelvic exam by a health care provider in a clinical setting. More recently, technology has developed to allow for HPV testing to be performed using self-collected samples. There are two ways in which self-collection can occur:
- Self-collection in a health clinic or office: Tests that are approved by the United State Food and Drug Administration (FDA) to self-collect specimens in a health care facility under the supervision of a health care provider. As of September 2025, three in-clinic self-collection tests have received FDA approval.
- Self-collection at home: Tests that are approved, authorized, or cleared by the FDA to self-collect specimens in the home or a similarly private setting. Home test kits are provided by a health care provider and mailed back by the user to a lab for processing In May 2025, the FDA authorized the first device for self-collection of cervical specimens in the home. This test – the Teal Wand – is the only one of its kind with FDA authorization on the market. This bill aims to ensure coverage, at zero cost sharing, for this type of HPV screening.
Federal and state coverage of cervical cancer screening. Both the California Preventive Services Mandate and the Federal Preventive Services Mandate require coverage of certain preventive services without cost sharing. Federal bodies, including the United States Preventive Service Task Force, Health Resources & Services Administration (HRSA), and Advisory Committee on Immunization Practices review preventive services and make recommendations on coverage. Plans are required to provide such coverage within 12 months of the recommendation's publication. On January 5, 2026, the HRSA guidelines for women's preventive services updated its recommendation for cervical cancer screening to include self-collected HPV testing as a service to be offered as an option for cervical cancer screening in women aged 30 to 65 years at average risk. As such, impacted plans will be required to cover some form of self-collected HPV tests without cost sharing by January 2027. However, at-home test kits for cervical cancer screening are only one form of patient-collected testing, impacted plans may not necessarily cover them without cost sharing as a result of this HRSA recommendation. Some patient-collected tests are performed in a clinical setting, and plans may choose to cover this form of testing without cost sharing instead.
Despite the federal government moving to mandate the coverage of self-collected HPV testing without cost sharing, coverage in California is unclear. AB 144 (Committee on Budget), Chapter 105, Statutes of 2025, froze federal preventive service recommendations as of January 1, 2025, and empowered the State Department of Public Health (DPH) to modify or supplement these recommendations going forward. At the time this analysis was finalized, DPH had not published a recommendation for self-collected HPV tests. DPH indicated that they are still evaluating the recommendation and "if the department finds credible evidence and support for recommendation and reimbursement of these tests, then the recommendation will be filed with the Office of Administrative Law and posted on our website."
California Health Benefits Review Program (CHBRP). CHBRP was created in response to AB 1996 (Thomson), Chapter 795, Statutes of 2002, which requests the University of California to assess legislation proposing a mandated benefit or service and prepare a written analysis with relevant data on the medical, economic, and public health impacts of proposed health plan and health insurance benefit mandate legislation. SB 125 (Hernandez), Chapter 9, Statutes of 2015, added an impact assessment on essential health benefits, and legislation that impacts health insurance benefit designs, cost-sharing, premiums, and other health insurance topics to CHBRP's purview. CHBRP reviewed this bill and included the following impact estimates in their analysis:
- Premium increases & enrollee out-of-pocket decreases. Premiums paid by employers and enrollees would increase upon enaction of this bill by an estimated $1,580,000 annually, impacting market segments differently at a range of $0.00002-$0.0111 per member per month. This bill would expand coverage without cost sharing for at-home HPV kits to 60% of enrollees who currently lack it.
- Increased utilization of care. This bill would result in 6,798 enrollees using at-home HPV test kits, an increase of 5,753 new users. CHBRP estimates that 13% of women enrolled in state-regulated commercial plans and 8% of women enrolled in state-regulated Medi-Cal plans aged 30 to 65 years currently use cervical cancer screening services annually, with 1% of those screenings conducted using at-home test kits. CHBRP attributes the increases in utilization to the expansion of coverage for those who don't have it, the removal of cost sharing for those who currently have it, and increased awareness and convenience of the at-home screening option.
- Public health impacts. CHRBP determined that this bill would produce no measurable short-term public health impact. However, over time, home test kits may address disparities in screening rates by reducing certain barriers to screening, including structural, individual, and cultural barriers.
Office of Health Care Affordability (OHCA) cost targets. OHCA was established in 2022 in response to widespread cost-related access challenges across California. According to the California Health Care Foundation (CHCF), over half of Californians say they skip or delay health care due to costs. OHCA collects, analyzes, and publicly reports data on total health care expenditures and enforces spending targets. OHCA's spending targets are intended to reduce excess spending and slow health care spending growth. In April of 2024, OHCA approved a statewide cost growth target of 3.5% starting in 2025 and phasing down to 3% by 2029. Health care entities, including health plans and insurers, are subject to the statewide spending target and are subject to progressive enforcement if the entity's costs exceed the target. Some entities have raised concerns that new legislative insurance mandates will make it difficult for them to meet the established cost growth target.
Current law does not explicitly require OHCA to adjust the cost growth targets based on changes to state policy, such as insurance mandates, that may increase spending. However, it does require OHCA to consider state benefit mandates in its development and enforcement of cost growth targets. Specifically, when establishing cost growth target methodology, OHCA is required to review relevant state policy changes impacting covered benefits, provider reimbursement, and costs, among other factors. In addition, in enforcing cost growth targets, OHCA is required to consider factors that contribute to spending in excess of the applicable target, and the extent to which each entity has control over the applicable components of its cost target.
According to the Author
Cervical cancer is the fourth most common cancer among women and is almost always caused by HPV. The author continues that if caught early, it's highly treatable—but too many Californians, especially those in rural communities and Black and Native populations, face deadly late-stage diagnoses. The author notes that cervical cancer screenings have cut deaths by about 70% since 1950, but many people still do not get tested because they lack coverage or cannot easily access a clinic. The author continues that recent federal guidance has confirmed the importance of expanding access to cervical cancer screenings by requiring private health plans to cover at-home test kits beginning in 2027. The author states that DPH has not yet adopted these federal guidelines, leaving Californians without this life-saving care. The author continues that this bill will require coverage of at-home cervical cancer tests at no cost to patients, making preventive care affordable, promoting early detection, and reducing health disparities. The author concludes that this bill also offers significant long-term cost savings for the state, health systems, and insurers by reducing the need for in-person visits and preventing costly late-stage cancer treatments.
Arguments in Support
Planned Parenthood Affiliates of California (PPAC) support this bill, stating that cervical cancer is the fourth most common cancer among women globally, with about 99.7% of cases caused by persistent HPV infection. PPAC notes that cervical cancer has a five-year survival rate of about 91% which drops to about 20% for late-stage diagnoses. PPAC continues that disparities exist with rural women 25% more likely to be diagnosed and 42% more likely to die, while Black and Native women experience mortality rates about 55% and 80% higher than white women. PPAC cites the Centers for Disease Control and Prevention (CDC), which found that widespread screening has reduced cervical cancer incidence and mortality by about 70% since the 1950s. PPAC continues that CDC research also shows that at-home HPV test kits can more than double screening participation and reduce costs for health systems and insurers by eliminating the need for in-office visits and clinician time. PPAC notes this is particularly helpful for people already facing barriers to in-person care. PPAC concludes that this bill expands access to critical preventive care that will save lives, especially for rural and working Californians facing barriers to in-person cervical cancer screening
Arguments in Opposition
The California Association of Health Plans, Association of Life and Health Insurance Companies, and America's Health Insurance Plans oppose this bill and 10 others that mandate new benefit coverage. The opposition states that these bills will increase costs, reduce choice and competition, and further incent some employers and individuals to avoid state regulation by seeking alternative coverage options. The opposition continues that state mandates increase premium costs for families and individuals and small business owners who cannot or do not wish to self-insure. The opposition argues that large employers, unions, small businesses, and hard-working families value their ability to shop for the right health plan – at the right price – that best fits their needs. The opposition continues that benefit mandates impose a one-size-fits-all approach to medical care and benefit design without consideration for consumer choice. The opposition states that while OHCA is working to curb healthcare costs and ensure resources are allocated in an efficient and affordable manner, adding new mandates at this pivotal moment could disrupt these efforts by driving up costs for insurers, employers, and consumers, while making it difficult for health care entities to meet the established spending target. The opposition argues that by halting new mandates, the Legislature can support OHCA's efforts of making quality health care accessible and affordable for Californians. The opposition concludes that now is the time to focus on stability and affordability for all Californians.
FISCAL COMMENTS
According to the Assembly Committee on Appropriations:
- CHBRP estimates this bill will increase premiums in health plans and insurance policies offered though the California Public Employees Retirement System (CalPERS) by $69,000 for Department of Managed Health Care (DMHC)-regulated plans, of which the state's share would be around $30,000 (General Fund (GF)). There would also be increases to CalPERS premiums for health insurance policies regulated by the California Department of Insurance (CDI), the state's share of which would likely be less than $30,000 (GF).
- Minor and absorbable costs to DMHC.
- California Department of Insurance estimates costs of $7,000 in fiscal year (FY) 2026-27 and $19,000 in FY 2027-28 (Insurance Fund).
- CHBRP estimates the bill could increase costs to the Medi-Cal program by $2,000 (GF, federal funds (FF)). However, the Department of Health Care Services (DHCS) states this bill could increase Medi-Cal expenditures in the range of low hundreds of thousands to low millions of dollars (GF, FF) due to indeterminate increased utilization that may result from requiring broad-based coverage of home cervical cancer screening kits versus case-by-case, individual medical necessity determinations. Actual expenditures may vary from this estimate based on the clinical guidelines ultimately adopted by the U.S. Preventive Services Task Force and uptake of the new at-home cervical cancer screening kits by Medi-Cal members. DHCS notes that it may be required to cover these increased costs using 100% GF if the federal Centers for Medicare and Medicaid Services determines the intended use is not medically necessary.
VOTES
ASM HEALTH: 16-0-0
YES: Bonta, Chen, Addis, Aguiar-Curry, Ahrens, Caloza, Carrillo, Mark González, Johnson, Patel, Patterson, Rogers, Sanchez, Schiavo, Sharp-Collins, Stefani
ASM APPROPRIATIONS: 14-0-1
YES: Wicks, Hoover, Aguiar-Curry, Calderon, Caloza, Dixon, Fong, Mark González, Krell, Pacheco, Pellerin, Sharp-Collins, Solache, Ta
ABS, ABST OR NV: Tangipa
UPDATED
VERSION: February 12, 2026
CONSULTANT: Riana King / HEALTH / (916) 319-2097 FN: 0002892
Date of Hearing: May 13, 2026
ASSEMBLY COMMITTEE ON APPROPRIATIONS
Buffy Wicks, Chair
ABPCA Bill Id:AB 1906
Author:(Aguiar-Curry) – As Introduced Ver:February 12, 2026
Policy Committee: | Health | Vote: | 16 - 0 |
|
| ||
|
|
Urgency: No State Mandated Local Program: Yes Reimbursable: No
SUMMARY:
This bill requires a health plan, health insurer, and the Medi-Cal program to cover cervical cancer screening home kits without cost sharing, upon referral of a patient’s health care provider.
FISCAL EFFECT:
- The California Health Benefits Review Program (CHBRP) estimates this bill will increase premiums in health plans and insurance policies offered though the California Public Employees Retirement System (CalPERS) by $69,000 for Department of Managed Health Care (DMHC)-regulated plans, of which the state’s share would be around $30,000 (General Fund (GF)). There would also be increases to CalPERS premiums for health insurance policies regulated by the Department of Insurance (CDI), the state’s share of which would likely be less than $30,000 (GF).
- Minor and absorbable costs to DMHC.
- CDI estimates costs of $7,000 in fiscal year (FY) 2026-27 and $19,000 in FY 2027-28 (Insurance Fund).
- CHBRP estimates the bill could increase costs to the Medi-Cal program by $2,000 (GF, federal funds (FF)). However, DHCS states this bill could increase Medi-Cal expenditures in the range of low hundreds of thousands to low millions of dollars (GF, federal funds) due to indeterminate increased utilization that may result from requiring broad-based coverage of home cervical cancer screening kits versus case-by-case, individual medical necessity determinations. Actual expenditures may vary from this estimate based on the clinical guidelines ultimately adopted by the U.S. Preventive Services Task Force and uptake of the new at-home cervical cancer screening kits by Medi-Cal members. DHCS notes that it may be required to cover these increased costs using 100% GF if the federal Centers for Medicare and Medicaid Services determines the intended use is not medically necessary.
The Legislative Analyst’s Office recently warned of General Fund structural deficits of around $35 billion per year in the 2027-28 fiscal year and ongoing.
COMMENTS:
- Purpose. According to the author:
Cervical cancer is the fourth most common cancer among women and is almost always caused by HPV. If caught early, it’s highly treatable—but too many Californians, especially those in rural communities and Black and Native populations, face deadly late-stage diagnoses. Cervical cancer screenings have cut deaths by about 70% since 1950, but many people still do not get tested because they lack coverage or cannot easily access a clinic. Recent federal guidance has confirmed the importance of expanding access to cervical cancer screenings by requiring private health plans to cover at-home test kits beginning in 2027. [The Department of Public Health] has not yet adopted these federal guidelines, leaving Californians without this life-saving care.
[This bill] will require coverage of at-home cervical cancer tests at no cost to patients, making preventive care affordable, promoting early detection, and reducing health disparities. This bill also offers significant long-term cost savings for the state, health systems, and insurers by reducing the need for in-person visits and preventing costly late-stage cancer treatments.
- Background. Cervical cancer develops in the cells of the cervix. Persistent infection with high-risk human papilloma virus (HPV) can cause cells of the cervix to go through changes and become cancerous if they are not destroyed or removed. HPV is the most common sexually transmitted infection in the U.S., with an estimated 13 million new cases each year, and will infect approximately 85% of the population at some point in their lifetime. Although HPV vaccination is anticipated to lead to a 90% reduction in cervical cancer among those vaccinated during adolescence, studies have shown that the full benefits of vaccination do not occur until the vaccinated population reaches mid- to late life.
Cervical cancer screening detects precancerous changes in cervical cells so that treatment can prevent the development of invasive cancer. Historically, samples for both the HPV test and Pap test have been collected from the cervix during a pelvic exam by a health care provider in a clinical setting. More recently, technology has developed to allow for HPV testing to be performed using self-collected samples, including self-collection at home. Home test kits are provided by a health care provider and mailed back by the user to a lab for processing. In May 2025, the FDA authorized the first device for self-collection of cervical specimens in the home. This test – the Teal Wand – is the only one of its kind with FDA authorization on the market. This bill aims to ensure coverage, without cost sharing, for this type of HPV screening.
Analysis Prepared by: Allegra Kim / APPR. / (916) 319-2081
Date of Hearing: April 21, 2026
ASSEMBLY COMMITTEE ON HEALTH
Mia Bonta, Chair
ABPCA Bill Id:AB 1906
Author:(Aguiar-Curry) – As Introduced Ver:February 12, 2026
SUBJECT: Cervical cancer screening.
SUMMARY: Requires a health plan, health insurer, and the Medi-Cal program to cover cervical cancer screening home kits at zero cost sharing, upon referral of a patient’s health care provider.
EXISTING LAW:
- Establishes the Department Managed Health Care (DMHC) to regulate health plans under the Knox-Keene Health Care Service Plan Act of 1975 and California Department of Insurance (CDI) to regulate health insurers. [Health and Safety Code (HSC) § 1340, et seq. and Insurance Code (INS) § 106, et seq.]
- Establishes the Medi-Cal Program, administered by the Department of Health Care Services (DHCS), to provide comprehensive health benefits to low-income individuals who meet specified eligibility criteria. [Welfare and Institutions Code (WIC) § 14000, et seq.]
- Establishes California's Essential Health Benefit (EHB) benchmark under the federal Patient Protection and Affordable Care Act (ACA) as the Kaiser Small Group Health Maintenance Organization contract. Establishes existing California health insurance mandates and the 10 ACA mandated benefits. [HSC § 1367.005 and INS § 10112.27]
- Specifies EHBs in the following 10 categories: ambulatory patient services; emergency services; hospitalization; maternity and newborn care; mental health and substance use disorder services; prescription drugs; rehabilitative and habilitative services and devices; laboratory services; preventive and wellness services and chronic disease management; and, pediatric services, including oral and vision care. [HSC § 1367.005 and INS § 10112.27]
- Defines “basic health care services” as all of the following:
- Physician services, including consultation and referral;
- Hospital inpatient services and ambulatory care services;
- Diagnostic laboratory and therapeutic radiologic services;
- Home health services;
- Preventive health services;
- Emergency health care services, including ambulance and ambulance transport services and out-of-area coverage. Basic health care services includes ambulance and ambulance transport services provided through the 911 emergency response system; and,
- Hospice care. [HSC § 1345]
- Requires health plans and insurers, as specified, to provide coverage for an annual cervical cancer screening test upon referral by a health care provider, as specified. [HSC § 1367.66, INS § 10123.18, and WIC § 14132.17 ]
- Requires health plans and insurers to cover home test kits for sexually transmitted diseases (STDs), including laboratory costs of processing the kit, deemed medically necessary or appropriate and ordered directly by a clinician or furnished through a standing order for patient use based on clinical guidelines and individual patient health needs. [HSC § 1367.34 & INS § 10123.208]
- Requires health plans and insurers, at a minimum, to provide coverage for and prohibits any cost-sharing requirements for the following:
- Evidence-based items or services that had in effect on January 1, 2025 a rating of “A” or “B” in the recommendations of the United States Preventive Services Taskforce (USPSTF);
- Immunizations that had a recommendation in effect on January 1, 2025 from the Advisory Committee on Immunization Practices (ACIP) of the Center for Disease Control; and,
- With respect to infants, children, adolescents, and women, additional preventive care and screenings provided for in comprehensive guidelines supported by the United States Health Resources and Services Administration (HRSA) as of January 1, 2025. [HSC § 1367.002 and INS § 10112.2]
- Permits the State Department of Public Health (DPH) to modify or supplement baseline recommendations by the USPSTF, ACIP and HRSA that were in effect on January 1, 2025. Allows DPH to take into consideration guidance and recommendations from additional medical and scientific organizations, including the American Academy of Pediatrics, American College of Obstetricians and Gynecologists, and the American Academy of Family Physicians. [HSC § 120164]
- Establishes the California Health Care Quality and Affordability Act, which creates the Office of Health Care Affordability (OHCA) within the Department of Health Care Access and Information (HCAI). Identifies OHCA’s three primary responsibilities: managing spending targets, monitoring system performance, and assessing market consolidation. Requires OHCA to collect, analyze, and publicly report data on total health care expenditures, and enforce spending targets set by a Health Care Affordability Board (Board). [HSC § 127500, et seq.]
FISCAL EFFECT: Unknown. This bill has not been analyzed by a fiscal committee.
COMMENTS:
- PURPOSE OF THIS BILL. According to the author, cervical cancer is the fourth most common cancer among women and is almost always caused by the human papillomavirus (HPV). The author continues that if caught early, it’s highly treatable—but too many Californians, especially those in rural communities and Black and Native populations, face deadly late-stage diagnoses. The author notes that cervical cancer screenings have cut deaths by about 70% since 1950, but many people still do not get tested because they lack coverage or cannot easily access a clinic. The author continues that recent federal guidance has confirmed the importance of expanding access to cervical cancer screenings by requiring private health plans to cover at-home test kits beginning in 2027. The author states that DPH has not yet adopted these federal guidelines, leaving Californians without this life-saving care. The author continues that this bill will require coverage of at-home cervical cancer tests at no cost to patients, making preventive care affordable, promoting early detection, and reducing health disparities. The author concludes that this bill also offers significant long-term cost savings for the state, health systems, and insurers by reducing the need for in-person visits and preventing costly late-stage cancer treatments.
- BACKGROUND. Cervical cancer is a type of cancer that develops in the cells of the cervix, the lower, narrow end of the uterus. Persistent infection with high-risk HPV can cause cells of the cervix to go through dysplasia, a change that causes abnormal cells called precancers to appear in the cervical tissue. These abnormal cells can become cancerous if they are not destroyed or removed. HPV is the most common STD in the United States, with an estimated 13 million new cases each year, and will infect approximately 85% of the population at some point in their lifetime. Cervical cancer remains the most common HPV-related cancer. Although HPV vaccination is anticipated to lead to a 90% reduction in cervical cancer among those vaccinated during adolescence, studies have shown that the full benefits of vaccination do not occur until the vaccinated population reaches mid- to late life. As a result, cervical cancer screening remains an important preventative measure against cervical cancer. Cervical cancer screening detects precancerous changes in cervical cells so that treatment can prevent the development of invasive cancer. There are three primary methods for screening for cervical cancer: HPV testing, which checks cells for infection with high-risk HPV; Pap testing, where cervical cells are checked for abnormalities caused by HPV that may indicate precancerous or cancerous cells on the cervix; and the HPV/Pap co-test, which combines both methods to detect both high-risk HPV and cellular abnormalities.
- Self-collected HPV screenings. Historically, samples for both the HPV test and Pap test have been collected from the cervix during a pelvic exam by a health care provider in a clinical setting. More recently, technology has developed to allow for HPV testing to be performed using self-collected samples. There are two ways in which self-collection can occur:
- Self-collection in a health clinic or office: Tests that are approved by the United State Food and Drug Administration (FDA) to self-collect specimens in a health care facility under the supervision of a health care provider. As of September 2025, three in-clinic self-collection tests have received FDA approval.
- Self-collection at home: Tests that are approved, authorized, or cleared by the FDA to self-collect specimens in the home or a similarly private setting. Home test kits are provided by a health care provider and mailed back by the user to a lab for processing In May 2025, the FDA authorized the first device for self-collection of cervical specimens in the home. This test – the Teal Wand – is the only one of its kind with FDA authorization on the market. This bill aims to ensure coverage, at zero cost sharing, for this type of HPV screening.
- Federal and state coverage of cervical cancer screening. Both the California Preventive Services Mandate and the Federal Preventive Services Mandate require coverage of certain preventive services without cost sharing. Federal bodies, including the USPSTF, HRSA, and ACIP review preventive services and make recommendations on coverage. Plans are required to provide such coverage within 12 months of the recommendation’s publication. On January 5, 2026, the HRSA guidelines for women’s preventive services updated its recommendation for cervical cancer screening to include self-collected HPV testing as a service to be offered as an option for cervical cancer screening in women aged 30 to 65 years at average risk. As such, impacted plans will be required to cover some form of self-collected HPV tests without cost sharing by January 2027. However, at-home test kits for cervical cancer screening are only one form of patient-collected testing, impacted plans may not necessarily cover them without cost sharing as a result of this HRSA recommendation. Some patient-collected tests are performed in a clinical setting, and plans may choose to cover this form of testing without cost sharing instead.
- Self-collected HPV screenings. Historically, samples for both the HPV test and Pap test have been collected from the cervix during a pelvic exam by a health care provider in a clinical setting. More recently, technology has developed to allow for HPV testing to be performed using self-collected samples. There are two ways in which self-collection can occur:
Despite the federal government moving to mandate the coverage of self-collected HPV testing without cost sharing, coverage in California is unclear. AB 144 (Committee on Budget), Chapter 105, Statutes of 2025, froze federal preventive service recommendations as of January 1, 2025, and empowered DPH to modify or supplement these recommendations going forward. At the time this analysis was finalized, DPH had not published a recommendation for self-collected HPV tests. DPH indicated that they are still evaluating the recommendation and “if the department finds credible evidence and support for recommendation and reimbursement of these tests, then the recommendation will be filed with the Office of Administrative Law and posted on our website.”
- California Health Benefits Review Program (CHBRP). CHBRP was created in response to AB 1996 (Thomson), Chapter 795, Statutes of 2002, which requests the University of California to assess legislation proposing a mandated benefit or service and prepare a written analysis with relevant data on the medical, economic, and public health impacts of proposed health plan and health insurance benefit mandate legislation. SB 125 (Hernandez), Chapter 9, Statutes of 2015, added an impact assessment on EHBs, and legislation that impacts health insurance benefit designs, cost-sharing, premiums, and other health insurance topics to CHBRP’s purview. CHBRP reviewed this bill and included the following impact estimates in their analysis:
- Premium increases & enrollee out-of-pocket decreases. Premiums paid by employers and enrollees would increase upon enaction of this bill by an estimated $1,580,000 annually, impacting market segments differently at a range of $0.00002-$0.0111 per member per month. This bill would expand coverage without cost sharing for at-home HPV kits to 60% of enrollees who currently lack it.
- Increased utilization of care. This bill would result in 6,798 enrollees using at-home HPV test kits, an increase of 5,753 new users. CHBRP estimates that 13% of women enrolled in state-regulated commercial plans and 8% of women enrolled in state-regulated Medi-Cal plans aged 30 to 65 years currently use cervical cancer screening services annually, with 1% of those screenings conducted using at-home test kits. CHBRP attributes the increases in utilization to the expansion of coverage for those who don’t have it, the removal of cost sharing for those who currently have it, and increased awareness and convenience of the at-home screening option.
- Public health impacts. CHRBP determined that this bill would produce no measurable short-term public health impact. However, over time, home test kits may address disparities in screening rates by reducing certain barriers to screening, including structural, individual, and cultural barriers.
- OHCA cost targets. OHCA was established in 2022 in response to widespread cost-related access challenges across California. According to the California Health Care Foundation (CHCF), over half of Californians say they skip or delay health care due to costs. OHCA collects, analyzes, and publicly reports data on total health care expenditures and enforces spending targets. OHCA’s spending targets are intended to reduce excess spending and slow health care spending growth. In April of 2024, OHCA approved a statewide cost growth target of 3.5% starting in 2025 and phasing down to 3% by 2029. Health care entities, including health plans and insurers, are subject to the statewide spending target and are subject to progressive enforcement if the entity’s costs exceed the target. Some entities have raised concerns that new legislative insurance mandates will make it difficult for them to meet the established cost growth target.
- California Health Benefits Review Program (CHBRP). CHBRP was created in response to AB 1996 (Thomson), Chapter 795, Statutes of 2002, which requests the University of California to assess legislation proposing a mandated benefit or service and prepare a written analysis with relevant data on the medical, economic, and public health impacts of proposed health plan and health insurance benefit mandate legislation. SB 125 (Hernandez), Chapter 9, Statutes of 2015, added an impact assessment on EHBs, and legislation that impacts health insurance benefit designs, cost-sharing, premiums, and other health insurance topics to CHBRP’s purview. CHBRP reviewed this bill and included the following impact estimates in their analysis:
Current law does not explicitly require OHCA to adjust the cost growth targets based on changes to state policy, such as insurance mandates, that may increase spending. However, it does require OHCA to consider state benefit mandates in its development and enforcement of cost growth targets. Specifically, when establishing cost growth target methodology, OHCA is required to review relevant state policy changes impacting covered benefits, provider reimbursement, and costs, among other factors. In addition, in enforcing cost growth targets, OHCA is required to consider factors that contribute to spending in excess of the applicable target, and the extent to which each entity has control over the applicable components of its cost target.
- SUPPORT. Planned Parenthood Affiliates of California (PPAC) support this bill, stating that cervical cancer is the fourth most common cancer among women globally, with about 99.7% of cases caused by persistent HPV infection. PPAC notes that cervical cancer has a five-year survival rate of about 91% which drops to about 20% for late-stage diagnoses. PPAC continues that disparities exist with rural women 25% more likely to be diagnosed and 42% more likely to die, while Black and Native women experience mortality rates about 55% and 80% higher than white women. PPAC cites the Centers for Disease Control and Prevention (CDC), which found that widespread screening has reduced cervical cancer incidence and mortality by about 70% since the 1950s. PPAC continues that CDC research also shows that at-home HPV test kits can more than double screening participation and reduce costs for health systems and insurers by eliminating the need for in-office visits and clinician time. PPAC notes this is particularly helpful for people already facing barriers to in-person care. PPAC concludes that this bill expands access to critical preventive care that will save lives, especially for rural and working Californians facing barriers to in-person cervical cancer screening.
- OPPOSITION. The California Association of Health Plans, Association of Life and Health Insurance Companies, and America’s Health Insurance Plans oppose this bill and 10 others that mandate new benefit coverage. The opposition states that these bills will increase costs, reduce choice and competition, and further incent some employers and individuals to avoid state regulation by seeking alternative coverage options. The opposition continues that state mandates increase premium costs for families and individuals and small business owners who cannot or do not wish to self-insure. The opposition argues that large employers, unions, small businesses, and hard-working families value their ability to shop for the right health plan – at the right price – that best fits their needs. The opposition continues that benefit mandates impose a one-size-fits-all approach to medical care and benefit design without consideration for consumer choice. The opposition states that while OHCA is working to curb healthcare costs and ensure resources are allocated in an efficient and affordable manner, adding new mandates at this pivotal moment could disrupt these efforts by driving up costs for insurers, employers, and consumers, while making it difficult for health care entities to meet the established spending target. The opposition argues that by halting new mandates, the Legislature can support OHCA’s efforts of making quality health care accessible and affordable for Californians. The opposition concludes that now is the time to focus on stability and affordability for all Californians.
- PREVIOUS LEGISLATION.
- AB 144 (Committee on Budget) requires health plans and insurers to cover an evidence-based item, service, or immunization that had in effect on January 1, 2025 a specified recommendation by the USPSTF, HRSA, or ACIP. Authorizes DPH to modify or supplement those baseline recommendations, as specified. Requires DPH to publish recommendations and any updates, modifications, or supplements.
- SB 306 (Pan), Chapter 486, Statutes of 2021, requires California health plans to cover at-home test kits for sexually transmitted infections, including HPV.
REGISTERED SUPPORT / OPPOSITION:
Support
American Association of University Women - California
American College of Obstetricians & Gynecologists - District IX
American College of Surgeons, Southern California Chapter
CA Commission on the Status of Women and Girls
California Life Sciences Association
California Retired Teachers Association
Health Access California
Planned Parenthood Affiliates of California
Opposition
America's Health Insurance Plans
Association of California Life & Health Insurance Companies
California Association of Health Plans
California Small Business Association
Analysis Prepared by: Riana King / HEALTH / (916) 319-2097
Bill Author
Bill Co-Author(s):